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Abstract 
A prominent consequence of injury in the adult brain is astrogliosis, in which 
reactive astrocytes undergo hypertrophy and results in the formation of “glial scars". 
The glial scar that result may inhibit neuron regeneration or become the focus of 
electrical instability. Many studies have shown that astrocytes, a major glial cell 
types in the brain, secrete a number of cytokine including TNF-a. Moreover, it has 
been demonstrated that TNF-a gene expression was significantly elevated 1 to 4 
hours and the agents which block TNF-a synthesis, such as pentoxifylline and H U 
211, improved neuronal and/or neurological recovery after traumatic brain injury. 
Taken together, these showed that the elevated TNF-a level was associated with the 
regulation of astrogliosis and TNF-a plays a critical role in neuron regeneration and 
} 
recovery of brain injury. However, the signaling cascade involved and genes 
induced/inhibited by TNF-a in astrocytes are still unclear. Since C6 glioma cells 
have many properties similar to those of cultured rat astrocytes, this cell line was 
used to examine the signaling pathway mediating the proliferative action of TNF-a. 
Fluorescent differential display (FDD) technique was applied to screen the up-
and down-regulated genes following TNF-a treatment in C6 cells. Among the genes 
identified, one was p38 mitogen activated protein kinase (p38 MAPK), an enzyme 
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known to mediate cell proliferation in many cell types. Although all the four p38 
M A P K isoforms: p38 a, p, y and 5 were up-regulated, their responses and sensitivity 
to TNF-a were different and the induction of p38 a M A P K being most prominent in 
C6 cells. 
Results of the present study indicated that the protein kinase C (PKC) and 
protein kinase A (PKA) were the upstream regulators the TNF-a-induced p38 a 
M A P K expression as this was stimulated by phorbol 12-myristate 13-acetate (PMA)， 
a P K C activators, or N'-2'-dibutyryl cyclic adenosine-3',5'-monophosphate, a PKA 
activator, while the TNF-a-induced stimulation was reduced by Ro31-8220 (Ro31) 
and staurosporine, potent PKC inhibitors, and 14-22 and H-89, potent PKA 
inhibitors . 
Recent studies have also provided evidence that p-adrenergic mechanism plays 
an important role in astrocytes and C6 cell proliferation. The present study illustrated 
that (31- and [32-agonist stimulated, while both types of p-antagonists attenuated the 
TNF-a-induced ofp38 a M A P K . 
As for the pathway down-stream of p38 a M A P K , we found the inhibitor of p38 
M A P K , SB 203580, attenuated the TNF-a-induced iNOS expression. In addition，we 
found that some transcription factors that have been proposed to regulate the cell 
proliferation and cell survival were affected by p38 a M A P K and TNF-a. Our results 
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showed that transcription factors: cAMP-responsive element binding (CREB). c-fos 
and N F K B expression induced by TNF-a were attenuated by SB 203580. Also, the 
expression of C R E B and c-fos were stimulated by P M A and dbcAMP，while Ro31 or 
staurosporine and 14-22 or H-89，suppressed the TNF-a-induced C R E B and c-fos 
expression. This supported that both P K C and P K A also participated in the induction 
of C R E B and c-fos expression and that both kinases were involved in the TNF-a 
induction pathway. Moreover, isoproterenol stimulated the expression of CREB and 
c-fos while propanol inhibited the C R E B and c-fos expression induced by TNF-a. 
These data suggests that (3-adrenergic mechanism was also involved in mediating the 
TNF-a-induced C R E B and c-fos expression. 
Taken together, the above findings suggest that the TNF-a-induced signaling 
process in C6 cells was mediated by PKA, P K C and p-adrenergic mechanism which 
) 
then activated p38 a M A P K activity and followed by iNOS expression as well as the 
regulation of transcription factors: CREB, c-fos and NFKB expression. Our study 
indicates that manipulator! of PKA, PKC, p38 a M A P K , iNOS and some 
transcription factors expression may provide effective therapeutic interventions, in 
















MAPK同功霉如p38a , P, 丫及3的表達被調高，但以p38 a M A P K於 C 6細胞 
中爲最顯著調高的表達。 
現時的實驗結果証實PKC的激活劑phorbol 12-myristate 13-acetate (PMA) 
及 蛋 白 激 霉 甲 型 （ P K A ) 的 激 活 劑 N^ -2’-dibutyryl cyclic 













發的CREB和 c - f o s的表達。這些結果証明PKC及PKA均有份參與並誘發 
CREB和c/os•的表達。同時，P-AR的激活劑（isoproterenol)能剌激TNF-a所 
誘發的CREB和 c - f o s的表達，相反TNF-a所誘發的CREB和o f o s的表達被 
P-AR的抑制劑(propranolol)所壓止。 
總括來說，上述的發•出TNF-a於C6細胞所誘發的信息傳遞過程 
過PKA^ PKC及P-賢上腺素系統，隨之弓丨發p38 MAPK的活動而對iNOS與及 
一些轉錄因子如CREB, c-fos及NF-KB的表達作出調節。我們的實驗顯示出對 
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Chapter 1. INTRODUCTION 
1.1 Traumatic Brain Injury 
Traumatic brain injury (TBI) is among the leading cause of mortality and 
neurological disability in the western world (Waxweiler, 1995). Neuronal 
degeneration after traumatic brain injury is believed to evolve in a biphasic manner 
consisting of the primary mechanical insult followed by a progressive secondary 
necrosis (Mattson & Scheff, 1994; Siesjo et al., 1995). Characteristic responses to 
trauma or excititoxic insults to the central nervous system (CNS) include the 
extravasation of serum proteins through the damaged blood brain barrier (BBB) 
(Povlishock and Kontos, 1992; Dietrich et al., 1994; Baldwin et al., 1996), and 
activation of resident neuroglial (glial) cells (Jensen et al., 1997). In recent years, 
much emphasis have been put on the role of rapid increase in proinflammatory 
cytokines production (Feuerstein et al., 1994), most notably tumor necrosis factor 
alpha (TNF-a), by glia and microglia in the process of and after TBI. 
1.2 Cells of the Nervous System: Glia 
The nervous system is built of two major types of cell: neurons and neuroglia 
(glia). Both play essential roles in the function of the system. Neurons, are able to 
transmit messages from one part of the CNS to another or out of the system altogether 
to the muscles and glands, and vice versa from the sense organs into the CNS (Smith, 
1996). 
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Glia are spindle-shaped cells, morphologically distinct from neurons, which was 
considered them to form a structural "glue" holding together the other elements of the 
nervous system by Virchow (Siegel, 1999). It is now clear that glia is the non-neural 
cells of the CNS. Depending on the region, they outnumber the neurons from 5 to 
over 50 times and comprise about 40% of the total CNS volume (Noback, 1996). 
The main functions of the neuroglia are to support, to nurture, and to maintain a 
relatively constant environment for the neurons (Noback, 1996). Glial cells differ 
from neurons in that they possess no synaptic contacts and retain the ability to divide 
throughout the life, particularly in response to injury (Siegel, 1999). This means that 
they are able to invade damaged regions and clear away necrotic material and in so 
doing they leave a glial scars (Smith, 1996). It is recognized that glia belongs to three 
major types: astroglia, oligodendroglia and microglia. 
1.2.1 Astroglia 
Astroglial cells, as the name implies, possess a number of radiating (star-like) 
processes from a large central cell body (c. 20jj,m in diameter) which contains the 
nucleus (Smith, 1996). The cytoplasm has numerous processes and contains the 
characteristic organelles of these cells, the gliafilaments, which are slightly finer than 
neurofilaments and are gathered into bundles. The filaments are made of a substance 
known as glial fibrillary acidic protein (GFAP) (Kieman, 1998). Astrocytes 
traditionally have been subdivided into protoplasmic and fibrous astrocytes, these two 
forms probably represent the opposite ends of a spectrum of the same cell type. 
Fibrous astrocytes occur in the white matter. They have long processes with coarse 
bundles of gliofilaments. Protoplasmic astrocytes are found in the gray matter. Their 
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processes are greatly branched and flattened to form delicate lamellae around the 
terminal branches of axons, dendrites and synapses (Kieman, 1998). 
1.2.1.1 Molecular Markers of Astrocytes 
It is now known that GFAP with a molecular weight of 47 kDa, is the main 
constituent of astroglial filaments (Eng & Shiurba, 1998). Thus, a positive 
immunohistochemical reaction for GFAP has been used as a major criterion for 
identifying astrocytes. 
Molecular markers other than intermediate filaments have been used as 
additional aids in defining astrocytes. For example, the enzyme glutamine synthetase 
(GS) is enriched in astrocytes, and fibrous and protoplasmic astrocytes are equally 
labeled by antibodies to GS (Norenbery & Martinez-Hernandez, 1979). The calcium-
binding protein and S-100 are also be useful as markers for astrocytes (Boyes et al., 
1986; Cammer et al., 1989). It is interesting to note that C6 glioma cells also have 
many of these markers. 
1.2.1.2 Functions of astrocyte 
a. Homeostasis 
Astrocytes serve to maintain the composition of the fluid in the extracellular space 
of the brain. The homeostatic functions, which are most directly pertinent to injury, 
are regulation of extracellular K+ concentration, particularly in C〇2 metabolism, and 
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clearance of neurotransmitter from the extracellular space. Astrocytes are involved in 
several of the mechanisms that modulate local blood supply in response to neuronal 
needs. Finally, astrocytes appear to provide substrates for energy metabolism to 
neurons (Benvenisate, 1992). 
b. Structural support 
The concept that astrocytes play a role as structural supporting elements within the 
C N S was put forward by Weigert in 1895. He emphasizes that in the CNS, astrocytes 
fill the space that is not occupied by neurons and their processes (Peters, 1991). The 
fibres (microfilaments) in the cytoplasm are believed to confer a certain tensile 
strength and as astrocytes are often firmly bound to each other and to neurons by way 
of tight junctions. They may be regarded as giving structural support to the nervous 
tissue (Smith, 1996). 
c. Graft survival and function 
Responses of astroglia in implanted and host central nervous tissue may be 
important for the survival and function of grafts (Reier et al, 1986). Of interest one 
study showed that radioactivity of fetal grafts prelabeled with tritiated thymidine was 
found in the host CNS indicating immature astroglia or their precursors can migrate 
into adult host central nervous tissue form substantial distances (Lindsay and 
Raisman, 1984). This suggested that immature astroglia in grafts may have some of 
the guidance and trophic functions that they possess during CNS development. 
4 
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d. Blood brain barrier (BBB) 
A barrier exists between the blood and the brain has the function that substances 
circulating in the blood reach equilibrium with the brain tissues at different rates. In 
general, vascular endothelial cells restrict the passage of most polar molecules, 
provide facilitated transport for selected nutrients by membrane-bound carriers and do 
not exclude lipid soluble molecules (Stewart & Coomber, 1986). This B B B limits the 
fluctuations that might occur in the brain. The B B B is provided with specific transport 
systems to allow the C N S to acquire both the nutrients and other substances it needs 
as well as to allow the brain to get rid of potentially toxic metabolites (Murphy, 1993). 
In the brain, astrocytes extend processes, called "end feet" to contact nearby blood 
vessels which is believed to form part of the B B B (Benveniste, 1992). 
e. Repair 
One well-known function of the astrocyte is concerned with repair. Subsequent to 
trauma, astrocytes invariably proliferate, swell, accumulate glycogen and undergo 
fibrosis by the accumulation GFAP. This state of gliosis may be in total, in which case 
all other elements are lost, leaving a glial scar. Or it may be generalized response 
occurring against a background of regenerated or normal CNS parenchyma (Siegel, 
1999). These suggest that astrocytes play important role in the pathophysiology of 
brain injury as well as neurological diseases. 
1.2.2 Oligodendrocyte 
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Oligodendroglial, myelin-producing cells constitute another class of glial cells 
found in the CNS. These cells have fewer processes radiating from the cell body than 
do astrocytes, and the cell body is itself much smaller (c. 5jLim in diameter). 
Oligodendroglia also differs from astrocytes in having few if any microfilaments but 
large numbers of microtubules in their cytoplasm. These cells are found in both the 
grey matter and the white matter. In the white matter, they have very important role of 
investing axons in their myelin sheaths; in the grey matter they may be involved in 
close metabolic interactions with neuronal perikarya (Smith, 1996). 
1.2.2.1 Molecular Markers of Oligodendrocyte 
The oligodendrocye is potentially highly vulnerable to immune-mediated 
damage since its myelin sheath shares with many molecules with known affinities to 
elicit specific T- and B-cell responses. Many of these molecules, such as myelin basic 
protein, proteolipid protein, myelin-associated glycoprotein, myelin/oligodendrocyte 
protein, galactoceramide, myelin oligodendrocyte glycoprotein have been used to 
generate specific antibodies, which are routinely applied to anatomical analysis of 
oligodendrocytes in vivo and in vitro. However, unlike astrocytes, the 
oligodendrocytes express no class I or II major histocompatibility complex (MHC) 
molecules suggestive of interactions with the immune system (Raine et al., 1994). 
1.2.2.2 Functions of Oligodendrocyte 
Oligodendroglia are the myelin-forming cells of the central nervous system, and 
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provide vital support to the propagation of action potentials by axons (Benveniste, 
1992). The role of oligodendrocytes in myelination is supported by the fact that they 
first appear immediately before the time when myelination begins (Skoff, Toland & 
Nast, 1980; Davidson et al., 1989), and the most rapid rate of myelin formation in the 
rat optic nerve is synchronous with the mitotic proliferation and cellular 
differentiation of the oligodendrocyte (Matheson et al., 1970; Skoff, Toland, & Nast, 
1980). Recently, there is evidence supporting the concept that oligodendroglia is the 
cell responsible for myelin sheath maintenance. This observation also indicates that 
while responding to injury, mature oligodendroglia may divide although remaining 
connected to myelin sheaths (Peters, 1991). 
1.2.3 Microglia 
Virtually all body tissues contain cells competent to act as macrophages, and are 
able to recruit bloodbome macrophages. In brain tissue, a cell population termed 
"microglia" has the capacity to carry out phagocytosis after injury (Benveniste, 1992). 
Microglial cells constitute the third major class of glia to be found in the adult 
nervous system. About 5% of the total neuroglial populations were identified as 
resting microglial cells in the white matter (Vaughan and Peters, 1974). A microglial 
cell is generally smaller than either an astrocyte or an oligodendrocyte, and its nucleus 
is usually oval with clumps of chromatin beneath the nuclear envelope and throughout 
the nucleoplasm (Peters, 1991). 
1.2.3.1 Molecular Markers of Microglial Cells 
7 
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While no particularly microglia-specific molecule has been identified, a number 
of antibodies raised against monocytic markers and complement receptor molecules 
stain microglial cells in situ and in vitro. There is strong evidence that microglia 
express class II M H C upon activation (Matsumoto & Ohmori, 1992; Ling & Wong, 
1993), frequently in the absence of a T-cell response. This suggests that class II M H C 
expression may represent a marker of activation, or in some way, elevates the cells to 
a state of immunological awareness. 
1.2.3.2 Functions of Microglial Cells 
The most important function of microglial cells is to serve as the brain's 
macrophage precursors by reacting to injury and diseases (Peters, 1991). During 
trauma, microglia are stimulated and migrate to the area of injury, where they 
phagocytose debris and play a role in inflammatory responses (Siegel, 1999). Also, it 
has been suggested that microglia may help regulate astroglia during development and 
during responses to injury (Peters, 1991). 
1.3 Cytokine and the Brain Injury 
Cytokine has been shown to play an important pathophysiological role in 
inflammatory diseases of the CNS (Rothwell & Hopkins, 1995). Recent studies have 
demonstrated that local synthesis of cytokines by resident cells, including glia, in the 
CNS is initiated in response to TBI (Shohami et al., 1999). 
Cytokines, a diverse group of secreted protein ranging in size from 
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approximately 8-26 kDa, are produced by a wide variety of cell types, including glia 
in the C N S (Bartfai & Schultzberg, 1993; Rothwell et al., 1996). Traditionally, 
cytokines are recognized as playing an important role in the initiation, propagation, 
regulation, and suppression of immune and inflammatory responses occurring in 
peripheral tissues (Glabinski et al., 1995). However, recent studies showed these 
processes also occurred in injured brain (Ghimikar et al, 1998; Shohami et al., 1999). 
Cytokines usually initiate their actions locally by binding to specific cell-surface 
receptors, with dissociation constants for their ligands in the range of M. 
This binding activates intracellular second messenger systems, ultimately leading to 
the effects on the target cell via protein kinase and/or phosphatase pathways. 
1.4 Tumor Necrosis Factor Alpha (TNF-a) 
Among the cytokines, TNF-a has attracted most attention because of its diverse 
actions. TNF-a, originally identified for its ability to cause the necrosis of some 
transplantable tumors, is now recognized to function as a pleiotropic cytokine. It is a 
peptide secreted by macrophages upon stimulation with lipopolysaccharide, an 
endotoxin of Gram-negative bacteria (Beutler et al., 1985). Its gene has been cloned 
in human (Shiga et al., 1991), rat (Estler et al., 1992) and mouse (Pennica et al., 
1985). It is a member of a family of peptide signaling molecules and is synthesized as 
a membrane-bound polypeptide precursor (pro-TNF-a) of 26 kDa. It then undergoes 
proteolytic cleavage to yield the soluble form (17kDa) which forms the active trimer 
polypeptide (Pennica et al., 1985; Vilcek & Lee, 1991). This proinflammatory 
cytokine is produced upon the stimulation, by monocytes, macrophages, T and B-
lymphocytes, neutrophils and mast cells in peripheral tissue and by glia and microglia 
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in the CNS. In the nervous system, this cytokine has been implicated in the 
pathogenesis of several C N S disorders including cerebral ischemia, Pakinson's 
disease, and brain trauma (Taupin et al., 1993; Rothwell and Hopkins, 1995). In 
addition, TNF-a has been shown to cause damage to myelin and oligodendrocytes 
(Selmaj & Raine, 1988) and to induce astrocytic proliferation (Selmaj & Farooq, 
1990), thus probably contributing to demyelination and reactive gliosis during brain 
damage. For example, TNF-a was elevated in the serum and cerebrospinal fluid in 
humans after TBI (Goodman et al., 1990; Ross et al., 1994). TNF-a m R N A and TNF-
a were also elevated after injury in clinically relevant animal models of brain trauma, 
such as closed head impact (Shohami et al., 1994) and lateral fluid-percussion (Taupin 
et al., 1993; Yakovlev & Faden, 1995; Fan et al” 1996). In these models, TNF-a 
increases occurred from 1 to 4 hours after injury. TNF-a has long been postulated to 
contribute to the neuropathology observed after TBI because of its upregualtion 
during inflammatory responses, and strategies to inhibit the actions of TNF-a have 
been developed as a potential treatment for TBI (Morganti-Kossmann et al., 1992). 
However, evidence has also emerged suggesting that TNF-a may be neuroprotective 
after CNS insults (Cheng et al,, 1994; Barger et al, 1995; Bruce et al., 1996; Mattson 
et al., 1997; Liu et al,, 1998). Therefore, whether TNF-a plays a beneficial or 
detrimental influence in the TBI is still controversial. 
1.5 TNF-a Receptor 
The biological activities of TNF-a are mediated through two distinct, high-
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affinity cell surface receptors. TNF receptor 1 (TNF-R 1) and TNF receptor 2 (TNF-
R2), also known as p55 and p75, respectively, have been found in almost all cells 
(Tartaglia et al., 1992). These receptors belong to a super family that includes Fas, 
nerve growth factor receptor, CD30 and CD40. The number of receptors varies from 
about 200 up to 10,000 per cell, and the binding constant is around 2 x 10—川 M. 
Although the presence of the TNF receptor is a prerequisite for biological effect, there 
is no correlation between the number of receptors and the magnitude of the response 
(Vilcek&Lee, 1991). 
The two receptors differ not only in size, but also in their transmembrane and 
cytoplasmic domains. Both have four structural domains: a hydrophobic signal 
sequence, an extracellular cystein-rich domain, a single transmembrane segment, and 
an intra-cytoplasmic domain (Lewis et al., 1991). The two receptors, TNF-R 1 and 
TNF-R2, are 30% homologous in their extracellular domains, with almost no 
homology in their intracellular domains. These receptors do not possess tyrosine 
kinase activity, hence it has been suggested that signal transduction proceeds via 
direct protein-protein interactions with the cytosolic domain of the ligand-occupied 
receptor. Current data support a model that ligand association with the receptors 
results in clustering, which exposes cytosolic receptor domains capable of interacting 
with signaling molecules (Vandenabeele et al., 1995). As the two receptors show 
different extracellular and cytoplasmic domains, this suggests that they utilize distinct 
signaling pathways and have different functions. Indeed, studies with other cell types 
showed that most biological effects like cytotoxicity, were mediated through TNF-R 1, 
while proliferation was mainly signaled through TNF-R2 (Tartaglia et al., 1991). 
1.6 Biological Activities of TNF-a 
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Driven by the imperative of redesigning the cytokine to minimize side effects 
and maximize efficacy as an anticancer agent, several studies have been carried out to 
establish the relationship of the T N F structure to function. Site-directed mutational 
analysis of the TNF-a molecule indicated that multiple sites in the protein interacted 
with the receptor and that the formation of a trimer was obligatory for it to bind to the 
receptor and for cytotoxicity (Van Ostade et al., 1993). Mutagenesis also revealed that 
regions in the TNF-a molecule could be altered to enhance some of its biological 
activities (Xi & Shi, 1996). Later study showed the C-terminal end of TNF-a was 
more critical than its N-terminal end for biological activity (Kircheis et al., 1992). 
At the cellular level, TNF-a has been shown to be capable of regulating 
differentiation, cell proliferation and apoptosis (Fiers et al., 1991). It has been 
demonstrated to function as a mediator in numerous disease states as well as during 
immune and inflammatory responses (Tracey & Cerami，1993). In vitro studies 
showed that TNF-a stimulated acute-phase protein production in the liver (Guy et al., 
1991; Marino et al, 1991), enhanced permeability of the blood-brain barrier (BBB), 
and induced expression of endothelial adhesion molecules and release of 
inflammatory mediators from macrophages, endothelial cells, and glial cells (Briscoe 
et al., 1992; Feuerstein et al., 1994). TNF-a also induced synthesis or gene expression 
of manganese superoxide dismutase in mitochondria (Szuki et al., 1993; Mokuno et 
al., 1994), up-regulated nitric oxide synthetase in endothelial cells (Tureen, 1995), 
and induced growth factors production from astrocytes contributing to neuronal 
survival after insults (Donate et al., 1989; Feuerstein et al., 1994). As stated before, 
TNF-a was one of the pro-inflammatory cytokines elevated in ischemic brain (Liu et 
al., 1994). The above evidence supports the diverse functions of TNF-a; however, the 
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signaling pathway in astrocytes remains unclear. 
1.7 Signaling Mechanism 
Understanding of TNF signaling pathways has been particularly interesting and 
challenging because of the extremely wide varieties of cell-specific TNF responses 
and the lack of similarities with other cell surface receptor signaling pathways. It is 
clear that signaling events of cellular responses to TNF were initiated by the 
interaction between TNF and its receptors (Thomson, 1998). Binding of TNF-a to its 
receptor resulted in various biochemical changes that were important for signal 
transduction. 
1.7.1 Protein Kinase C 
Protein kinase C (PKC) comprises at least nine isoforms probably with subtly 
different activation requirements and substrate specificities (Nishizuka, 1988; Ohno et 
al., 1991; Krizbai et al., 1995). All of them possess regulatory and catalytic domains, 
with a site between them that is susceptible to proteolytic cleavage. C1-C4 are regions 
of conserved amino acids, VI-V5 are variable regions (contains the site of proteolytic 
cleavage) from N-terminal regulatory domain (Hug & Sarre, 1993). In the a, pi, p2, 
and Y species of PKC all these regions are present, whereas in PKC 5, s and C^  the C2 
sequence is absent. These subtle differences in amino acid sequence may give rise to 
different regulatory properties and different substrate specificities for these enzymes. 
These serine/threonine-specific protein kinases are important regulators of cell 
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proliferation and differentiation (Clements, 1991). 
The hydrolysis of the membrane phospholipids such as phosophatidylinositol 
4,5-bisphosphate (PtdIns(4,5)P2) by phospholipase C generates two biologically 
active molecules, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Bell & 
Bums, 1991; Gschwendt et al； 1991; Zidovetzki & Lester, 1992). Both IP3 and D A G 
act as second messengers and play major roles in regulating intracellular calcium 
levels and in activating PKC, respectively. 
The ability of D A G to activate P K C can be mimicked by tumor promoters, of 
which the phorbol esters including PMA, are the most widely studied examples. This 
suggests that P K C activity is involved in regulating cell growth, and that, perhaps, 
abnormal control of PKC function can contribute towards the development of tumor 
cells. 
1.7.2. Protein Kinase A (VKA^ 
The best-characterized second messenger system in mammalian cells is the well-
known adenylate cyclase/3,5,-cyclic adenosine monophosphate (cAMP) pathway. 
cAMP-depcndenl protein kinase A (PKA) mediates a wide variety of 
serine/lhreonine-specific protein phosphorylation events, directly or indircclly 
(Clemens, 1991). The wide range of PKA substrates explains why ligands thai 
activate or inhibit adenylate cyclase (via stimulatory or inhibitory G proteins) have so 
many diffcrenl cffecls, and is perhaps a precedent for understanding the multiple 
effects of other cytokines that use alternative pathways. Surprisingly, few cytokines 
appear to act directly through cAMP as a second messenger, with the possible 
exception of interleukin-l (IL-1) (Clemens, 1991). However, there is evidence for 
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regulation of the adenylate cyclase system by other cytokine-responsive pathways 
(e.g. by P K C that is activated by binding of various cytokines to their receptors). 
Conversely, P K A can phosphorylate and regulate proteins involved in other signal 
transduction mechanisms. 
3'5'-cyclic guanosine monophosphate (cGMP) has a much more restricted 
second messenger role than cAMP. It is synthesized by guanylate cyclase and 
removed by phosphoesterase-catalyzed hydrolysis to 5' GMP. As yet there are only a 
few reports suggesting possible involvement of c G M P in cytokine-stimulated signal 
transduction systems (Clemens, 1991). 
1.7.3 p38 Mitogen Activated Protein Kinase (p38 MAPK^ 
Gene induction by cellular stresses is mediated through biochemical processes 
that mostly involve the interplay of multiple signaling pathways. Depending on the 
nature of the stimulus, intricate protein kinases are activated that ultimately 
phosphorylate transcription factors and result in gene expression. In recent years, an 
effort has been mounted to delineate the intracellular signaling cascades in cells that 
mediate inflammation. Much attention has been given to the mitogen-activated 
protein kinase (MAPK) superfamily due to their consistent activated by pro-
inflammatory cytokines, and their role in nuclear signaling (Cobb et al., 1995; Davis 
et al, 1995). Four distinct subgroups within the M A P K family in mammalian cells 
have been described. These include (1) extracellular signal-regulated kinase (ERK); 
also referred to as p42/44 M A P K ) (Cobb et al, 1991), (2) c-jun N-terminal or stress-
activated protein kinases (JNK/SAPK) (Davis et al., 1994), (3) ERK5/big M A P 
kinase 1 (BMKl) (Zhou et al., 1995), and (4) the p38 group of protein kinases (Han & 
15 
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Lee, 1994; Rouse et al., 1994). The mammalian ERKs are activated by growth factors 
and mitogenic stimuli (Karin et al, 1995) whereas p38 and INK are regulated by 
stress-inducing signals including U V irradiation, heat shock, osmotic stress, bacterial 
lipopolysaccharide (LPS) and by proinflammatory cytokines such as IL-1 and TNF-a 
(Han & Lee, 1994; Raingeaud & Gupta，1995; Herlaar & Brown, 1999). At the same 
time, p38 M A P K might play its action partly through the regulation of 
proinflammatory molecules, since intervention of the p38 M A P K pathway by its 
selective inhibitors or genetic means prevented the expression of cytokines including 
IL-1, IL-6 and TNF-a (Lee et al., 1994; Wysk et al, 1999). 
Activation of p38 follows a distinct protein kinase cascade in which the upstream 
activator of p38 is classified as a M A P K kinase (MKK). For example, M K K 6 , 
M K K 4 , M K K 3 and MKK3-b are dual specificity kinases that phosphorylate p38 on 
both Thr and Tyr in the activation loop (Raingeaud & Gupta, 1995) and have been 
shown in vivo and in vitro to be direct upstream activators of p38 (Cobb & Goldsmith, 
1995; Hanks & Hunter, 1995). Once activated, p38 phosphorylate several 
transcription factors such as activating transcription factor-2 (ATF-2) (Raingeaud & 
Gupta, 1995), growth arrest and D N A damage (CHOP/GADD153) (Wang & Ron, 
1996), and NF-KB (Zechner et al., 1998). Activation of these transcription factors by 
p38 M A P K induces the expression of various genes, including many proinflammatory 
cytokines (Beyaert et al., 1996; Matsumoto et al,, 1998), inducible nitric oxide 
synthase (Da Silva et al., 1997), E-selectin (Read et al” 1997), and vascular cell 
adhesion molecule-1 (Pietersma et al., 1997). 
p38 was originally identified in LPS-stimulated mouse macrophages and was 
found to have substantial homology to the Saccharomyces cerevisae H O G I kinase 
(Han et al, 1995). The human homologues of p38 has been cloned and identified with 
16 
A 
— I n t r o d u c t i o n 
a radiophotoaffinity-labeled pyridinyl imidazole compound (Lee and Lay don, 1994). 
Several isoforms of p38 M A P K (now referred to as p38 a) (Han et al., 1994; 
Wang & Diener, 1997; Keesler & Bray, 1998) have been identified: p38 P shows 74% 
amino acid identity to p38 a (Jiang et al., 1996); p38 y is 60% identical to p38 a 
(Lechner et al., 1996; Li & Jiang, 1996). p38 5 has 57% identical to p38 a (Jiang & 
Gram, 1997; Wang et al, 1997;). All four members differ in their substrate 
preference, activation modes, and responses to inhibitors (Goedert et al., 1997; Wang 
et al., 1997). Among the four p38 isoforms, p38 a and p38 (3 are inhibited by the 
pyridinyl imidazoles, SB203580 and SB202190 (Goedert et al” 1997) by binding 
specifically to the ATP pocket of p38 M A P K (Tong & Pav, 1997; Young et al., 1997; 
G u m & McLaughin, 1998). 
p38 M A P K was more abundantly expressed in brain than in peripheral tissues 
(Jiang et al., 1996). The two p38 M A P K isoforms, p38 a and p38 p are the major 
forms of p38 M A P K s in the brain (Lee & Park, 1999, 2000). The p38 a and p38 p 
genes are ubiquitously expressed (Jiang et al., 1996). However, p38 y and 5 are 
differentially expressed in different tissues--p38 y is predominately expressed in 
skeletal muscle (Lechner et al., 1996; Li & Jiang, 1996) and p38 5 is enriched in lung, 
kidney, testis, pancreas and small intestine (Kumar et al” 1997). Moreover, p38 y 
expression was reported to be induced during muscle differentiation and p38 6 
expression was shown to be developmentally regulated (Lechner et al., 1996; Hu & 
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1.7.3.1 Biological Activities ofp38 MAPK 
1. p38 M A P K and Cell Signaling 
In addition to p38 M A P K effects at the cellular level, p38 M A P K also assists in 
coordinating responses to stresses at the tissue and organ level via modulating the 
production of cytokines, catecholamines, and nitric oxide (NO). In many of these 
pathways, p38 M A P K functions both in the generation of, and subsequent 
intracellular responses to, the signal. 
a) Adrenergic Signaling 
p38 M A P K is involved in the cellular responses to adrenergic signaling since it 
is activated upon a 1-adrenergic (Suzuki & Palmer, 1999; Zhong & Minneman; 1999) 
and (3-adrenergic receptor occupancy (Moule & Denton, 1998). In chromaffin and 
pheochromocytoma cells, the p38 M A P K enhances catecholamine biosynthesis by 
phosphorylation and activation of tyrosine hydroxylase (Sutherland & Campbell, 
1993; Thomas & Haavik, 1997; Zaheer & Lim, 1998), a very early and rate-limiting 
step in the catecholamine synthetic pathway. This suggests that this kinase regulate 
catecholamine synthesis in these cells. 
b) Cytokine Signaling 
p38 M A P K plays a similar dual role in the generation of and cellular responses 
to certain cytokines. It has been recognized in the production of cytokines, such as 
TNF-a and IL-lp (Lee & Laydon, 1994; Perregaux & Dean, 1995), IL-4 (Schafer & 
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Wadsworth, 1999). IL-6 (Beyaert et al., 1996), IL-8 (Marie et al., 1999), and IL-12 
(Lu & Yang, 1999). p38 M A P K is also critical for cell responses to certain cytokines. 
For example, treatment of human neutrophils with GM-CSF (but not G-CSF), TNF-a 
or TGF-P results in p38 M A P K activation (Hannigan & Zhan, 1998; Suzuki & Hino, 
1999). GM-CSF and TNF-a are potent enhancers of neutrophil respiratory burst 
activity, while G-CSF is a very weak enhancing agent, suggesting a role for p38 
M A P K in respiratory burst activity (Lai & Clifton, 1999; Yaffe & Xu, 1999). 
c) Nitric Oxide (NO) Signaling 
p38 M A P K is involved in the generation of N O at two points. First, the p38 
M A P K pathway can enhance N O production by increasing the intracellular 
concentration of substrate for N O synthase via stimulation of arginine transporter 
activity (Caivano et al； 1998). Second, p38 M A P K activity is required for increased 
gene expression of the inducible form of N O synthetase (iNOS) (Guan & Baier, 
1997). p38 M A P K may also be involved in the transduction of N O signaling. 
Activation of p38 M A P K in human neutrophils following LPS stimulation is 
attenuated by inhibitors of N O synthetase and by N O scavengers, whereas treatment 
with N O releasing agents increased p38 phosphorylation (Browning & Windes, 
1999). 
2. p38 M A P K in Cell Cycle Control 
The involvement of p38 a M A P K in cell growth became apparent when it was 
noticed that overexpression of p38 a M A P K in yeast led to significant slowing of 
19 
A 
— I n t r o d u c t i o n 
proliferation and a slower proliferation of cultured mammalian cells was observed 
when the cells were treated with SB 203580, a selective inhibitory of this kinase 
(Zieger-Heibrock et al., 1992). Recently, a study has reported that p38 a M A P K was 
activated in mammalian cultured cells when the cells were arrested in M phase by 
disruption of the spindle with nocodazole (Takenaka & Moriguchi, 1998). 
3. p38 M A P K and Cell Differentiation 
p38 a and/or p38 p were found to play an important role in cell differentiation for 
several different cell types. The differentiation of 3T3-L1 cells into adipocytes and the 
differentiation of PC 12 cells into neurons both require p38 a and/or p38 p (Engelman 
& Lisanti, 1998; Morooka & Nishida, 1998). The p38 M A P K pathway was found to 
be necessary and sufficient for SKT6 differentiation into haemoglobinised cells as 
well as C2C12 differentiation into myotubes (Zetser & Gredinger, 1999). The 
transcription factors e.g., CREB and c-fos have suggested to be the downstream of the 
p38 M A P K pathway and participate in the differentiation process described above. 
1.7.4 Inducible Nitric Oxide HNOS� 
Nitric oxide (NO) is a short-lived and highly reactive free radical that mediates a 
wide range of biologic effects. It acts as an intercellular messenger and plays a role in 
neurotransmission, antimicrobial defense, and vascular homeostasis (Nathan et al., 
1992; Moncada & Higgs, 1993). The enzyme responsible for the N O synthesis, nitric 
oxide synthase (NOS), which convert the L-arginine to L-citmlline and NO. It has 




neuronal N O S (nNOS), the third isoforms of N O S is inducible (iNOS). The iNOS 
expressed in various types including smooth muscle cells, macrophages, 
keratinocytes, hepatocytes and brain cells are induced in response to a series of 
proinflammatory cytokines including bacterial LPS during infection, or during 
ischemic events via TNF-a, IL-lp and IFN-y (Leone & Palmer, 1991; Assreuy & 
Cunha, 1993). 
Little is known about the intracellular signaling pathways of iNOS induction in 
astrocytes. Studies with various immune cell systems have suggested that the 
regulation is complex and contains multiple factors, such as NF-KB (Xie & 
Kashiwabara, 1994; Nishiya & Ueham, 1995;)，inhibitory-KB (IKB) (Young & Yang, 
1996), P K C (Diaz-Guerra et al, 1996; Chen & Wang, 1998) and p38 M A P K (Guan & 
Baier，1997; Bhat & Zhang, 1998; Chan & Winston, 1999;). Whether these pathways 
are also involved in astrocytes remain to be elucidated. 
1.7.5 cAMP-Responsive Element Binding Protein rCREB) 
The cAMP-responsive element binding protein (CREB) is a 43-kDa protein that 
has been implicated in the transcriptional control of many genes, in particular those 
that are rapidly induced by elevation in cytoplasmic c A M P or calcium. Although 
CREB is normally expressed at high levels, its activity at the Ca^VcAMP-responsive 
element (CRE) is dependent on phosphorylation at Ser^ ^^  (Walton et al., 1999). The 
mechanism by which Ser^ ^^  phosphorylation activates CREB remains unclear; 
however, it has been suggested that this modification induces a conformational 




al., 1991; Brindle et al., 1993). Alternatively, phosphorylated C R E B (pCREB) which 
may enhance transcription via recruitment of coactivators, such as C R E B binding 
protein (Chrivia et al., 1993; Arias et al., 1994; Kwok et al, 1994). 
The active form of C R E B regulates many aspects of neuronal functioning, 
including excitation of nerve cells (Moore et al” 1996), circadian rhythms (Ginty et 
al., 1993), C N S development (Imaki et al., 1994), pituitary proliferation (Stmthers et 
al., 1991) and long-term memory formation (Silva et al, 1998). 
Recently, C R E B is believed to be one of the potential candidates that are 
activated in reactive glial cells. It has shown that kainate-induced neuronal injury 
leads to persistent phosphorylation of C R E B in glial and endothelial cells in the 
hippocampus (Ong & Lim, 2000), and that the phosphorylated C R E B (pCREB) could 
drive the expression of downstream genes in these cells to promote cell proliferation 
and survival (Walton et al., 1996). Since TNF-a was found to activate CREB 
expression (Jomot & Peterson, 1997; Pan & Xia, 1998), it is important to characterize 
the signaling pathway mediating the TNF-a proliferative action in astrocytes as well 
as C6 cells. 
Upon activation of distinct intracellular signal transduction pathways, kinases 
such as P K A (Gonzalez & Montminy 1989), Ca^^/calmodulin-dependent kinase IV 
(CaMKIV) (Sun et al., 1994), Ras-dependent protein kinase (RSK2)(Xing et al., 
1996), p38 M A P K (Tan et al., 1996; Deak et al., 1998) are able to phosphorylate 
Ser ‘ of CREB. The phosphorylated CREB protein then binds to CREB-binding 
protein (Chrivia & Knok, 1993; Kwok & Limdblad, 1994), and this complex is 
thought to induce transcription genes encoding for the brain-derived neurotrophic 
factor (Shieh & Ghosh, 1999), which might mediate some aspects of neuroprotection, 
and the induction of anti-apoptotic gene bcl-2 (Pugazhenthi et al., 1999). 
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Furthermore, pCREB was shown to activate genes containing CRE sequences, such as 
tyrosine hydroxylase (Kim & Lee, 1993), enkephalin (Kobierski & Wong, 1999), 
somatostatin (Gonazalez & Montminy, 1989), vasoactive intestinal peptide (Deutsch 
& Hoeffler, 1988; Bito et al., 1996), and downstream genes such as c-fos (Liu & 
Graybriel 1996). These suggest the diverse effects including proliferative action of 
C R E B in cells. 
1.7.6 Transcription Factor c-fos 
The genes whose transcription is activated transiently and rapidly within minutes 
of stimulation (Greenberg et al., 1985; Morgan & Curran, 1986; Bartel et al, 1989) 
are termed the cellular immediate early genes (lEGs). The c-fos protooncogene was 
among the first lEGs to be identified (Kelly et al., 1983; Greenberg & Ziff, 1984). In 
general, lEGs share some characteristics that their expression is low or undetectable 
in quiescent cells, but is rapidly induced and the transcriptional level within minutes 
of extracellular stimulation. This transcriptional induction is transient and independent 
of protein synthesis, while the subsequent shut-off of transcription requires protein 
synthesis. The m R N A s transcribed from these genes often have a very short half-life 
(in the case of c-fos, approximately 10-15 minutes). This tightly controlled expression 
of lEGs suggests a role for their protein products in the cellular response to external 
stimuli (Morgan et al., 1990). The lEGs encode proteins whose structures fall into a 
number of distinct classes. In neurons, they are rapidly induced in response to 
synaptic activity, and can bind to specific sites in the genome to modulate the rate of 
transcription of downstream genes (Morgan et al., 1987; Sheng & Greenberg, 1990). 
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Induction of lEGs is likely to provide a link between events at the cell membrane and 
long-term alternations in neuronal gene expression. 
In the nervous system, induction of c-fos and its product protein, c-FOS, has 
been investigated in focal ischemia in the cerebral cortex in rats (Uemura & Kowall, 
1991; Gass & Spmnger, 1992). Recently, a study showed that early c-fos induction 
after cerebral ischemia might account for neuroprotection by means of up-regulating 
late gene expression for survival (Cho & Park, 2001). 
Moreover, this transcription factor has been reported to be activated by TNF-a 
(Lin & Vilcek, 1987), and there are reports suggesting that c-fos plays a key role in 
the control of intracellular modifications leading to cell proliferation (Greenberg & 
Ziff, 1984; Fisch et al., 1987; Bravo et al., 1987; Condorelli et al., 1989) and 
differentiation (Gubits et al., 1988; Bardoscia et al., 1992; Didier et al., 1992). 
However, the relationship between TNF-a and c-fos induction in astrocytes remained 
unclear. 
Recently, induction of the c-fos proto-oncogene has been linked to specific signal 
transduction pathways involving either CREB kinase or M A P K phosphorylation 
(Marais et al., 1993; Ghosh et al., 1994; Xing et al., 1996; Ahn et al., 1998). Also, 
LPS administration could induce c-fos through M A P K and resulting in the activation 
of the transcription factor AP-1 (Han & Ulevitch, 1997; Hazzalin et al., 1997). 
Whether similar picture occurs in astrocytes is still unknown. 
1.7.7 Nuclear Factor Kappa-B (NF-KB) 
Association of the inflammatory cytokines, such as TNF-a and IL-1, with their 
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respective cell surface receptors trigger intracellular signal transduction cascades that 
may culminate in gene activation (Aggarwal & Damay, 1998; Auron et al., 1998). 
Among the events leading to enhanced gene expression by these cytokines is the 
activation of ubiquitous expressed NF-KB, a transcription factor which is important in 
the regulation of genes involved in immune and inflammatory responses in many cell 
types. Conventional NF-KB is a heterodimer that consists of p50 and p65 subunits. 
The activity of NF-KB is strictly regulated by one of the IKB inhibitory proteins, such 
as IKBOC or IKB|3, which forms a complex with NF-KB and keeps NF-KB in the 
cytoplasm (Baldwin & Ito, 1994; Siebenlist & Franzoso, 1994). When cells receive 
signals that activate NF-KB, IKBS are phosphorylated and degraded through a 
ubiquitin/proteasome pathway (Tanaka et al., 2001). Coincident with IKB 
degradation, activated NF-KB translocates to the nucleus where it binds to specific KB 
D N A consensus sequence located in the enhancer region of target genes and 
participates in the trans activation of a variety of genes, including manganese 
superoxide dismutase (MnSOD) (Das et al., 1995; Wong et al., 1995) and calbindin 
(Mattson et al； 1995). 
Interesting observations linking cytokines and NF-KB have been reported, and 
these include the increase in production of IL-1 and, TNF-a occurred after brain 
injury could activate NF-KB, and this leads to induction of the expression of a range 
of pro-inflammatory genes (Salminen & Liu, 1995; Bowie & Moynagh, 1996). 
Previous work has showed that TNF-a induced NF-KB is necessary for cell survival 
(Beg & Baltimore, 1996; Liu & Hsu, 1996; Van Antwerp & Martin, 1996; Wang & 
Mayo, 1996). These suggest that TNF-a and NF-KB play important roles m the 
pathophysiology of and recovery after brain injury. Activation of NF-KB in many cell 
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types is a PKC-dependent process (Shirakawa & Mizel, 1989). Instead, a variety of 
evidence suggests that p38 M A P K plays a key role in regulating anti-apoptotic effects 
and cell proliferation (Craxton & Shu, 1998; Roulston & Reinhard, 1998; Rausch & 
Marshall，1999). Moreover, some studies (Liu & Fan，1999; Liu & Fan, 2000) have 
showed that activation of both NF-KB and p38 M A P K are required for TNF-a-
induced cell proliferation, and activation of p38 M A P K has a critical role in the 
expression of KB-driven genes, thus, providing the linkage of activation of p38 
M A P K and NF-KB with TNF-a-mediated cell survival and proliferation. The 
relationship between these three parameters in astrocytes and C6 cells remains to be 
established. This is of particular importance as astrocytes are activated in brain injury. 
1.8 Brain Injury, Astrogliosis and Scar Formation 
i 
In the mammalian CNS, traumatic injury leads to changes in shape and morphology 
of astrocytes and the process is known as reactive astrogliosis (gliosis). In this 
process, astrocytes undergo hypertrophy of cell bodies, in which nuclei and numerous 
thicker cytoplasmic processes appear (Eng, 1987; Norton et al., 1992; Norenbery, 
1994) and an elevated expression of GFAP is observed (Bignami & Dahl, 1976; 
Norton et aL, 1992; Hausmann & Riess, 2000), Moreover, angiogenesis and 
hypertrophy of vascular endothelium, and the invasion of fibroblasts which deposit 
extracellular collagen fibres are frequently observed. Collectively, these cellular 
changes constitute the "glial scar" (Sutin & Griffith, 1993). The glial scar that result 




1986). Astrogliosis is usually assumed to be a stereotypic response of astrocytes to 
insult. Recent studies have demonstrated the biochemical and functional heterogeneity 
of reactive astrocytes depending on the location or the kind of injury (Norton et al., 
1992; Hoke & Silver, 1994; Schroeter et al., 1995; Hill et al., 1996). A variety of 
substances, such as neurotransmitter (for example, noradrenaline/adrenaline), growth 
factor (for example, transforming growth factor) and cytokines (for example, TNF-a) 
may influence the astroglial response. Interestingly, recent study found that specific 
P K C isoforms plays a differential role in the proliferation of glial cells and the 
expression of the astrocytic markers, GFAP and glutamine synthase (Brodie & 
Kuperstein, 1998). 
As stated before, astrocytes can be activated in vivo to secrete a number of 
cytokines (Benveniste, 1992) some of which are involved in tissue repair, for 
example, IL-6 enhances the expression of nerve growth factor, and TNF-a which can 
initiate gliosis. Indeed, TNF-a in bacterial meningitis (Beutler et al, 1989) and IL-6 ‘ 
following trauma (Hariri et al., 1994) results in tissue injury and cerebrovascular 
dysfunction with the breakdown of the blood brain barrier. This suggests that over-
production of cytokines by the astrocytes may be involved in the development of 
brain damage and the blockade of the elevated production of cytokines by 
pharmacological inhibitors may prevent tissue injury to the brain. For example, Thery 
et al. (1994) reported that isoproterenol, an p-adrenoceptor agonist, provided a 
significant inhibition of macrophage neurotoxicity within the brain. 
With reference to (3-adrenergic mechanism, some studies have revealed that 
extracellular noradrenaline concentration is transiently increased after brain ischemia 
as revealed by microdialysis (Globus et al” 1989; Gustafson et al., 1991). The source 
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of noradrenaline was suggested to be released from the nerve terminals under 
ischemic conditions (Santos et al,, 1996). p-AR, one of the targets of endogenous 
noradrenaline, is widely expressed within the CNS (Alexander et al, 1975), including 
astrocytes (Salm & McCarthy, 1992). These studies have provided evidence that (3-
A R plays an important role in developing controlling reactive gliosis. 
1.9 B-Adrenergic receptor fB-AR) 
It has been established that astrocytes grown in primary culture can express p-
ARs (Stone and Ariano, 1989). p-ARs have been subdivided into at least three distinct 
pharmacological and molecular subtypes: pi-, |32- and p3-ARs and functionally 
expressed in mammals (Johnson, 1998). All three subtypes belong to the superfamily 
of receptors coupled to G proteins, characterized by an extracellular glycoslated N-
terminal and an intracellular C-terminal region and seven transmembrane domains, 
linked by three extra- and three intra-cellular loops. It is composed of 413 amino acid 
residues of approximately 46 kDa (Strosberg, 1995). 
The functional response produced by the receptor depends on subsequent 
interactions between these three components: (1) the catecholamine binds to the 
receptor and converts it to its active form; (2) the activated receptor interacts closely 
with the G protein, which in turn becomes active; (3) lastly, the activated G protein 
activates the enzyme adenylate cyclase. This then converts ATP to cAMP, which acts 
as an intracellular second messenger (De Blasi, 1990). 
Of the P-receptors, (31-ARs are predominately found in the heart and in the 
cerebral cortex, whereas |32-AR predominate in the lung and cerebellum. However, in 
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many cases, both (31- and P2-AR coexist in the same tissue, sometimes mediating the 
same physiological effect (De Blasi, 1990). 
The first description of P3-AR in humans was by the positive polymerase chain 
reaction (PGR) procedure which revealed production of P3-specific m R N A in fat and 
in gut, but nowhere else (Strosberg, 1995). This p3-AR m R N A was often, but not 
always，associated with the brown adipose tissue marker-uncoupling protein 
(Strosberg, 1995). 
1.9.1 Functions of (3-ARs in astrocytes 
a) Regulation of Cytokine Gene Expression 
Nakamura et al. (1998) reported that P-AR plays a role in modulating TNF-a and 
i 
IL-6 gene expression in the rat astrocytes. P2-AR, but not Bl-AR activation 
！ 
suppressed LPS-induced TNF-a and IL-6 gene transcription and their respective 
m R N A accumulation. ; 
Recent studies have shown that isoproterenol, an p-adrenoceptor agonist, could 
induce a significant inhibition of macrophage neurotoxicity within the brain (Thery et 
a/., 1994). Also, some studies have demonstrated that the isoproterenol could suppress 
TNF-a m R N A and secretion especially via its p2-adrenergic activity in amoeboid 
microglial cell (Hetier et al., 1991), THP-1 cells (Severn et al., 1992) and IL-6 
secretion in the spleen (Straub et al., 1996). These suggest that interaction exists 
between TNF-a and P-adrenergic mechanism in many cell types. However, the 
signaling pathway mediating this interaction remains to be established. 
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b) P-AR Expression in Reactive Gliosis 
Recent studies have provided evidence that P-AR plays an important role in 
developing reactive gliosis (Sutin & Griffith，1993; Mantyh et al, 1995). As stated 
before, astrocytes grown in primary cultures can express P-adrenergic receptors 
(Stone et al., 1989; Salm & McCarthy, 1992; Sutin & Shao，1992). For example, optic 
nerve crush could increase P2-AR in astrocyte density (Mantyh et al., 1995), and 
infusion of an P-AR antagonist attenuated the hypertrophic change and proliferation 
of astrocytes (Hodges Savola et al., 1996). P-AR antagonists also suppressed the 
hypertrophy and the increase in GFAP after sciatic nerve injury (Sutin & Griffith, 
1993). Additionally, an increase in p2-AR-like immunoreactivity was more prominent 
compared with pi-AR-like immunoreactivity (Sutin and Shao, 1992; Mantyh et al., 
1995; Imura et al., 1999) in the crushed optic nerve. This suggests a differentiation 
role of these two subtypes in this process. 丨 
t 
c) P-AR Agonist Regulate Cell Differentiation and Proliferation 丨 
1 
In addition, P-AR stimulation can change the shape of cultured astrocytes 
from a fibrous to a satellite form and this morphological change is related to heat 
shock protein 27 (HSP27) (Imura et al., 1999). Supporting this notion is the finding 
that isoproterenol increase HSP27 expression in astrocytes (Wagstaff et al., 1996). 
The formation of reactive astrocytes in vivo seems to depend on the overexpression 
and reorganization of cytoskeletal proteins such as GFAP and actin (Imura, 1999). 
Apart from this, recent studies have demonstrated that small HSPs can modulate not 
only GFAP assembly (Nicholl & Quinlan, 1994), but also actin microfilament 
dynamic (Lavoie et al., 1993). By phosphorylating the non-a-helical head domains of 
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the receptor (McCarthy et al, 1985; Ralton et al., 1994), P-AR activation was 
observed to increase the synthesis of GFAP (Segovia et al, 1994) and also to regulate 
GFAP assembly. These studies indicate that P-AR activation and an increase in 
HSP27 may play an important role in cytoskeletal reorganization and gliosis observed 
after ischemic injury. 
d) P-AR Blockade Suppresses Glial Scar Formation 
Some studies have suggested that P-AR activation is an essential step in astrocyte 
scar formation. Recently, a report by Sutin & Griffith (1993) reported that the 
continuous systemic administration of P-antagonist, propranolol for 7 days from the 
time of injury greatly reduced the intensities of GFAP-immunoreactivity following 
ricin-induced motor neuron degeneration in the rat spinal cord. This suggests that glial 
scar formation and astrocyte hypertrophy is attenuated in vivo by P-adrenergic 
antagonists. Another study by Hodges-Savola et al. (1996) also demonstrated that 
propranolol infusion directly diminished the extent of crush-induced changes in optic 
nerve GFAP immunofluorescence and that the P-antagonist attenuated the 
concomitant increase in cell number within injured nerves. Taken together, these 
reports suggest that P-adrenergic mechanism involved in the regulation of astrogliosis 
after CNS damage has occurred. 
1.10 Why do We Use C6 Glioma Cells? 
The term glioma describes the group of glial neoplasma including astrocytoma, 
glioblastoma, ependynoma, oligodendroglioma and mixed gliomas, such as 
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oligoastrocytoma. Glioma cells are particularly easy to grow in tissue culture 
(Westermark et al., 1973). Although they may not be "perfect" representatives in all 
aspects of glial cells in vivo, the relative ease with such cell lines can be established 
has made them widely used as a model system for studies on the biology of glial cell. 
A number of rat brain tumors can be induced by N-nitrosomethylurea, and some of 
the more or less differentiated astrocyte-like cells are found to contain S-100 protein, 
a characteristic protein of glial cells. It was shown that injection of newborn rats with 
these cultured tumor cells resulted in a high efficiency of tumor formation (Benda et 
a/., 1968). Five morphologically distinct clonal cell strains were established from 
these tumors, only one contains appreciable amounts of S-100, and this is the C6 
glioma cell line (Benda et al., 1968). 
C6 Glioma cells have provided a useful model to study glial cell properties, glial 
factors and sensitivity of glial cells to various substances and conditions (Kempski et 
al’, 1992; Vemadakis et ah, 1992). As a kind of transformed cell line, the growth 
characteristics of C6 cells are immortal, anchorage independent, loss of contact 
inhibition, high plating efficiency and shorter population doubling time. In addition to 
its homogenous genetic properties, C6 cells are tumorigenic and angiogenic 
(Freshney, 1987). C6 Cells express several glial specific markers, such as S-100, 
GFAP and GS, the markers for astrocytes, as well as CNP, an enzyme marker for 
oligodendrocytes (Kempski et al., 1992; Vemadakis et al., 1992). Moreover, the 
expression of activity of in C6 cells could be induced. For instance, CNP is induced 
by neuron-derived factors, epidermal growth factor and fibroblast growth factor, 
whereas GFAP and GS are induced by insulin, cyclic AMP, platelet-activating factor, 
muscle-derived factors, chronic |3-receptor activation and interleukin-4 (IL-4) (Parker 
et al, 1980; Brodie & Vemadakis，1991; Brodie & Goldreich, 1994). Interestingly, 
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cytokines are known to be involved in astrocytic and oligodendrocytic property 
expression in C6 cells of early passages (Brodie & Goldreich, 1994). 
C6 Glioma cells have been found to respond to several cytokines, such as TNF-
a, IL-6, interferon-y (IFN-y) and IL-4. The growth of C6 glioma cells is stimulated by 
the TNF-a, IL-6 and IFN- (Munoz-Femandez et al., 1991; Munoz-Femandez & 
Fresno, 1993). In addition, IL-4 exerts a biphasic effect on C6 cell proliferation, 
increasing cell proliferation at concentrations ranging from 10-50 ng/ml, while 
exhibits inhibitory effect at higher concentrations (Brodie & Goldreich, 1994). The 
inhibition of cell proliferation is associated with differentiation of the cells to express 
astrocytic phenotypes as evidenced by morphology, increased GFAP 
immunoreactivity and elevated GS expression (Brodie & Goldreich, 1994). IL-4 also 
induced the secretion of nerve growth factor in C6 glioma cells (Brodie & Goldreich, 
1994). 
The rat C6 glioma cell line has an (3-aderenoceptor (P-AR) population (pi and 
P2 subtypes) that is tightly coupled to the Gs-cAMP-dependent pathway and provides 
a suitable model system for the general study of intracellular P-AR-mediated signal 
transduction events (Fishman & Mallorga, 1981; Kassis & Zaremba, 1985; Fitzgerald 
& Li, 1996). Furthermore, C6 glioma cells express the receptors and effector coupling 
machinery for both 5-hydorxytryptamine-mediated (Bartrup & Newberry, 1994; 
Elliott & Newberry, 1995) mitogen-induced signaling (Pasumarthi & Jin, 1997) 
offering further opportunities to explore the potential for drug-induced multiplex 
signaling lying downstream of the P-AR binding sites. Furthermore, an effect of P-AR 
stimulation on either a decrease or increase in M A P K kinase activity has been 
reported in PC-12 cells (Frodin & Peraldi, 1994) and a finding that has also been 
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demonstrated that in adult mouse cardiac myocytes (Zheng and Zhang, 2000). In the 
latter, P2-AR stimulation by isoproterenol induced a time- and dose-dependent 
increase in p38 M A P K activation. This is of considerable interest since a large 
fraction of P-ARs are present on glia rather than neurons in the brain (Stone & 
Ariano, 1989), and that the relationship between p-adrenergic mechanism and p38 
M A P K in astrocytes remains to be elucidated. These observations suggest that the C6 
cell line represent a good cell model for the study of the proliferation and 
differentiation of glial cells in vitro. 
1.11 Fluorescent Differential Display (FT^m 
Many techniques have been developed to distinguish the difference in m R N A 
transcription in different cell types or in cells grown under different conditions. These 
include the subtractive hybridization (St. John et al., 1988; Ermolaeva et al., 1996; 
I 
Swendeman et al., 1996) and differential hybridization (Marley & Robinson, 1994). 
Major disadvantages of these approaches are that they are technically very 
demanding, time-consuming and require large amounts of RNA, and only a limited 
number of specific genes can be isolated in each system (Poirier et al., 1999). 
Recently, a powerful new differential display technique has been employed 
which based on the assumption that virtually every m R N A expressed in a cell can be 
detected on gels by reverse transcription (RT) followed by polymerase chain reaction 
(PCR) reamplification (Liang & Pardee, 1995). This method is rapidly replacing 
conventional methods of identification of the differentially expressed gene because it 
has proved to be highly effective and efficient in identifying genes that are 
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differentially expressed in various cell types and especially for genes with low 
abundance (Bauer & Muller, 1993; Liang and Bauer, 1995). Differential display 
involves isolation of high-quality nondegraded RNA, selective reverse transcription 
(RT) of polyadenylated m R N A using specific anchored oligopolydeoxythymidine 
[oligo(dT)] primers, and the subsequent PGR amplification of the c D N A with the 
same oligo(dT), an arbitrary upstream primer and radioisotopes for labeling the PGR 
products. The radioisotopically labeled products are then separated on a separating gel 
(Susan al, 1997). 
Since its first publication, this novel method has undergone several modifications 
and an alternative approach; fluorescent differential display (FDD) has been emerged 
(Ito et al, 1999). In this approach, after first-strand c D N A synthesis with the 
anchored primers (AP) has been completed, aliquots of these reactions are subjected 
to PGR amplification using the fluorescently tagged version of the original AP in 
combination with a second unlabelled, arbitrary primer (ARP). ARPs contain 
sequences that are designed to anneal at site 5' or upstream of the AP annealing site, 
converting the first-strand c D N A into one or more truncated c D N A fragments. The 
use of fluorescently labeled oligonucleotides has a number of potential advantages in 
addition to safety benefits of avoiding radioactivity. Since the fluorescent tag is 
present only on the APs, the observed fluoro DD-PCR bands most likely represent 
products generated from the poly(A)+ m R N A . The signal intensity of the fluorescent-
labeled band is also more representative of the actual number of cDNA molecules 
present in the band. The F D D has at least two advantages over the radioactive 
procedures. First, radioactive incorporation tends to give a stronger signal for longer 
cDNA products compared to shorter cDNA products, this in turn overestimate the 




patterns are even and easier to interpret than radioactive D D patterns because of lower 
background and fewer doublet bands. Because of the above, F D D was used to screen 
genes up- and down-regulated after TNF-a treatment. 
1.12 Aims and Scopes of the Project 
The C N S has traditionally regarded as an immunologically privileged site. TNF-
a is a pleiotropic inflammatory cytokine associated with host-defense and 
homeostatic responses to injury or invasion. In the injured CNS, such responses may 
have both pathobiological and adaptive consequences. TNF-a is elevated in the serum 
and cerebrospinal fluid of humans after TBI (Goodman et al., 1990; Ross et al,, 1994) 
and acute increases in TNF-a m R N A and protein have also been observed in injured 
i 
rat brain (Fan et al., 1996; Scherbel et al, 1999). TNF-a m R N A and TNF-a are also 
elevated after injury in clinically relevant models of brain trauma, such as closed head i 
impact (Shohami et al., 1994) and lateral fluid-percussion (Taupin et al., 1993; 
Yakovlev & Faden, 1995; Fan & Faden, 1998). In these models, substantial elevations 
of TNF-a occur from 1 to 4 hours after injury. Furthermore, involvement of TNF-a in 
the pathobiology of TBI is suggested by observations that agents which block TNF-a 
synthesis, such as pentoxifylline and HU211, improved neuronal survival and/or 
neurological recovery after traumatic injury (Shohami et al., 1997; Knoblach & 
Faden, 1999). However, the signaling cascades in response to TNF-a were still 
unclear. Therefore, attempts were made to find out the signaling pathway genes 
responsive to TNF-a treatment in C6 cells. The genes that we are most interested in 
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are those that participate in the signaling pathway mediating the proliferative action of 
TNF-a. As C6 cells, like cultured astrocytes, are known to express both TNF-a 
receptor subtypes and TNF-a selectively TNF-R2 expression (Huang et al, 1998; 
Lung et al., 2001), we shall try to examine the receptor subtype responsible for the 
induction. This shall be carried out with selective receptor subtype antiserum. (FDD) 
was used to screen differentially expressed genes following TNF-a treatment in C6 
cells. Previous studies have found that P K A and P K C are activated by cytokines in 
various cell types (Benveniste & Himeycutt, 1995; Lung, 1999), attempts shall be 
made to elucidate the relationship between these two kinases and the genes induced 
by TNF-a. In this study, the action of selective activators and inhibitors of P K A and 
P K C (Messaen & Siegers, 1992; Tsang et al” 1997) with or without TNF-a treatment 
shall be examined. 
As stated in Section 1.14, C6 cells are very similar to cultured astrocytes in terms 
of biochemical properties and characteristics, and that they also respond to cytokines 
similar to astrocytes. More importantly, astrocytes are one of the major sources of 
cytokine production; thus, C6 cells should be a very good model for studying 
signaling pathway genes induced by TNF-a. 
Recent studies have revealed that P-adrenergic mechanism plays an important 
role in the development of reactive gliosis (Sutin & Griffith，1993; Mantyh et al., 
1995). So, TNP-a could mediate certain pathological events after brain injury via p_ 
adrenergic mechanism. Previous studies in our laboratory showed that TNF-a and (3-
adrenergic mechanism interacts in C6 cells (Lung, 1999; Shan, 2000), so we also 
attempt to elucidate the signal transduction pathway(s) mediating the proliferation 
effects of TNF-a and P-adrenergic mechanism in C6 cells. 
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The last part of m y study is to investigate the transcription factors regulated by 
these signaling molecules. A potential candidate which is activated in reactive glial 
cells is the transcription factors C R E B (Ong & Lim, 2000). The observations that 
C R E B overexpression protects cells against toxin-induced apoptosis in vitro and is 
phosphorylated in damage-resistant neurons in vivo (Walton et al., 1996) suggest that 
C R E B activation is a potent survival signal in times of cellular stress. The CREB 
protein and the C R E site are therefore potential targets for both existing and future 
neuroprotective agents (Walton, 1999). It is postulated pCREB could drive the 
expression of downstream genes to promote cell proliferation and survival. pCREB 
has been shown to activate downstream genes, such as c-fos (Bito et a/., 1996; 
Deisseroth et al., 1996; Liu & Graybriel, 1996). Furthermore, it has been shown that 
ischemia up-regulates c-Fos immunoreactivity and suggests the early c-Fos induction 
after cerebral ischemia may account for neuroprotection by means of up-regulating 
late gene expression for survival (Cho & Park, 2001). It would, therefore, be natural 
to include the induction of this factor in this study. Moreover, it has been found that 
NF-KB level was increased as a consequence of brain injury (Salminen & Liu, 1995; 
Yang & Mu, 1995), and NF-KB was activated by pro-inflammatory cytokines such as 
IL-1 and TNF-a (Moynagh & Williams, 1993). Also, it has found that early response 
of TNF-a-induced NF-KB is also necessary for cell survival (Beg & Baltimore, 1996; 
Liu & Hsu, 1996; Van Antwerp & Martin, 1996; Wang & Mayo, 1996). Because of 
the above reasons, the actions of TNF-a and relevant signal pathway molecules on 
this gene's expression were also included in this study. 
The major aim of the present study is to elucidate the signaling cascade 
mediating the astrocyte proliferation and cell survival using C6 cells as a model. 
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Findings obtained should provide better understanding of the regulatory mechanism 
leading to cell survival so as to enhance the treatment of brain injury. 
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Chapter 2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Cell TJne 
Rat C6 glioma cells were obtained from the American Type Culture Collection 
(U.S.A.). They were originally cloned from a rat glial tumor induced by N-
nitrosomethylurea after a series of alternate culture and animal passages (Benda et al., 
1968). 
2.1.2 Cell Culture Reagents 
2.1.2.1 Complete Dulbecco, s Modified Eagle Medium ( C D M E M ) 
Dulbecco, s modified Eagle medium (DMEM) with glucose and L-glutamine 
was purchased from Gibco B R L (U.S.A.). The powered D M E M (for 1 litre solution) 
and 3.7 g sodium bicarbonate were dissolved in 1 litre (L) of double-distilled water. 
The medium was adjusted to pH 7.2 and filtered (filter: 0.2 jaM, Micro filtration 
Systems, Dublin, U.S.A.) under suction. Then, heat-inactivated fetal bovine serum 
(HI-FBS; Gibco BRL, U.S.A.), and antibiotics (penicillin, 10,000 U/ml; streptomycin, 
10,000 i^g/mL; fungizone, 25 |ig/mL; Gibco BRL, U.S.A.) were added to make the 
complete D M E M (CDMEM). The final C D M E M contained 10% (v/v) HI-FBS, 100 
U/mL penicillin, 100 ^ ig/mL streptomycin, and 0.25 ^ g/mL fungizone. This medium 
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was stored at 4 until use. 
2.1.2.2 Rosewell Park Memorial Institute (RPMI) Medium 
Rosewell Park Memorial Institute (RPMI) medium was prepared almost the 
same as D M E M , except that 0.2 g sodium bicarbonate was added. The final complete 
R P M I (CRPMI) medium contained 10% (v/v) HI-FBS, 100 U/mL penicillin, 100 
l^g/mL streptomycin, and 0.25 ^g/mL fungizone. This medium was stored at 4 °C 
until use. Because R P M I medium contained N-[2-hydroxyethyl]piperazme-N' -[2-
ethane sulfonic acid] (HEPES) as a buffering system, its pH is more stable than 
D M E M , hence, the C D M E M was used in the maintenance of cell culture, while the 
C R P M I medium was used for proliferation assays. 
2.1.2.3 Phosphate Buffered Saline (PBS) 
Phosphate buffered saline (PBS) was prepared by dissolving 8.18 g sodium 
chloride, 0.2 g potassium chloride, 0.2 g potassium dihydrogen phosphate and 1.44 g 
sodium hydrogen phosphate in 1 litre of nano-pure water, and the pH of PBS was 
adjusted to 7.4 then autoclaved. 
2.1.3 Recomhinant Cytokines 
Recombinant mouse tumor necrosis factor-a (TNF-a; specific activity: 6 x 10^  
U/mL), and mouse interleukin-6 (IL-6; specific activity: 1 x 10^ U/mL) were 
purchased from Boehringer Mannheim Biochemica, Germany. TNF-a had been 
shown to be biological active in C6 glioma cells (Huang et al., 1998). All cytokines 
were stored in aliquots at -20。C until use. 
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2.1.4 Chemicals for Signal Transduction Study 
2.1.4.1 Modulators of p38 Mitogen Activated Protein Kinase (p38 M A P K ) 
p38 mitogen activated protein kinase (p38 M A P K ) inhibitor: SB 203580; 
(Sigma, U.S.A.) (Tong et al., 1997; Wilson & McCaffrey, 1997) was dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 100 m M . All the dissolved p38 
M A P K inhibitors were used immediately or stored at -20 °C until use. 
2.1.4.2 Modulators of Protein Kinase C (PKC) 
Protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate P M A ; (Sigma, 
U.S.A.) was dissolved in complete culture medium at a final concentration of 4 ^iM 
and stored at -20。C until use. P K C inhibitors: 3-{l-[3-(amidinothio) propyl]-3-
indolyl}-4-(l-methly-3-indolyl)-lH-pyrrole-2,5-dione methanesulfonate (Ro-31; 
Calbiochem, U.S.A.) and staurosporine (Sigma) were dissolved in dimethyl sulfoxide 
(DMSO) and absolute ethanol, respectively at a concentration of 100 juM. All the 
dissolved P K C inhibitors were used immediately or stored at -20。C until use. These 
modulators had been shown to be very selective in C6 glioma cells (Tsang et al., 
1997). 
2.1.4.3 Modulators of Protein Kinase A (PKA) 
Protein kinase A (PKA) activator, -dibutyryl cyclic adenosine-3，，5,-
monophosphate (dbcAMP; Sigma, U.S.A.), was dissolved in complete culture 
medium at a final concentration of lOOmM and stored at -20 °C until use. On the 
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Other hand, two P K A inhibitors, 14-22 (Calbiochem, U.S.A.) (Rimon & Rubin, 1998) 
and H-89 (Calbiochem, U.S.A.) (Siegers and Anciaux, 1997), were dissolved in PBS 
at concentrations of 5mg/mL and lOOmM respectively, and used immediately or 
stored at -20 °C until use. 
2.1.4.3 P-Adrenergic Agonist and Antagonist 
Isoproterenol, an P-adrenergic receptor (p-AR) agonist (Storm & Khawaja, 
1999), and propranolol, an P-AR antagonist (Sutin & Griffith, 1993), were purchased 
from Sigma, U.S.A. They were dissolved in double-distilled water at final 
concentrations of 250 m M and 10 m M respectively, and used immediately or stored at 
-20 °C until use. 
i)Pl-Adrenergic Agonist and Antagonist 
Dobutamine, a p 1-adrenergic receptor ((31-AR) agonist (Deighton et al., 1992) 
and atenolol, an pi-AR antagonist (Koganei et al., 1995), were purchased from 
Sigma, U.S.A. They were dissolved in double-distilled water at final concentrations of 
10 m M and 50 m M respectively, and used immediately or stored at -20。C until use. 
ii) (32-Adrenergic Agonist and Antagonist 
Procaterol, a P2-adrenergic receptor (P2-AR) agonist (Koganei et al., 1995), and 
ICI 118,551, a P2-AR antagonist (Deighton et al., 1992), were purchased from Sigma, 
U.S.A. They were dissolved in double-distilled water at a final concentration of 10 
m M , and used immediately or stored at -20 °C until use. 
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2.1.5 Antibodies 
2.1.5.1 Anti-p38 Mitogen Activated Protein Kinase (p38 M A P K ) Antibody 
Antibody against p38 mitogen activated protein kinase (p38 M A P K ; 200 
|ig/mL), an affinity-purified mouse monoclonal antibody IgGi raised against a peptide 
corresponding to amino acids 26 to 45 mapping at the carboxyl terminus of the p38 
M A P K of human origin, was purchased from Santa Cruz Biotechnology, Inc., U.S.A. 
According to the manufacturer, this antibody only reacts with p38 a and p38 (3 of 
mouse, rat and human origin by Western blotting, immunoprecipitation and 
immunohistochemistry; and is non-cross-reactive with other M A P kinases. This 
antibody was stored at 4 °C until use. 
2.1.5.2 Anti-phosphorylation p38 Mitogen Activated Protein Kinase (p-p38 M A P K ) 
Antibody 
Antibody against p38 mitogen activated protein kinase (p38 M A P K ; 200 
|ig/mL), an affinity-purified mouse monoclonal antibody IgM raised against a peptide 
corresponding to phosphorylated Tyr-182 at the carboxyl terminus of the p38 M A P K 
of human origin, was purchased from Santa Cruz Biotechnology, Inc., U.S.A. 
According to the manufacturer, this antibody only reacts with p38 a and p38 p of 
mouse, rat and human origin by Western blotting and is non-cross-reactive with other 
phosphorylated M A P kinases. This antibody was stored at 4。C until use. 
2.1.5.3 Antibody Conjugates 
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Goat anti-rabbit biotin conjugate and anti-biotin alkaline phosphatase conjugates 
were supplied by Tropix, Inc. (Massachusetts, U.S.A.). Monoclonal mouse anti-goat 
biotin conjugate (1 )ig/mL) was purchased form Sigma, U.S.A. All antibody 
conjugates were stored at 4 °C until use. 
2.1.6 Reagents for RNA Tsolatinn 
TheTRIzol reagent (Gibco, U.S.A.) and isopropanol (Promega, U.S.A.) were 
stored at 4。C, while chloroform (AnalaR, England) and ethanol (AnalaR, England) 
were stored at room temperature. 
2.1.7 Reagents for DNase T Treatment 
The RNase-free DNase I (Promega, U.S.A.) and RNase inhibitor (Boehringer 
Mannhem, Germany) were stored at -20� C until use. Sodium acetate and ethidium 
bromide were purchased from Sigma, U.S.A. Phenol:chloroform:isoamyl alcohol 
(125:24:1; pH 4.7) and agarose were obtained from Life Technologies, U.S.A. 
2.1.8 Reapents for Reverse Transcription nf mRNA and Fluorescent PPR 
Amplification 
The HIEROGLYPH kit, dNTP mix (1:1:1) and fluorescent differential display 
(FDD) kit 1 were purchased from Genomyx (U.S.A.) and stored at -20。C until use. 
The Superscript II Reverse transcriptase (RT) buffer, SuperScript II Reverse 
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transcriptase (RT) enzyme and dithiothreitol (DTT) were obtained from Life 
Technologies, U.S.A. 
2.1.9 Reagents for Fluorescent Differential Display 
TMR-molecular weight D N A standard marker, fluoroDD loading dye, 5.6% 
clear denaturing HR-1000 gel, Ix Tris-boric acid-EDTA (TBE) and 0.5 x Tris-boric 
acid-EDTA (TBE) buffers were purchased from Genomyx (U.S.A.). Ammonium 
persulfate and (TEMED) were obtained from Sigma, U.S.A. 
2.1.10 Materials for Excision of Differentially Expressed cDNA Fragments 
Tris-ethylenediaminetetraacetic acid disodium salt (TE) buffer was used to 
resuspend the gel band, the TE buffer contained lOmM Tris-HCl (pH 7.4) and 0.1 
m M ethylenediaminetetraacetic acid disodium salt (EDTA). Both chemicals were 
purchased from Sigma, U.S.A. The Excision Workstation equipped with a physical 
grid was purchased from Genomyx, U.S.A, while sterile scalpel blades were obtained 
from Hecos (Shanghai, China) 
2.1.11 Reagents for Reamplification of Differentially Expressed cDNA Fragments 
The Ml3 reverse (-48) 24-mer primer, T7 promotor 22-mer and dNTP mix 
(1:1:1) were purchased from Genomyx, U.S.A. and stored at - 2 0� C until use. 
AmpliTaq® enzyme, magnesium chloride and 10 x P G R buffer were obtained from 
Perkin Elmer, U.S.A. The 100 bp D N A marker was purchased from Life 
Technologies, U.S.A. Genemler™ 100 bp D N A marker and Generuler™DNA marker 
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mix were purchased from Fermentas, U.S.A. 
2.1.12 Reagents for Subcloning of Reamplified cDNA Fragments 
The AdvaTAge^cloning kit was purchased from Clontech, U.S.A. and stored at 
-20 °C until use. X-Gal and isopropyl-P-D-thiogalactoside (IPTG) were obtained 
from Boehringer Mannhem, Germany. Bacto-typtone and yeast extract were 
purchased from Becton Dickinson, U.S.A. Potassium acetate, amplicillin, acetic acid 
and sodium chloride were obtained from Sigma, U.S.A. Phenol:chloroform:isoamyl 
alcohol (125:24:1; pH4.7) and agarose were obtained from Life Technologies, U.S.A. 
EcoRI buffer and EcoRI restriction enzyme were purchased from New England 
Biolabs, UK. E D T A and SDS were obtained from Riedel-de Haen (Seelze, Germany). 
2.1.13 Reaeents for Purification ofPlasmid DNA from Recombinant Clones 
The QIAprep® MiniprepWizard™p/i/5 Minipreps D N A Purification System was 
purchased from Promega, U.S.A. The Bacto-typtone and yeast extract were purchased 
from Becton Dickinson, U.S.A, while EcoRI buffer and EcoRI restriction enzyme 
were purchased from New England Biolabs (UK). 
2.1.14 Reagents for DNA Sequencing of Differentiallv Expressed rPNA 
Fragments 
The C E Q 2000 terminator cycle sequencing kit was purchased from Beckman, U.S.A. 
M13 sequencing, M13 reverse primers were synthesized by Life Technologies, U.S.A. 
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Fomiamide, NasEDTA solution (100 m M ) and sodium acetate (3 M) were obtained 
from Sigma, U.S.A. Ethanol was purchased from AnalaR, England. 
The ABI P R I S M ™ dRhodamine terminator cycle sequencing ready reaction kit 
and magnesium chloride were purchased from Perkin Elmer (U.S.A.). M13 
sequencing, Ml3 reverse primers were obtained from Life Technologies, U.S.A. 
Formamide, 100 m M NazEDTA and 3 M sodium acetate were obtained from Sigma, 
U.S.A. Ethanol was purchased from AnalaR, England. 
2.1.15 Reagents for Reverse Transcription-Polvmerase Chain Reaction (RT-
PCR� 
The deoxynucleotide mix (dNTP, lOmM each dNTP), A M V reverse transcriptase 
(specific activity: 25 U/^L), RNase inhibitor (specific activity: 50 U/juL), random 
primer p(dN)6 (2 ^ig/mL), Taq D N A polymerase (produced in E. Coli; specific 
activity: 5 U/|iL) were purchased from Boehringer Mannheim, Germany. All 
restriction enzymes used in this study were purchased from New England Biolabs, 
U.S.A. The following chemicals: TE buffer, containing 10 m M Tris, pH 8.0, used to 
reconstitute and dilute PGR primers, and ethylenediaminetetraacetic acid disodium 
salt (EDTA) (1 m M ) were purchased from Sigma, U.S.A. 
The sets of specific primers for PGR amplification of the corresponding specific 
cD>L\s were purchased from Gibco (Hong Kong) and summarized in Table 1. The 
primers were designed on the basis of previous published data. 
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Table 1 Primers used in RT-PCR and the predicted sizes of the PGR primers 
c D N A Amplified Nucleotide Amplified 
Primer sequences (5 ‘ - 3' ) position PGR 
fragment 
size (bp) 
P-Actin Sense strand: 
T G A G A C C T T C A A C A C C C C A G 2166-2185 
Antisense strand: 
T T C A T G A G G T A G T C T G T C A G G T C C 2343-2366 201 
p38 a M A P K Sense strand: “ “ 
A C C G A T G A C C A C G T T C A G T T 378-397 
Antisense strand: 
A C A A C G T T C T T C C G G T C A A C 678-697 301 
p38 p M A P K Sense strand:  
G A C A C C C C C T G C T T A T C T C A 441 -460 
Antisense strand: 
A A A G T A G G C A T G C G C A A G A G 645-664 205 
P 3 8 y M A P K Sense strand:  
C A A G C A C C T T C A C T C T G C T G 592-611 
Antisense strand: 
G T C A G G G A T C T T T G G T G G T G 1192-1211 601 
P38 5 M A P K Sense strand: “ 
A C T C C T G C T G T T G A A G C A C A 224-243 
Antisense strand: 
C C C A A A G T C C A G G A T C T T C A 518-537 295 
iNOS Sense strand: 
G A G C T G A A T T T G G G A A C C A T 1659-1678 
Antisense strand: 
C G C C T T T A C T T C C A G G A T T C 1960-1979 302 
CREB Sense strand: ‘  
T G T T G T T C A A G C T G C C T C T G 759-778 
Antisense strand: 
A T C C A G T C C A T T T T C C A C C A 1110-1129 352 
c-fos Sense strand: 
C T G C A A G A T C C C C A A T G A C C 875-895 
Antisense strand: 
A G G T C C A C A T C T G G C A C A G A 1179-1199 325 
NF-KB/p50 Sense strand: 
G A G A T T C T G A A T C C C C C T G A 4-23 
Antisense strand: 
[TTCCAGCCGCTATGTGTAGA 1807-826 +823 
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And these nucleotides were derived from the sequences of the corresponding rat 
genes and cDNA，with nucleotide positions as indicated in Table 1. In addition, the 
primer sequences were chosen from separate exons of the genes so that the RT-PCR 
product could readily be distinguished from any genomic DNA-induced PCR 
products. Each primer was diluted to 2.5 |iM and stored at 一 2 0� C until use. 
2.1.16 Reagents for Electrophoresis 
Ten X D N A loading buffer contained 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue and 60 m M E D T A (pH 8.5). Ten x T B E buffer was prepared by 
dissolving 108 g Tris base, 55 g boric acid and 7.44 g E D T A in 1 L double-distilled 
water, and the pH was adjusted to 8.3. All of above chemicals were obtained from 
Sigma, U.S.A. D N A ladder purchased from Bio-Rad, U. S. A. was used as markers. 
2.1.17 Reagents and Buffers for Western Rlnt 
I-Block™ (highly purified casein), CSPD® Ready-to-Use substrate solution (0.25 
mM), Nitro-Block™ (20 x chemiluminescent enhancer), and protein molecular 
markers were supplied by Tropix, Inc. (Massachusetts, U.S.A.). Two x loading buffer 
contained 0.5 M Tris, pH6.8, 10% (v/v) glycerol, 2 % (w/v) SDS, 5% (v/v) 2-p-
mercaptoethanol and 0.03 % (w/v) bromophenol blue. One x running buffer was 
made up of 0.025 M Tris, 0.19 M glycine and 0.1% (w/v) SDS. Transfer buffer 
contained 39 m M glycine, 4 8 m M Tris, 0.037 %(w/v) SDS and 20% (v/v) methanol. 
PBS for preparation of blocking buffer contained 0.058 M sodium hydrogen 
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phosphate, 0.017 M sodium dihydrogen phosphate and 0.068 M sodium chloride, and 
blocking buffer was prepared by dissolving 0.2 % (w/v) I-Block™ (Tropix, 
Massachusetts, U.S.A.) and 0.1% (v/v) Tween®20 (Sigma, U.S.A.) in PBS. Wash 
buffer was PBS plus 0.1% (v/v) Tween®20, and assay buffer contained 20 m M Tris 
(pH 9.8) and I m M magnesium chloride. 
2.1.18 Other Chemicals and Reagents 
All other chemicals and reagents were purchased from Sigma, U.S.A. 
2.2 Maintenance of Rat C6 Glioma Cell T Jnp 
Rat C6 glioma cells were cultured, under aseptic conditions, in C D M E M at 37。C 
in a humidified incubator (Mode 2400, Shel-Lab., Inc) under an atmosphere of 5 % 
CO2 /95% air. The cells were sub-cultured after 2 to 3 days in culture, at which time 
they had reached confluence. All subculture procedures were performed under aseptic 
conditions in a culture hood (Biogard hood, Baker Company，Inc.) as follows: the 
medium was discarded, and cells were washed with sterile PBS. The cells were 
treated with ImL of 0.25% (w/v) trypsin (Gibco BRL, U.S.A.) at 37。C for 5 minutes 
and then dispersed by shaking. After washed once with lOmL C D M E M , the cells 
were adjusted to a cell density of 10^ cells/mL, and further cultured in a 75 cm^ 
culture flask (Coming Laboratory Sciences Company, U.S.A.) containing 20 m L 
C D M E M . 
For long-term storage, ImL of cells (lO? cells) suspended in FBS containing 5% 
(v/v) dimethyl sulfoxide (DMS〇，Sigma, U.S.A.) was stored in liquid nitrogen in 
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plastic ampoules (Nunc, Denmark). When required, aliquots were thawed in C D M E M 
at 37。C, subcultured, and cells of passages 18 to 28 were used in this study. 
2.3 RNA Isolation 
C6 Cells were seeded on 60-mm culture dishes and incubated at 3 7� C under a 
humidified atmosphere of 5% C02/95% air. A stock solution of TNF-a and/or drugs 
as mentioned in Section 2.1.3 prepared in C D M E M was added to the culture medium 
to achieve the desired final concentration. The time for the addition of drug was 
varied in such a way that all cells were harvested at the same time. All R N A 
extraction procedures were done at 4 Cells were washed twice with 3 m L ice-cold 
PBS and ImL of TRIzol reagent were added to each dish. After 5 minutes, cells were 
scrapped off using a cell scrapper and transferred to an 1.5 m L Eppendorf tube, then 
pipetted up and down several times to ensure cell breakage and R N A release. 
Afterwards, 0.2 m L of chloroform was added to each tube and followed by vortexing 
for 15 seconds. The tubes were allowed to stand at room temperature for 5 minutes, 
and centrifuged at 11,900 x g for 15 minutes at 4 � C . The supernatant was removed 
and 0.5 m L isopropanol was added, the solution was then vortexed thoroughly. The 
tubes were put into a freezer (-20。C) overnight to allow the R N A to precipitate. 
Then, the tubes were centrifuged at 11,900 xg for 15 minutes at 4 °C, and the pellet 
in each tube was washed with 1 m L 75% ethanol and centrifuged at 7,500 xg at 4 °C 
for 5 minutes. The R N A pellet was resuspended in 30 juL nuclease-free water which 
was kept at -70 °C until use. 
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23.1 Measurement of RNA Yield 
The R N A concentration was determined spectrophotometry at 260 nm. A n 
aliquot of 4 ^ iL R N A was mixed with 996 juL H2O, and the absorbance at wavelength 
260 n m (A260) was measured to determine the concentration of R N A . The purity was 
determined by calculating the ratio of the absorbance at wavelength 260 n m to that at 
wavelength 280 n m (A260/A280) and a pure R N A preparation should have an A260/A280 
value of 2.0. The yield and purity of R N A were calculated by the following equations: 
A260 X 40 \ig/\i\ 
Yield = 
(4/1000) X 103 
Purity = A260/A280 
All R N A samples were adjusted to 0.5 ^ g/juL, and this R N A concentration was 
used for all reverse transcription (RT) reactions. 
2.4 DNase T Treatment 
Even trace amounts of contaminating D N A will be amplified and thus false 
positive will be contributed to the D D banding pattern. Therefore, DNase I treatment 
was performed in order to ensure the total R N A samples to be analyzed by D D is 
completely free of D N A contamination. The integrity of the DNase I-treated total 
R N A was verified before proceeding with the c D N A synthesis. 
Thirty |ig of total R N A was incubated with 1 x DNase I buffer, 10 units RNase-
free DNase I and 100 units RNase inhibitor at 37 °C for 15 min. Fifty ^ iL of phenol: 
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chloroform: isoamyl alcohol (125: 24:1; pH 4.7) was added to the reaction mixture 
and it was vortexed for about 1 minute until two phases of the mixture was totally 
mixed. The aqueous phase containing the R N A sample was then separated from the 
organic phase by centrifuging the mixture at 15,000 xg or 5 minutes. Then, 50 ^ L of 
LOQO/O ethanol and 10 |LIL of 3 M sodium acetate were added and kept at -80°C 
overnight to precipitate the RNA. The R N A pellet was obtained by centrifuging the 
R N A solution at 15,000 x g for 15 minutes and the pellet in each tube was washed 
with 1 m L 70% ethanol twice and recentrifuged at 7,500 x g at 4°C for 5 minutes. 
The R N A pellet was air dried, resuspended in 30 ^ iL nuclease-free water and kept at -
70 °C until use. The R N A concentration was determined by spectrophotometry at 260 
n m as mention in Section 2.3.1. Only the R N A without degradation was used for 
further analysis. 
2.5 Reverse Transcription of mRNA and Fluorescent VCR Amplification 
0.2 ^ g of DNase-treated total R N A was reverse-transcribed in a 10 juL-reaction 
mixture containing 0.2 juM anchored primer (AP) (Table 2), 1 x SuperScript II RT 
buffer, 25 ^ iM dNTP mix (1:1:1)，10 m M D T T and 2 units SuperScript II RT enzyme. 
The mixture was incubated at 4 2 � C for 5 minutes, then 50。C for 50 minutes, 
followed by a final extension at 70。C for 15 minutes and hold at 4。C. Reverse 
transcription reaction was performed with a thermal cycler (Perkin Elmer GenAmp 
9600). 
After the first-strand c D N A synthesis, PGR was performed in a total volume of 
10 iiL mixed of 1 ^ iL of RT sample, 1 x P C R buffer, 3.75 m M M g C l�，5 0 juM dNTP 
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mix (1:1:1), 0.35 juM 5' -arbitrary primer (ARP) (Table 3), 0.35 iiM 3' -TMR-AP 
(Table 4) and 0.05 units AmpliTaq enzyme. The thermal cycling profile of PGR was 
as follows: 9 5 � C for 2 minutes, 30 cycles at 92 °C for 15 seconds, 60 for 30 
seconds, and 72 °C for 2 minutes, followed by a final extension at 7 2 � C for 7 
minutes and hold at 4 °C. P G R was performed with a thermal cycler (Perkin Elmer 
GenAmp 9600). 
2.6 Fluorescent Differential Display fFDD^ 
Following fluoroDD-PCR, the TMR-labeled c D N A fragments were 
electrophoretically separated on a high-resolution polyacrylamide gel under 
denaturing conditions. Each high resolution fluoroDD gels was prepared by mixing 80 
m L of 5.6% clear denaturing HR-1000 gel with 360 juL of freshly prepared 10% 
ammonium persulfate and 36 juL of TEMED. The fluoroDD gel was wrapped with 
plastic wrap and aluminium foil to prevent the gel from drying and to avoid excessive 
light penetrates into the gel. Then, the gel was allowed to polymerase for overnight at 
room temperature. On the next day, 4 juL of each fluoroDD-PCR sample with 1.5 juL 
of fluoroDD loading dye were heated at 95。C for 2 minutes to denature and 
concentrate the sample. At the same time, the TMR-molecular weight was prepared in 
the same way as the fluoroDD PGR samples (one tube containing 4 }iL D N A standard 
markers plus 1.5 |iL of fluoroDD loading dye for each gel). The lower and upper 
buffer chambers were filled with 250 m L of 1 x TBE buffer and 120 m L of 0.5 x TBE 
buffer, respectively. The wells of the fluoroDD gel were flushed thoroughly with 
upper buffer before loading the samples in order to remove all the urea in each well. 
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Table 2. Sequence of anchored primers (AP) used for first-strand c D N A synthesis 
(Adapted from the FluoroDD manual, Genomyx) 
API 5' ACGACTCACTATAGGGrTTTTTTTTTTTTnA T 
AP2 5' A C G A C T C A C T A T A G G G r T T T T T T T T T T T T n r 3’ 
AP3 5' A C G A C T C A C X A T A G G G r T T T T T T T T T T T T r i n 3' 
AP4 5' A C G A C T C A C T A T A G G G r T T T T T T T T T T T T n T 3' 
AP5 5' A C G A C T C A C T A T A G G G C T T T T T T T T T T T T r A 3, 
AP6 5' A C G A C T C A C T A T A G G G r T T T T T T T T T T T T r r 3' 
AP7 5' A C G A C T C A C T A T A G G G r T T T T T T T T T T T T r n 3, 
A P 8 5' ACGACTCACTATAGGGCTTTTTTTTTTTT A ^  3’ 
A P 9 5' A C G A C T C A C T A T A G G G r T T T T T T T T T T T T A r - 3, 
APIO 5' ACGACTCACTATAGGGCTTTTTTTTTTTT八G), 
APll 5’ A C G A C T C A C T A T A G G G r T T T T T T T T T T T T ” 
AP12 5' A C G A C T C A C T A T A G G G r T T T T T T T T T T T T r - x 3' 
Note: The 17 nucleotides of the T7 promotor sequence are underlined and the two 
bases locate upstream are bolded. According to the manufacturer. Most APs use a 
group of 10-12 dTs to achieve annealing with the poly(A+) tail of the mRNAs. First 
strand c D N A synthesis occurs by extension of the AP, thereby anchoring the 3, end 
of the transcript. There are twelve different two-base combinations. Each respective 
two-base anchored primer would encompass approximately one-twelfth (8%) of the 
m R N A pool constituency, and would render approximately 800-1,200 different first 
strand cDNAs. 
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Table 3. Sequence of arbitrary primers (ARP) used for FDD-PCR reaction (Adapted 
from the FluoroDD manual, Genomyx) 
A R P l 5， A C A A T T T C A C A C A G G A r G A r T r r A A O T 
ARP2 5' A C A A T T T C A C A C A G G A G C T A n c A T O T ^ 
ARP3 5' ACAATTTCACACAGGAGArrATrnrA V 
ARP4 5' ACAATTTCACACAGGAGCTAGCAGAC V 
ARP5 5’ A C A A T T T C A C A C A G G A A T G G T A G T r T 3 丨 
ARP6 5' A C A A T T T C A C A C A G G A T A C A A C G A G G 
ARP7 5' A C A A T T T C A C A C A G G A T r T G A T T G n T ^ 
ARP8 5' A C A A T T T C A C A C A G G A T G G T A A A G G G T 
ARP9 5' ACAATTTCACACAGGATAArTArTAOr T 
ARPIO 5' A C A A T T T C A C A C A G G A G A T C T r A G AT^' 
ARPll 5' ACAATTTCACACAGGAArrrrTAnrrrT V 
ARP12 5' A C A A T T T C A C A C A G G A G G T A r T A A r ^ 
ARP13 5’ ACAATTTCACACAGGAGTTGCACC^' 
ARP14 5' A C A A T T T C A C A C A G G A T r r ATG A crr V 
ARP15 5' ACAATTTCACACAGGACTTTCTACrrr T 
ARP16 5' A C A A T T T C A C A C A G G A T r G G T r A T A n 
ARP17 5' A C A A T T T C A C A C A G G A r T G r T A O G T r r 
ARP18 5' A C A A T T T C A C A C A G G A T G A T G C T A C r ^ 
ARP19 5' ACAATTTCACACAGGATTTTGnrrrr T 
ARP2Q 5 ‘ A C A A T T T C A C A C A G G A T r o ATA r A nrn ’ 
Note: The 16 nucleotides of the M l 3 reverse (-48) sequence are underlined. The core 
annealing sequences of the arbitrary 5, primers used in the H I E R O G L Y P H System 
are 10 bases in length to reduce the number of priming events per cDNA. According 
to the manufacturer, this simplifies the final c D N A fragment display pattern by 
reducing the number of multiple size versions generated from each first strand cDNA. 
The long length of the anchoring and arbitrary primers allow for stringent annealing 
conditions during fluoroDD-PCR step, and thereby prevent misprimmg and 
nonspecific products and ‘  false positives" and ensures high reproducibility 
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between samples. 
Table 4. Sequence of fluorescent-tagged anchored primers (TMR-AP) used for first-
strand c D N A synthesis (Adapted from the FluoroDD manual, Genomyx) 
A P I 5’ T M R-ACGACTCAC^TATAGGnrTTTTTTTTTTT丁G A T 
AP2 5' TMR-ACGACTCACTATAGGGCTTTTTTTTTTTTGC 3' 
AP3 5' TMR-ACGACTCACTATAGGnrTTTTTTTTTTTTGr^ ‘^ 
AP4 5' TMR-ACGACTCACTATAGGnrTTTTTTTTTTTjQj 3' 
AP5 5’ TMR-ACGACTCACTATAGGrrCTTTTTTTTTjjjr^ q, 
AP6 5' TMR-ACGACTCAnTATAGrTGrTTTTTTTTTT丁丁pr^ 3' 
AP7 5, TMR-ACGACTCACTATAGrTrTrTTTTTTTTTTTT^G^' 
AP8 5' TMR-ACGACTCACTATAGCrGrTTTTTTTTTTTjA^ ^ 
AP9 5' T M R - A C G A C T C A C T A T A G n n r T T T T T T T T T T T T A ^ 3’ 
APIO 5' TMR-ACGACTC；AC^TATArTGGrTTTTTTTTTT丁丁4^ 
APll 5' TMR-ACGACTCACTATAOrTrTrTTTTTTTTTTTTAT^' 
AP12 5' T M R - A C G A C T C A C T A T A G r T O r T T T T T T T T T T T T ^ T ^ ' 
Note: The 17 nucleotides of the T7 promotor sequence are underlined and the 
fluorescent tag is bolded. Since there is only one fluorescent tag tetramethylrodamine 
(TMR) present in the each primer sequence, the observed fluoroDD-PCR bands most 
likely represent products generated from the poly(A)+ m R N A . The signal intensity of 
the TMR-labeled band is also more representative of the actual number of c D N A 
molecules present in the band. 
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The TMR-labeled fluorescent P C R products and TMR-molecular weight marker were 
electrophoresed on a 5.6% denatured polyacrylamide gel at 3,000V, lOOW and 50 °C 
for 4.5 hours using a GenomyxLR^^ D N A electrophoresis system (Genomyx, 
U.S.A.). After gel electrophoresis, the gel was dried in the same machine and the 
image was scanned in GenomyxSC™ fluorescent imaging scanner (Genomyx, 
U.S.A). 
2.7 Excision of Differentially Expressed cDNA Fragments 
The Excision Workstation (Genomyx, U.S.A) was used to hold the fluoroDD gel 
and a physical grid (Genomyx, U.S.A) was placed on the fluoroDD gel platform of 
the Excision Workstation to locate the exact position of the bands of interest. The 
excision bridge which spanning the width of the glass plate was used as an arm 
support to avoid touching the gel surface. Four juL of TE buffer (lOmM Tris-HCl, 0.1 
m M EDTA, pH7.4) was dropped carefully onto the surface of the cut band, then the 
gel was allowed to absorb the moisture for a few seconds, followed by scraping the 
gel slice off the plate with sterile scalpel blades. The gel slice was transferred into a 
sterile 1.5 ml eppendrof containing 25 i^L TE buffer. Tubes with different gel slices 
were incubated at 37 °C for 1 hour in order to allow the D N A diffuse out of the gel 
slices. After gel band excision, the fluoroDD gels were re-scanned in order to check 
for the accuracy of band excision. 
2.8 Reamplification of Differentially Expressed cDNA Fragments 
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P C R reamplification was performed in a total volume of 20 juL containing of 4 
|iL gel band eluent and mixed with 1 x P C R buffer, 1.5 m M M g C l�，2 0 )aM dNTP mix 
(1:1:1) , 0.2 I^M M 1 3 reverse (-48) 24-mer primer, 0.2 |LIM T7 promotor 22-mer primer 
and 0.05 units AmpliTaq enzyme. The thermal cycling profile of P C R was as follows: 
95 °C for 2 minutes, 4 cycles at 92。C for 15 seconds, 50。C for 30 seconds, 7 2� C 
for 2 minutes, 25 cycles at 92 °C for 15 seconds, 60。C for 30 seconds, 72 °C for 2 
minutes, followed by a final extension at 72 °C for 7 minutes and hold at 4 °C. P C R 
was performed in a thermal cycler (Perkin Elmer GenAmp 9600). Ten juL reamplified 
P C R product was resolved on 1% agarose, 0.5 x TBE gel followed by ethidium 
bromide staining. 
2.9 Subclonin^ of Reamplified c D N A F r a g m e n t s 
The reamplified PCR product was ligated with a pT-Adv vector for a 1:1 molar 
ratio as this ratio gives the best ligation efficiency (Adapted from AdvanTAgeT序CR 
Cloning Kit User Manual). In general, 1 ^ L of PCR sample with an average insert 
length of 400-700 bp will give the proper vector: insert ratio of 1:1. Ligation was 
performed in a total volume of 10 ^ L containing of 1 ^ iL reamplified PCR product, 
mixed with 1 x ligation buffer, 50 ng pT-Adv vector and 4 units of T4 D N A ligase. 
The ligation reaction was incubated at 14 °C overnight. 2 |LIL of 0.5 M (3-
mercaptoethanol was added to 50 ^ iL of TOPI OF' E.coli competent cells and then 2 
|iL of each ligation mixture were added directly into the cell mixture and mixed by 
stirring gently with the pipette tip. The cell mixture was incubated on ice for 30 
minutes, the ligated vector was then transformed into the TOPI OF' E.coli competent 
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cells by heat shock for exactly 30 sec in a 42 °C water bath. The transformed cell 
mixture was then placed on ice for 2 minutes. 250 juL SOC medium (containing 0.5% 
yeast extract, 2 % tryptone, 10 m M NaCl, 2.5 m M KCl, 10 m M MgCl2.6H20 and 20 
m M glucose) were added into the cell mixture and was shaken horizontally at 37。C 
for 1 hour in a rotary shaking incubator (Lab-Line, U.S.A.) at a speed of 225 rpm. 50 
|iL and 200 |aL cell mixture were spreaded on two LB/X-Gal/IPTG plates containing 
50 i^g/ml amplicillin, 1.6 [ig X-Gal and 4 m M IPTG. The plates were then inverted 
and incubated at 37 °C for at least 18 hours. The plates were shifted to 4。C for 2 to 3 
hours to allow proper colour development. The partial restriction map and multiple 
cloning sites of pT-Adv vector are shown in Figure 1. 
In order to screen the recombinant clones, the chloroform extraction method was 
used. Briefly, fifteen white or pale blue colonies and blue colonies (self ligated clone 
acting as control) were picked with sterile toothpicks from each plate and then the 
bacteria were transferred into 15 mL-culture tubes which containing 3 m L LB 
medium with 50 ^ig/mL of amplicillin. The bacteria were incubated at 37。C for 
overnight in a rotary incubator (Lab-Line, U.S.A.) at a speed of 225 rpm. On the next 
day, 50 |iL phenol: chloroform: isoamyl alcohol (125:24:1; pH 4.7) were mixed with 
equal volume of bacterial culture by vortexing, centrifuged at 12,000 x g for 1 min 
and 15 |iL of supernatant was separated on a 1% agarose, 0.5 x T B E gel for screening 
the recombinant clones. If the D N A band was shifted up when comparing with the 
self-ligated clone, this indicated that this clone has greater size and possibly has a 
D N A insert. The size of the insert was checked by either ‘ Microprep' methods 
(Shepard and Rae, 1998). 
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1. cDNA fragment excised from the gel 
A R P 
5 ’ ACAATTTCACACAGGAXXXXXXYYYY ! ! 
3 / / 
G G m i l C G G G A T A T C A C T C A G r A S , " 
AP 
2. Priming of M13 (-48) 24-mer and T7 promotor 22-mer primers to cDNA 
fragments 
5 , A C A A T T T C A C A C A G G A X X X X X X Y Y Y Y Z F  
Ml3 reverse (-48) primer ^ ^ 3 ’ C G G G A T A T C A C T C A G C A T A ATG 
5 (8 nt longer than ARP) 
T7 promote primer 
(5 nt longer than AP) 
5 , AGCGGATAACAATTTCACACAGGA ^ , 一  
, 3 , — I I G G m 12CGGGATATC A CTC A GP A 
I “ 
5 ’ AGCGGATAACAATITCACACAGGA // 3 , 
千 3 ^ CGGGATATCACTCAACATA ATH 
5 ’ AGCGGATAACAATTTCACACAGGA ^ , ^ 
5 , 3 , I I G G m n C G G G A T A T C A r T r A r ^ r A 
Full-length Ml3 (-48) reverse sequence  \ ,,  
5 , A G C G G A T A A C A A T T T C A C A C A G G A X X X：^ / /  
3 , 
5 , 3 , I I G G m t . C G G G A T A T C A r T C A G C A T A A T C 
Full-length T7 promotor sequence 
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Fig. 1 Schematic diagram to show the c D N A fragment reamplification and 
priming site reconstruction using full-length Ml3 reverse (-48) 24-mer and 
T7 promoter 22-mer primers (Adapted from fluoroDD manuel, Genomyx). 
AP, anchored primer, ARP, arbitrary primer, nt, nucleotides. The sequence 
of M l 3 reverse (-48) and T7 promotor primers was bolded. 
For the 'Microprep' methods, bacterial cells from 500 i^L overnight bacterial 
culture were pelleted by centrifuging at 14,000 x g for 1 minute in a microcentrifuge. 
The LB medium was completely removed and the bacterial pellet was resuspended in 
19 |iL autoclaved distilled water by vigorous vortex mixing. The suspension was 
boiled for 1 min to allow the plasmid D N A to be liberated. Bacterial debris was 
removed by centrifuging at 14,000 x g for 1 minute and the supernatant was 
transferred to a new 1.5 m L Eppendorf containing premixed Ix EcoRI buffer and 1 
I^ L EcoRI restriction enzyme and incubated at 37 °C for 1 hour. Ten juL of the 
restriction digest was resolved on a 1% agarose, 0.5 x TBE gel followed by ethidium 
bromide staining. 
2.10 Purification of Plasmid DNA from Recombinant Clones 
The QIAprep® miniprep system was applied to purify the plasmid D N A for 
sequencing reaction. Interested clones were picked up again and transferred to 5mL 
LB with 50 |ig/mL amplicillin according to the appropriate cloning systems. The 
bacterial cells were shaken at 37。C in a rotary shaking incubator (Lab-Line, U.S.A.) 
at a speed of 225 rpm. After overnight incubation, bacteria were pelleted by 
centrifuging at 2,500 x g at 4 °C for 8 minutes. The supernatant was discarded and 
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excess LB medium removed. The bacterial cell pellet was resuspended in 250 ^ iL of 
Cell Resuspension Solution and transferred to a new 1.5 m L microfuge tube. Then, 
250 )iL of Cell Lysis Solution was added to the cell suspension and the tube was 
gently inverted 4 to 6 times until the solution becomes viscous and slightly clear. 
After 5 minutes, the cell lysate was neutralized with 350 juL of Neutralization 
Solution and mixed immediately and thoroughly by inverting the tubes 4 to 6 times 
again to avoid localized precipitation, followed by centrifuging at 10,000 x g for 10 
minutes and a compact white pellet was formed. The supernatant was applied onto a 
QIAprep column, centrifuged at 10,000 x g for 1 minute and the flow-through was 
discarded. The QIAprep spin column was washed with 0.75 m L of Buffer PE (wash 
buffer) and centrifuged for 1 minute at the same speed. The flow-through was 
discarded and additional centrifugation at 10,000 x g for 1 minute was applied to 
remove the residual wash buffer that may inhibit subsequent enzymatic reactions. For 
elution of the plasmid DNA, 50 |LIL of nuclease-free water were applied to the center 
of each QIAprep column and centrifuged at 10,000 x g for 1 minute. The 
concentration (ng/^L) of purified plasmid D N A was determined 
spectrophotometrically at 260 nm. 
2.11 DNA Sequencing of Differentiallv Expressed cDNA Fragments 
In brief, the sequencing mixture included 75 fmol purified plasmid D N A 
template, 1 x sequencing reaction buffer, 2 )LIL dNTP mix, 2 J^ L ddUTP dye 
terminator, 2 ^ iL ddGTP dye terminator, 2 |LIL ddCTP dye terminator, 2 IDL ddATP dye 
terminator, 1 i^L units Polymerase enzyme and 3.2 pmol sequencing primer. The 
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sequencing reaction was performed in a thermal cycler (Perkin Elmer GenAmp 9600) 
and the thermal cycle profile was: 30 cycles at 96 °C for 20 seconds, 50 °C for 20 
seconds, and 60。C for 4 minutes and hold at 4。C. Then, ethanol precipitation was 
applied to remove the excess dye terminators. Four microlitres stop solution (1.5 M 
sodium acetate and 50 m M EDTA) and 20 jug glycogen were added to each 
sequencing reaction. For precipitation, 60 )LIL of ice-cold 95% ethanol was added to 
the mixture and the tube was immediately centrifuged at 14,000 rpm at 4 °C for 15 
minutes. The supernatant was removed with a micropipette and the pellet was rinsed 
twice with 200 ^L ice-cold 70% ethanol. For each rinse, the tube was centrifuged 
immediately at 14,000 rpm at 4 °C for 15 minutes. After centrifugation, all of 
supernatant was carefully removed by a micropipette. The pellet was then dried under 
vacuum for 40 minutes and was resuspended in 40 ^L deionized formamide. 
Deionized formamide was prepared by mixing 5 g of resin with 100 m L formamide 
for 30 minutes. The resin and formamide mixture were the filtered through a 0.2 jum 
Nylon filter and filtered formamide was stored at -20。C. the resuspended samples 
were transferred to the appropriate wells of the C E Q polypropylene sample plate 
(Beckman, U.S.A.). Each of the resuspended samples was overlaid with one drop of 
light mineral oil from Beckman (U.S.A.). The C E Q sample plate was then loaded into 
the C E Q capillary automatic sequencer (Beckman, U.S.A.) for automated sequencing. 
The cycle sequencing reaction was prepared which contained 8 |LIL terminator 
ready reaction mix, 150 ng of plasmid DNA, 3.2 pmol sequencing primer. The 
sequencing reaction was performed in a thermal cycler (Perkin Elmer GenAmp 9600) 
and the thermal cycle profile was as follows: 25 cycles at 96。C for 10 seconds, 50 
°C for 5 seconds, and 60 °C for 4 minutes and hold at 4 °C. Then, ethanol 
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precipitation was applied to remove the excess dye terminators. The entire contents of 
sequencing reaction mix were transferred into new Eppendrof tube and mixed with 74 
I^ L of 70% ethanol/0.5 m M MgCl�. The tube was left at room temperature for 15 
minutes to precipitate the extension products. Then, the tube was centrifuged at 
13,000 rpm at room temperature for 15 minutes. The supernatant was carefully 
removed with a micropipette and the pellet was dried in vacuum centrifuge for 3 
minutes. The dried pellet was resuspended in 12 |LIL template suppression reagent. 
The mixture was denatured at 95 °C for 2 minutes and hold at 4。C The resuspended 
samples were transferred to the vial and was then loaded into the ABI PRISM 377 
D N A sequencer (Perkin Elmer, U.S.A.) for automated sequencing. 
D N A sequences obtained were first edited and then submitted to the Basic Local 
Alignment Search Tool (BLAST) rhttp://www.ncbi.rilTTi.riih.gov/cgi-bin/BLAST/nph-
newblast) for searching the homology of sequences against the known genes or ESTs 
in the genebank databases. 
i 
2.12 Reverse Transcription-Polymerase Chain Reaction fRT-PCR^ 
One |ig of total R N A was reverse-transcribed in a 20 juL reaction mixture 
containing 20 U of A M V reverse transcriptase (Boehringer Mannheim, Germany), 5 
m M MgCl2, 1 m M of each dNTP (Boehringer Mannheim, Germany), 40 U ofRNase 
inhibitor (Boehringer Mannheim, Germany), 3.2 g random primer p(dN)6 
(Boehringer Mannheim, Germany), 10 m M Tris/HCL, pH 8.3 and 50 m M KCl. The 
mixture was incubated at 25 °C for 10 minutes, then 42 °C for 60 minutes, heated to 
99 °C for 5 minutes and cooled to 4。C for 5 minutes. The RT samples were 
amplified immediately or stored at -20 °C until use. 
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P C R was performed in a total volume of 25 jiL containing of 0.625 to 0.5 \iL of 
RT sample (equivalent to 31.25-125 ng of total RNA), 0.625 U of Tag D N A 
polymerase (Boehringer Mannheim, Germany), 1.5 m M MgCb, 0.2 m M of each 
dNTP (Boehringer Mannheim, Germany), 0.2 |LIM of both sense and antisense 
oligonucleotides (Gibco, Hong Kong), 10 m M Tris/HCl, pH 8.3 and 5 0 m M KCl in a 
P C R machine (GeneAmp P C R system 9700, Perkin Elmer, U.S.A.). The PCR 
conditions were: 94 for 5 minutes, 25 to 35 cycles of 94 °C for 0.5 minutes, 56 to 
65 °C for 1 minutes to 1 minutes 15 seconds, 72 °C for 1 minute, followed by a final 
extension of 5 minutes at 72 °C. The sequences of PCR primers (Gibco, Hong Kong) 
were described in Table 1. 
A 5 |iL-aliquot of PCR products was loaded with 6 x loading buffer and 
separated on a 2 % (w/v) agarose gel. Each gel was run in 0.5 x TBE buffer at lOOV 
for 30 minutes, then stained with 1 jug/mL ethidium bromide solution and 
photographed under U V fluorescence, and the band density of the PCR was quantified 
by densitometry using the program ImageQuant (Microsoft) by Molecular Dynamics. 
Density of the band from the target gene being analyzed was first normalized by the 
corresponding band from P-actin gene, then the normalized value of the treated 
sample was divided by the normalized value of the control in the same set of 
treatment to obtain a relative density value. The higher densitometry value suggested 
higher gene expression. 
2.13 Western Riot Analysis 
To determine the kinase protein expression following cytokine and/or drug 
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treatment, C6 cells were seeded at 6 x 10^  cells/100-mm-diameter dish in 10 m L of 
C D M E M . Cells were cultured at 37。C in a humidified atmosphere of 5 % C02/95% 
air. On the next day, the culture medium was replaced with fresh medium. Stock 
solutions of individual cytokines and drugs were prepared in C D M E M and added to 
the culture medium to obtain the desired final concentrations. The time for the 
addition of drugs and/or cytokines was varied in such a way that all plates were 
harvested at the same time. 
At the time of harvest, the culture medium was removed and cells were washed 
with 5 m L PBS three times. One m L of Buffer A was added and the cells were 
scrapped with a plastic scrapper. Cells from 4 to 5 100-mm-dishes were combined 
into a 15 m L polypropylene centrifuge tube and centrifuged at 1,000 x g for 10 
minutes. Then, cell pellets were resuspended in 2 m L Buffer A and stored at — 70 °C 
until use. 
Frozen cells were thawed at room temperature. Rupture of cells was achieved by 
sonification at 5 microns twice for 20 seconds (Soniprep 150, M S E SANYO). 
Membrane and lysate fractions were separated by centrifugation at 46,000 x g for 30 
minutes in a Beckman J2-MC centrifuge. The supernatant containing protein kinase 
were resuspended in 1 m L Buffer A and the protein contents were determined 
according to the method of Lowry et al (1951) using bovine serum albumin as a 
standard. The cytosolic preparations were stored at -80 °C until use. 
Fifteen to twenty |Lig membrane preparation were loaded with 2 x loading buffer 
on a 10 to 15% polyacrylamide gel. The gel was run in 1 x running buffer at lOOV for 
1 1/2 hours. After electrophoresis, the gel, and the proteins on the gel were 
eletroblotted onto a nitrocellulose membrane (Schleicher & Schuell) using a semi-dry 
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blotting unit (Bio-Rad). The blot was set up as follows: five pieces of Whatman filter 
paper (presoaked with transfer buffer) were stacked on the platform of the semi-dry 
blotting unit, the wetted nitrocellulose membrane was laced on top of the filter paper 
stack, the gel was placed on the top of the membrane and three pieces of stacked filter 
paper were placed on the top of the gel. The transfer was carried out at a constant 
current of 30 m A per blot for two hours. 
Following protein transfer, the blot was washed with PBS, and incubated in 
blocking buffer for one hour. The primary antibody specific to the protein of interest 
was diluted 1:100 with blocking buffer, and the blot was incubated with diluted 
primary antibody overnight. The nitrocellulose membrane was washed twice for 5 
minutes each with wash buffer. The biotinated secondary antibody was diluted 
1:10,000 with blocking buffer, and the blot was incubated with the diluted secondary 
antibody for one hour. The nitrocellulose membrane was washed for 5 minutes in a 
wash buffer twice. Anti-biotin alkaline phosphatase conjugate was diluted 1 ：20,000 
with blocking buffer, and the blot was incubated with the diluted conjugate solution 
for 40 minutes. The nitrocellulose membrane was washed for 5 minutes in wash ； 
buffer three times, followed by washing twice each for 2 minutes with an assay buffer. 
Two i^ L CSPD® Ready-to-Use substrate (Tropix) containing 1:20 Nitro-Block™ 
(Tropix) were pipetted onto the membrane, and the blot was incubated with CSPD® 
solution for 5 minutes to allow the luminescent signal development. The 
nitrocellulose membrane was then exposed to a Kodak X-ray (XARR-5) film and the 
relative intensity of each band on the X-ray film was analyzed by ImageQuant 
(Microsoft) software on a densitometry system. The relative intensity greater than 
50% change comparing with the control was considered to be significant. 
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Chapter 3: RESULTS 
Recent studies showed that TNF-a was elevated in the serum and cerebrospinal 
fluid of humans after TBI (Goodman et al., 1990; Ross et al., 1994). The post-
traumatic inflammatory response was believed to be one of the causes contributing to 
tissue damage as well as to the induction of neuroprotective mechanism (Benveniste 
& Benos, 1995; Balasingam & Yong, 1996; Hessen et al., 1996; Kossmann et al,, 
1996, 1997). It has been known for a long time that astrocytes can be activated to 
secrete a number of cytokines including TNF-a (Benveniste, 1992) which can initiate 
gliosis. Moreover, some reports stated that TNF-a produced by glial cells could play 
an important role in nerve tissue regeneration by stimulating the proliferation of glial 
cells (Selmaj et al., 1990) as well as acting as an autocrine growth factor including 
differentiation of neurons (Munoz-Femandez et al., 1991). Recently, we showed that 
TNF-a could induce the C6 cell proliferation (Huang, 1996; Lung, 1999). However, 
the signaling cascades in response to TNF-a were still unclear. Therefore, attempts I 
i 
were made to find out the signaling pathway genes responsive to TNF-a in C6 cells. 
Therefore, F D D was used to screen differentially expressed genes following the TNF-
a treatment in C6 cells. To determine the effects of TNF-a on the expression of 
differentially displayed genes in C6 cells, the m R N A levels of these gene expression 
were measured by RT-PCR as described in Section 2.12, and the protein levels 
determined by Western blot analysis as described in Section 2.13. 
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3.1 DNase I Treatment 
C6 Cells were treated with TNF-a (100 U/mL) for different time periods, 0, 2, 5, 
15, 30, 60，120 and 240 minutes, R N A was harvested and subjected to fluorescent 
differential display reverse transcription-polymerase chain reaction (FDD RT-PCR) 
analysis. One hundred U/mL of TNF-a was used in this study as we found that this 
concentration produced maximum proliferation in C6 cells (Liu, 1996). As trace 
amounts of contaminating D N A in the R N A samples can produce false positives in 
the F D D banding pattern, all samples were treated with DNase L As shown in Figure 
2, no genomic D N A contamination was observed in the R N A samples after DNase I 
treatment. The ratio of OD260 to OD280 in the R N A samples was around 1.8 suggesting 
the samples were of high quality, R N A samples were subjected to F D D RT-PCR 
analysis. 
3.2 FDD RT-PCR and Band Excision 
Fluorescent differential display was applied to search for differentially expressed 
genes following treatment with TNF-a for times. One pair of AP and ARP 
combinations (API & ARP9) was used to screen for the differentially expressed genes 
(Fig. 3). The fluoroDD gel was separated by electrophoresis and three up-regulated 
c D N A fragments observed were chosen from the gels to undergo the reamplification 
and cloning study. 
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Figure 2. DNase I treatment of the m R N A of the rat C6 glioma cells. For each 
sample, approximately 10 |ig of total R N A was loaded per lane. No 
genomic contamination was observed in the R N A samples after DNase I 
treatment. Two of the high quality R N A samples derived from each time 
course treatment were chosen for the F D D RT-PCR analysis. The samples 
were loaded on 1% agarose, 0.5 X TBE gels with ethidium staining. 
I • r 
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700 bp 
inn . s , 
6 0 0 b p + — 、 ’ 举令、發i ^ ^ f : ; 、 《 ： ， ， + A 2 
Figure 3. Fluorescent differential display gel (Gel A). R N A in C6 cells treated with 
TNF-a (100 U/mL) for 0, 2, 5, 15, 30, 60, 120 and 240 minutes. Total R N A 
was reverse transcribed using the API primer. PGR reactions were 
performed in duplicate for each sample in the presence of 3, -TMR-labeled 
API and 5' ARP9 primers. The TMR-labeled fluorescent PGR products 
were run on a 5.6% denaturing polyacrylamide gel. Each lane represents 
one PGR reaction. Arrows indicate the fragments (A1-A3) excised for 
reamplification. M, TMR-labeled molecular weight D N A markers. 
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3.3 Reamplification of Excised cDNA Fragments 
The three up-regulated expressed c D N A fragments excised from the fluoroDD 
gels were subjected to the P C R reamplification using Ml3 reverse (-48) 24 mer and 
T7 promotor 22-mer primers. In order to obtain sufficient material for subsequent 
subcloning, several rounds of P C R reamplification were performed on each excised 
cDNA. 
The P C R products reamplified from the excised c D N A fragments from Gel A 
were illustrated in Figure 4. All three fragments excised from Gel A were successfully 
reamplified and the sizes were as expected fragment sizes (Table 5). The reamplified 
P C R were expected to have 13 nucleotides longer than the size of the fragments 
estimated from the fluoroDD gels. The faint bands observed in the reamplification 
could be due to artifacts generated during reamplification. Alternatively, these minor 
bands might be due to the reamplification of neighboring bands that co-migrated on 
the fluoroDD gel. 
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Table 5. Differentially expressed c D N A fragments after TNF-a treatment excised 
from Gel A. 
P r i m e r F r a g m e n t No. Approximate Size Up- or Down-
(bp) on FDD gel Regulated 
A P 1 & A P 9 Al 800b^ Up  
A P 1 & A P 9 A2 6 3 ^ Up  
A P 1 & A P 9 A3 Up  
7 5 
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Figure 4. Reamplification of c D N A fragments from Gel A. The c D N A fragments 
were excised from the fluoroDD gel, eluted with TE buffer and amplified 
by PCR using Ml3 reverse (-48) and T7 promoter primers. The PCR 
products were loaded onto 2% agarose, followed by ethidium bromide 
staining. M, 100 bp D N A marker. 
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3.4 Subcloning of Reamplified cDNA Fragments 
The AdvaTAge cloning systems was used to subclone the reamplified c D N A 
fragments. After subcloning, the high quality plasmid D N A from each recombinant 
clone was prepared using Wizard™ Plus Minipreps D N A purification system. Then 
the size of D N A inserts was checked by EcoRI restriction enzyme digestion for each 
recombinant clones subcloned in pT-Adv vectors respectively. 
The EcoRI digested D N A fragments derived from recombinant clones A3 and 
A5 were indicated in Figure 5. Three recombinant clones of Al (800 bp), A2 (650 bp) 
and A3 (520 bp) containing the correct insert sizes were observed. 
After confirming the insert size was equivalent with the reamplified cDNA 
fragments, the c D N A fragments were successfully subcloned into pT-Adv vectors. 
High quality plasmid D N A s was purified from all of these three recombinant clones 
for D N A sequencing. 
3.5 DNA Sequencing of Subcloned cDNA Fragment 
Three subcloned c D N A fragments (Al, A2 & A3) were successfully sequenced 
(Table 5). However, only two cDNA, A2 and A3 were successfully sequenced using 
with Ml3 and T7 primer, Al was successfully sequenced using T7 primer. The three 
c D N A fragments Al，A2 & A3 were derived from three known genes encoding rat 
5, -AMP-activated protein kinase, rat ribosomal protein L7a and rat p38 M A P K 
respectively (Fig. 6-9). 
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M A2 A3 Al 
m m “ r ； , vector 
p . . . plasmid 
舞 ‘ 攀 _ ‘ 
Figure 5. EcoRI restriction enzyme digestion of recombinant clones containing c D N A 
fragments, Al and A3. Plasmid D N A s were isolated from the recombinant 
clones according to the protocol of Promega Miniprep Method. The EcoRI 
digested D N A fragments were resolved with 1% agarose, 0.5X TBE gels 
followed by ethidium bromide staining. M, 100 bp D N A marker. 
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cDNA clone Sequence homology Transcript E-value Identities " 
(fragment size Primer (Nucleotide sequence) size 
or FDD gel) 
Al T7 Rat 5，-AMP- 1 5 ^ OO 424/430 
(800 bp) activated protein (98o/o) 
kinase 
(1132-1550) 
Ouery r 93 acatgatgnaaccttgtfccatttaatfcaggfctcgocacaaaaagcattaatcttacictcc 152 仇‘ , 1 …mnmmmm mmmiimmmimmmmmiT m ~ 
Ste3C2t’K 1S50 cftatgafcgaaaccttgt-cattta^ ttaggfctcgccaeaaaaageattaatcfcfcgggtcc 14 92 
Oueryi 153 ctacccaccg€cctactccaca9^ gcqafcctgccttc9tctgcacagc-<2casgagccqgg 212 
,… n i M i i M i i i i i i i i i K n m i m m 川 m m m n n n n m i i i ‘ 
Qu錢ryr 213 acgcacctcccgagactcafegggaaggacttgacagc^aacagcccagcatccfecaacaca 272 
編 , m i m i m ! m m i m " : m m 、 m , m m m m m n m m m 
Sbjefcs 1431 acgcaactcecgagactcatgggaaggactsacagcaaacaggccagcctcctccaeaca 1372 
Query; 273 gagtgaagaaagagg^ataaaaataott-tacc^aagacttctgcagagctattctcttaat 332 
, m i m i i m i m i m ' m m i m 川 m m m m m m i m m f i “ 
Sslxjet; li7l gagtgaagaaagaggaataaaaatacttfcaccaagacttotgcagagatattctcttagt 1312 
Q议錢ry; 333 ggagtaagggcagagacagaggtggggcgtggtgaggtctagggatetcfctagagatcaq 392 
. m H " ! m m m " m m m m m m m m m m i m i m m i 了 
••^fejets 1^11 sS^ Sfcaagggcagagacagaggtggggagtggtgag^ fcctcgggatccctcagagafccag 1252 
QiMdry: 393 gatctgcefcgaggagcaciaaaacccgttggttcacc^ acaagggggctqtqacqaqcQact- 452 
PM .…"JJi川m"jm""mm川mmmmm"1mm'M"i^ 、 
Sfejets XDBX gatat9cctgaggagcaeaa,aacccat.9gttcacccacaagggggctgtgacgagcgact 1192 
Qyexrys 453 ggpctg90ta9g,ctgii.caagtgttttctcaagtgtaHDaagatggt-ga3agaagctaac 512 
. 丨 川 i ⑴ H U ⑴ 川 m m i m m m m m m m m m m 
Sbjctt llBi ggggctggcfcaggct^ ag^ agtstfctfcctc^ astge^ gcacgatggtgiigagaagctaac 1x32 
Figure 6. Sequencing comparison between the c D N A fragments Al isolated from 
differentially display gel and rat 5 ’ A M P protein kinase. The insert was 
sequenced using C E Q 2000 dye terminator cycle sequencing system in the 
presence of T7 primer. The sequence of fragment Al was compared to 
entire non-redundant sequence database at the National Library of Medicine 
using BLAST. 
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cDNA clone Sequence homology Transcript E-value Identities 
(fragment size Primer (Nucleotide sequence) size 
or FDD gel) 
A2 T7 Rat ribosomal protein 446/460 
(650 bp) L7a (950/0) 
(400-850) 
Q u e r y : 8 1 a c t b t g t a ^ t t a t a f c - t t a t g t a c ' t g a a a a c t f c a a g t g t a c a t t f c a a c c ' c a g c t t a q t q q c 14 0 
J i m i m i m m m 丨 m m m m 丨 M m i m m i M m m i M i i • 
Sb:jC!tj 650 acfcfctgtaattatatttatgfcacagaaaacttaagtgtacatttaacccagctfcagtggc 791 
Ouery ? 141 gagttctttagcctttgccfctfctcaagcfcfcgscaatgcgagccacagacttaggacccag 200 
“ 111111111i111MI i 11111 n I i 11111111111111 f [ MI! I n M11111 n I i 
790 g a ^ t t c t t t a g c c t t t g c c t t . f c t c o a g c t t g g c a a t g c g a g c c a c a g a c t t a g g a c - c c a g 7rn 
O u e r y j 2 0 1 g a c g t t g c c t c c c s a g - t g e o g g c g g a t c t c g t c a t a t c t g t c a t t a t a a t t g g t c c t a a t 260 
k, I i M I! 11! 1 j! I n 1111! I n 11! 111111 j n 11111 i I i 111 n ! 11 I I! i i I M I 
S b j c t ! 730 g a c : g t t g a c t c c e c a g t 9 9 e g g c g g a t o t c 0 t e a t a t c t g t c a f c t a t a « ! > t t g g t c c t a a t 6 71 
Qu«尝2€X a0CttGcacca9Ctt,a0ccaga9a^ccJottgtct;tcccgagttcacctgt9tgaaggcaa 32 0 
. 丨 m m m m m m m i m m m m i i imiimm丨丨mm丨丨 
S b u e t f a g c t t c c a c c a g - c t f c a g c q a g a ^ c a c c c t t g t c t t c c - ^ a g t t c a c c t g t g t g a a g g c a a € 1 2 
Queryr cattgtggtgcafcgtcttectgfeggacoaggcgcicccagcctagcct;kUcccttqafcqat 380 
. ii i m i m m m m i m M m m m i m m i j m m m l H . m 
Sfo;3 e t ： 6 1 a c a — g t g g t s c a t g t c t f c c c t g t g g a c c a g g c g c c c c a ^ c c t g g c c t t t c c c t t g a f c g a t 554 
Query j 381 gcagtagggcacccccatctfcf:cgaGacagggca9ggacaggaaaaccaccaqcfcca,atq 440 
1 • M i m m m m m m m m m i m 丨 丨 u i i i i u M i i i n i i i M i i 
t々orjet 1 SS3 9cagtagggcacGC'ccatctfcfccgacacagggc:agg"~caggaaaaccaecc<gGtcaatg 496 
Qu©x'y? 441 ggggtctacatcatggggcaatcacccacscagctgagcettctfcgttcttccaccaa-qt; 439 
i f I I M M i m i m M I I U I I I ! f i I I I I ! ! I M H I I I M 1 1 i l l i l l l —" 
49S g g g - t c t a c c i t c a t g g g - ' c a a t c a c c - a c c a g c t g a g c c t t c t t g t t c t " c c a c c a a a g t 440 
Ouery； BQO ggtgactgfcafcagaaccctgc^cggaagacaggfcgotctc S39 
, m i m m i 丨丨 i i m i i m i 丨m m i i i m 
S b j c t ; 4 3 3 g g t g a c t g f c a t t g a c c c c t g c f c c g g ^ g g a c a g g t g g f c c t c 4 00 
Figure 7. Sequencing comparison between the cDNA fragments A2 isolated from 
differentially display gel and rat ribosomal protein L7a. The insert was 
sequenced using C E Q 2000 dye terminator cycle sequencing system in the 
presence of T7 primer. The sequence of fragment A2 was compared to 
entire non-redundant sequence database at the National Library of Medicine 
using BLAST. 80 
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cDNA clone Sequence homology Transcript E-value Identities 
(fragment size Primer (Nucleotide sequence) size 
or FDD gel) 
A2 M l 3 Rat ribosomal protein e-102 213/217 
(650 bp) L7a (930/0)  
J (270-482) ^ ^ 
109 acaggcaaacagcgactcagctgctfeaagcttgoGcacaagtioaggq^cagagacaaagc 168 
… i m i i i i i i i i i i m m i i m i i i i m i i m m i m i i m i i i m i i m 
Sbjct： '270 acaggcaaacagcgactcagctgctfcaagcttgcGcaca&g-tapaQgcfoa'gag^caaagc 329 
Query? 169 a09a9a,aga^gqagaggctgotggcccgG!gctgagaatgaaagctgcl:gg0aatggggac- 228 
i j . i i i i i i i i i M i i n i i i M i i i n i M i i i i i i i i i i i m m m m i m m i ‘‘ 
Sbjct： 330 aggigaagaagcagaggctgctggcccgcgctgagaa-gaaagctgctggcaaaggggac. 30$ 
Qu^ yy-. 22 9. gtcccaactaagagaccacotgtcetecgagcaggggtcaafcacagtcaccdactttggt 3S8 
i m i M i m m i i m i ' m m i i m i i m i m m m m iiiniiiii 
Sbjett 389 gtcccaactaagagaccacctgtcdtccgagca^gggtaaatacagtca-dcecbttggt 447 
Queryi 2B9 ggagaaccaaagaaggctcagctggtggtgatfcgccc 325 
I I II I II l l l l l l l l l l l l l i l l l l l lMIIIIII 
. Sbjct； 448 ggagaac—aagaaggctcagctggtggtgattgccc 482 
Figure 8. Sequencing comparison between the c D N A fragments A2 isolated from 
differentially display gel and rat ribosomal protein L7a. The insert was 
sequenced using C E Q 2000 dye terminator cycle sequencing system in the 
presence of Ml3 primer. The sequence of fragment A2 was compared to 
entire non-redundant sequence database at the National Library of Medicine 
using BLAST. 
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cDNA c l o n e S e q u e n c e homology Transcript E-Talu^^ TcJentities | 
(fragment size Primer (Nucleotide sequence) size I 
or FDD gel) 
A3 M13 Rat p38 M A P K n u m 
(520 bp) (2669-2888) (97%) 
；gi^ g?；^^^ . :.••‘ ；；；"•：：.• iI；-;；；：•.::：；•：：：憑：：；：；•；：：：'• ； ： 化 ： ： ： ： . ； 
.；‘；.-：.：；：.：：：；：：：^^^ . 
、'：、、、…、I、丨川 11111111 I f III111111 iT'i 111.1! I ！ I i III11 n I] I I'niVi 111 (11 ‘ 
aqagftctcg-tatttaggtcaaggtgtctccafctctctatqigtgeagggao^tgaagt 2727 
:tt^ tgtgggg<jag99tag0accot0catc4tctggagac.cagaaggaiggccg^ ct:'ggci2# 225 
;；;; - M I I 1111 I I I i 111 1111 {111 I {I 11 11 I 111111-|'(.|.||| If) I |,j ()[-|| I j 
妹、-37-28 tfeotgtggggeagggtagQaccctgeatcatttggagcccagaaggaggacs^cfcggcea n m 
ggcctcaccgcctcagtatgcagtcccagctccacgtcatcccctcacaatggfctagtiQ 285 
‘ r � 川mmmifiiimim iimmmmimimmmmmf 
m ^ t t 27as -ggccteaccgcctcagtatgaagt-dcagctacacgtcatcccctcacaatlftfcagtag 2646 
QmxY't 2m ca^ccgtctgggtttgaaccgccaggcgtsgfctatattattgag 329 
• --- - ‘ III irmmmm imimmmimimm 
Bpjcti 2847 daa-cgtctgggtttgaa-cgccaggcgtggttatattattgag 2888 
Figure 9. Sequencing comparison between the cDNA fragments A3 isolated from 
differentially display gel and rat p38 MAPK. The insert was sequenced 
using CEQ 2000 dye terminator cycle sequencing system in the presence of 
M13 primer. The sequence of fragment A3 was compared to entire non-
redundant sequence database at the National Library of Medicine using 
BLAST. 
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~ C D N A c l o n e S e q u e n c e homology Transcript E-value Identities 
(fragment size Primer (Nucleotide sequence) size 
or FDD gel) 
^ T7 Rat p38 M A P K 3 m 212/234 
(520 bp) (2872-3037) (900/。） 
.:.::了::::.:；^，、〉.::)5::‘5;^\>»乂::-》:.:.:^ ：.••：..：.> :::.v‘v,:.......,,:...:...:...:.........«...,.....,,.... 
Qmiy t gtetlxtGiaiittxecttgti^ tteis^ aatgga^ cjaaac^ tgggtggc^ QgcjaseaatcegcaG 270' 
u 丨 i m m i mill；! nil Hill iii.ii m i m i m i i m m iiiii ‘ 
wjcti 3(^ 37 §tcttatca"-ttccctt;gt6ttQCaa-tgga9-aaactgggtggcggGagdat--cgcac 29m 
Queiy丨 171 ciaafcggcatgccaaggcagctottctge^^agGtcfcagcattccaagtccgggccctgggg 330 
Bhjct； 2982 da-tgg»atgcdagg-»ag^tcttctgccagotetagctt--caagtccgggccct^ggg 2n$ 
Ouery^ 331 caaagfccctaacaacigcitgigccacatgtgaaaaagtgcatcctcaataatataaddM a^O 
, [ i m m m i i i i i i i i j i T i i i i i n m i n i i i i m ' m i i m i m H . � : ’ 
则et，’ 292-8 織卿购 g e e a G a t g t g Q繊鄉 -省 t G G t c料 t a a t a t a a舰 c i 2i,?a 
Figure 10. Sequencing comparison between the cDNA fragments A3 isolated 
from differentially display gel and rat p38 M A P K . The insert was 
sequenced using CEQ 2000 dye terminator cycle sequencing system in 
the presence of Ml3 primer. The sequence of fragment A3 was 
compared to entire non-redundant sequence database at the National 
Library of Medicine using BLAST. 
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3.6 Confirmation of the Differentially Expressed cDNA Fragments bv RT-PCR 
and Western Blotting 
As the major aim of this study was to understand the signaling pathway 
mediating the proliferative action of TNF-a in C6 cells, further studies were carried 
out to confirm whether p38 M A P K was indeed up-regulated after TNF-a treatment. 
3.6.1 Effects of TNF-g on D38 a Mitogen-Activated Protein Kinase RP38 a 
MAPK� 
To confirm whether the gene of interest was up regulated, a time course 
experiment on the effect of TNF-a on the p38 a M A P K expression was performed. 
Figure 11 showed the m R N A levels of the p38 a M A P K in C6 cells after exposure to 
TNF_ a (100 U/ml) for various time intervals (0, 2, 5, 15, 30，60, 120 and 240). This 
concentration of TNF-a had been found to induce maximum proliferative effect (Liu, 
1996). The p38 a M A P K level was enhanced in cells treated with 100 U/mL TNF-a 
as early as 2 minutes, continued to rise up to 4 hours and the maximum induction was 
observed at 4 hours (Fig. 11a). Thus, the induction is time-dependent. For the IL-6 
treatment, the p38 a M A P K expression was relatively constant (Fig. lib), suggesting 
the specificity of TNF-a action. On the other hand, the m R N A levels of p-actin, in the 
presence of TNF-a or IL-6, at all time points examined were relatively constant 
throughout the study. The P-actin m R N A level was used as an internal standard for 
equal loading in this and other studies. This indicates that TNF-a specifically induced 
p38 a M A P K expression in C6 cells. 
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Results 
a) TNF-a treatment 
M C 2 5 15 30 60 120 240(min) 
p38 a MAPK -301 bp 
1 5.87 6.14 15.35 8.92 9.06 17.53 23.55 
P-aetin -201 bp 
b) IL-6 treatment M C 2 5 15 30 60 120 240(min) 
MAPK -301 bp 
1 1.04 0.98 0.95 0.99 1.05 1.09 1.03 
-201 bp 
Fig. 11 Effects of TNF-a and IL-6 on the levels of p38 a M A P K m R N A in C6 
cells, (a) Effects of TNF-a on the levels of p38 a M A P K m R N A in C6 
cells. C6 Cells were treated with 100 U/mL TNF-a for 2 minutes to 4 hours 
and the total R N A was extracted and followed by RT-PCR as described in 
the Methods, (b) Effects of IL-6 on the levels ofp38 a M A P K and P-actin 
m R N A in C6 cells. C6 Cells were treated with 10 ng/mL IL-6 for 2 minutes 
to 4 hours. After 30 cycles of amplification, a 5-|iL aliquot of the PGR 
product was electrophoresed on a 2 % agarose gel, stained with ethidium 
bromide and photographed. The untreated cells (C) served as control. The 
sizes, in bp，of the PGR products were indicated on the right. The D N A 
markers (M) were also run on the same gel. The amounts of the PGR 
products were semi-quantified by densitometry, and the value below each 
band represents the relative intensity after normalization with respect to that 
of P-actin. Data presented are representatives of three separate experiments 
with similar results. 
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3.6.2 Effects of TNF-a on p38 a MAPK and p-p38 a MAPK Protein Level 
In order to examine whether the protein levels of phosphorylated p38 a M A P K 
(p-p38 a M A P K ) were affected in the similar manner as that of the m R N A , the 
expression of p38 a M A P K proteins after TNF-a treatment was analyzed by Western 
blotting. The phosphorylated state of p38 a M A P K was examined as p-p38 a M A P K 
becomes activated through phosphorylation on an exposed surface loop, usually 
referred to as the phosphorylation lip or activation loop (Hanks & Hunter, 1995； 
Raingeaud & Gupta, 1995). The p38 a M A P K acts as the total protein that is not 
activated. Fig. 12 showed the protein levels ofp38 a M A P K and p-p38 a M A P K in 
C6 cells after exposure to 100 U/mL TNF-a for different time intervals (0, 15, 30, 60， 
120, 240, 1440, 2880 mins). Only one single band of about 38 kDa was detected, and 
the molecular mass of this band was about the same as the protein product of the 
cloned p-p38 a M A P K (Wang et al., 1997). 
After exposure to TNF-a, the p-p38 a M A P K protein was selectively and much 
induced at 30 minutes and reached its optimum at 4 hour and then plateaued from 24 
to 48 hours. These data illustrated that TNF-a selectively up-regulated the protein 
level ofp-p38 a M A P K (Fig 12a) as well as that of m R N A (Fig. 11). On the other 
hand, the p38 a M A P K was relatively constant and was low in unstimulated cells. 
This suggests that p38 a M A P K needs phosphorylation before taking out any effects 
on the cells (Hanks and Hunter, 1995; Raingeaud and Gupta, 1995) and the induction 
of p-p38 a M A P K was coupled with that of the m R N A expression. The slight delay 
m the induction of protein expression compared to that of m R N A may be related to 
the time required for translation and phosphorylation. 
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TNF-a (100 U/mL) treatment 
M C 15 30 60 120 240 1440 2880 (min) 
P-P38 a MAPK ^ “ ， ， 辨 _ -38 kDa 
滅 ® ； 無 纖 編 纖 傭 缴 纖 礙 ^ ^ ^ ^ ^ ^ ^ 徽 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 縫 l ^ g l ^ ^ l l 騰 塞 翁 麗 
1 1.34 4.56 5.79 7.23 9.47 10.11 10.03 
p38 a MAPK ‘ 冷 ' ： 嫩 玲 勢 • 糠 m ^ _38 kDa 
1 1.12 1.03 1.14 1.17 1.06 1.19 1.24 
Fig. 12 Effect of TNF-a treatment on protein levels ofp-p38 a M A P K (a) and p38 
a M A P K (b) in C6 cells. C6 Cells were treated with 100 U/mL for 15, 30, 
60, 120, 240, 1440 and 2880 minutes. The untreated cells served as the 
control (C). Thirty jug of membrane protein were electrophoresed in a 10 % 
polyacrylamide gel and transferred onto a nitrocellulose membrane as 
described in the Methods. The protein bands of interest were detected using 
specific serum against p-p38 a M A P K (a) or p38 a M A P K (b), and the 
luminescent signal generated was detected by exposing the membrane to an 
X-ray film. Protein markers (M) were also run on the same gel, and the 
sizes，in kDa, of protein bands were indicated on the right. The amount of 
the protein in each band was semi-quantified by densitometry, and the value 
below each band represents the relative intensity with reference to the 
control which was taken as unity. Data presented are representatives of three 
separate experiments with similar results. 
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Together with the observation that TNF-a would induce the p38 a M A P K 
m R N A level (i.e. c D N A fragment A3) as revealed by fluorescent differential display 
(Fig. 3) and RT-PCR (Fig. 11), this study confirm that TNF-a induced the expression 
of both p38 a M A P K m R N A and protein. Moreover, p-p38 a M A P K was likely the 
product induced by TNF-a. 
3.7 Effects of TNF-g on p38 MAPK 
As stated in Sections 3.6.1 and 3.6.2, the p38 a M A P K expression elevated after 
the exposure of TNF-a. Further investigation was carried out to study on the 
differential expression of different isoforms of p38 M A P K after the treatment with 
TNF-a. 
3.7.1 Effects of TNF-g on p38 a. [3. y and 5 MAPK 
As p38 M A P K exists in several forms, e.g., a, p, y and 6, we examined the specificity 
of the TNF-a-induced p38 M A P K expression. A time course experiment on the effect 
of TNF-a on the p38 a, p，y and 5 M A P K expression was monitored by RT-PCR. 
Figure 13 showed the m R N A levels of the p38 a, p，y and 6 M A P K in C6 cells after 
exposure to TNF-a (100 U/ml) for various time intervals. This concentration ofTNF-
a had been found to stimulate the expression of p38 a M A P K as early as 2 minutes 
(Fig. 13). The p38 a M A P K level was enhanced by about 6 folds at 2 minutes after 
TNF-a treatment, continued to rise up to 15 minutes, declined slightly but still 
maintained at high level from 30 to 60 minutes, then increased greatly at 2 and 4 
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hours. The maximum induction was observed at 4 hours and at this time, the level was 
about 2-4 folds than that of the control. The p38 p m R N A was enhanced at around 60 
minutes and remained high up to 2 hours and then declined slightly. The highest 
stimulation observed was about 5 folds than that o the control (Fig. 13). The m R N A 
of p38 Y M A P K was slightly enhanced at 2 and 5, by 2 folds at 15 minutes and then 
maintained at 1.3 to 1.9 folds up to 4 hour. For the p38 5 M A P K , the TNF-a induction 
was relatively insignificant at the first hour, then increased by 3.5 folds at 2 hours then 
declined. The m R N A levels of p-actin in these cells were relatively constant 
throughout the study. As the level of p38 a M A P K isoforms was most rapidly and 
greatly induced by TNF-a, it suggested that this cytokine selectively induced this 
isoforms expression. More importantly, this finding indicates TNF-a exerts its 
proliferative action in C6 cells through this p38 M A P K isoforms. In the following 
section, the p38 a M A P K was abbreviated as p38 M A P K . 
3.7.2 Role of TNF-Receptor (TNF-R) Subtype in the TNF-g-Induced p38 MAPK 
expression in C6 cells 
To date, very little is known about the TNF-a receptor subtype mediating the 
signal transduction mechanism that leads to cell proliferation. Recent studies in our 
laboratory (Huang et al., 1998) showed that TNF-a selectively induced the expression 
of TNF-R2 and that using selective TNF-R antibodies, TNF-R2 was found to be 
responsible for the proliferative effects in C6 cells (To, 1999). Therefore, attempts 
were made to elucidate whether TNF-Rl or TNP-R2 or both was/were responsible for 
the TNF-a-induced p38 M A P K expression. 
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M C 2 5 15 30 60 120 240 (min) 
p 3 8 a M A P K bp 
''。力'心 * ' 么 “ 丄 ’ 众 . ^ " 〜 。 
1 5.87 6.14 15.35 8.92 9.06 17.53 23.55 
p38 P MAPK -205 bp 
1 0.91 0.97 0.99 0.84 4.68 5.37 3.12 
p38 Y MAPK -601 bp 
1 1.24 1.89 2.35 1.84 1.69 1.93 1.31 
p38 5 MAPK -295 bp 
1 1.23 0.91 0.89 0.88 0.92 3.56 1.56 
Fig. 13 Effects of TNF-a on the levels of p38 a, (3, y and 5 M A P K m R N A in C6 
cells. C6 Cells were treated with 100 U/mL from 2 minutes to 4 hours, the 
total R N A was extracted and followed by RT-PCR as described in the 
Methods. The untreated cells (C) served as control. The sizes, in bp, of the 
PCR products were indicated on the right. The D N A markers (M) were also 
run on the same gel. Data presented are representative of three separate 
experiments with similar results. 
9 0 
— — R e s u l t s 
a) TNF-Rl Ab Treatment 
M C TNF-a 1 2 5 20 30 60 120 (min) 
p 3 8 a 
MAPK -301 bp 
1 4.97 3.84 2.97 4.73 2.63 3.24 3.41 3.01 
一 -201 bp 
b) TNF-R2 Ab Treatment 
MAPK -301 bp 
1 7.93 5.21 7.72 3.30 1.49 1.02 1.26 1.17 
-201 
Fig. 14 Effects of TNF-receptor subtype antisera on the TNF-a-induced p38 
M A P K expression in C6 cells. C6 Cells were treated with TNF-Rl (0.08 
l^g/mL) or TNF-R2 antiserum (0.08 ng/mL) for 1, 2, 5, 20, 30, 60 and 
120 minutes, then TNF-a (100 U/mL) was added to the cell for another 2 
hours. The total R N A was extracted and followed by RT-PCR as 
described in the Methods. The untreated cells (C) served as control. The 
sizes, in bp, of the PGR products were indicated on the right. The D N A 
markers (M) were also run on the same gel. Data presented are 
representatives of three separate experiments with similar results. 
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In this experiment, cells were treated with TNF-R 1 (0.08 ug/ml) or TNF-R2 
antiserum (0.08ug/ml) alone for different time periods (1, 2，5, 20, 30，60 and 120 
minutes), followed by TNF-a (lOOU/mL) treatment for another 2 hours. Then TNF-
a-induced p38 M A P K and P-actin expression were measured by RT-PCR. It was 
found that TNF-Rl antiserum treatment caused 23% to 40% decreases in the 
expression of p38 M A P K , while that of P-actin was relatively constant. On the other 
hand, the addition of TNF-R2 antibody blocked the induction ofp38 M A P K by 81% 
at 20 minutes, and almost complete blockade was observed at 30 to 120 minutes. 
Even at 5 minutes following TNF-R2 antiserum treatment, the TNF-a-induced p38 
M A P K expression was decreased by 58%. Therefore, it suggests that the TNF-a-
induced p38 M A P K expression in C6 cells be mainly mediated through the binding of 
TNF-a to TNF-R2. 




The above study showed that p38 a M A P K was up-regulated after the addition 
of TNF-a and that this induction process was mediated through TNF-R2, it was 
therefore of our interest to investigate what was the signal transduction mechanism 
mediating this action of TNF-a. In this study, the possible roles of PKC and P K A 
pathways were concentrated, as both are common signaling pathways of TNF-a in 
other tissues (Zablocka et al., 1998; Saxena et al, 1999). 
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3.7.3.1 The Involvement of PKC in TNF-g-Induced D38 MAPK Expression in C6 
Cells 
In this study, the effect of a P K C activator, phorbol 12-myrisate 13-acetate 
(PMA) and a PKC inhibitor, 3-{l-[3-(amidinothio)propyl]-3-indolyl}-4-(l-methly-3-
indolyl)-lH-pyrrole-2,5-dione methanesulfonate (Ro-31) and staurosporine, on the 
induction of p38 a M A P K was investigated. These agents were found to be selective 
activator and inhibitors of P K C in C6 cells (Tsang et al., 1997). 
For the P K C activator study, different dosages: 0.0612, 0.162, 1.62, 16.2 and 
162 n M of P M A were added to the cultures and the p38 M A P K and p-actin m R N A 
contents were semi-quantified by RT-PCR. As shown in Fig 15, the m R N A levels of 
p38 M A P K was enhanced as the concentration of P M A increased from 0.0162 to 16.2 
nM, and the optimal stimulation was observed with 16.2 n M of P M A (Fig. 15). On 
the other hand, the P-actin level remains relatively constant at all P M A concentrations 
tested. This result suggests that activation of P K C can increase p38 M A P K expression 
f 
in C6 cells and this stimulation is concentration dependent. 
In order to ensure the stimulatory effect observed with P M A was specific and 
that the action of TNF-a was mediated through PKC, the inhibitory effect of Ro31 
and staurosporine on TNF-a induction of p38 M A P K was studied. The dosage effect 
of Ro31 in the presence or absence of TNF-a (100 U/mL) on the m R N A levels of p38 
M A P K was shown in Fig 16. In this study, C6 cells were pretreated with 10, 50, 100， 
200 or 500 n M Ro31 for 2 hours, then exposed to TNF-a (100 U/mL) for an 
additional 2 hours, and the m R N A levels for p38 M A P K and p-actin were semi-
quantified by RT-PCR as described in Fig 18a. Two hours pretreatment with this PKC 
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inhibitor has been found to have maximum inhibition effect (Tsang et al., 1997). 
TNF-a at 100 U/mL had been found to produce maximum proliferative effect (Lung, 
1999). Ro31 alone did not affect, to any significant extent, the expression of p38 
M A P K m R N A at all concentrations of Ro31 tested (Fig 16b). However, the 
inhibitory action of Ro31 on the TNF-a induction of p38 M A P K was dose-dependent, 
and greater than 50 % inhibition was observed with 10 n M ofRoSl and much greater 
inhibition was observed with 50, 100 and 200 n M of Ro31，and almost inhibition was 
observed with 100 and 200 n M of Ro31 (Fig. 16a). 
To ensure that the inhibition observed with Ro31 was selective, the action of 
another P K C inhibitor, staurosporine, was tested. In this study, C6 cells were 
pretreated with 10, 50, 100, 200 or 500 n M staurosporine alone for 2 hours, then in 
the presence of TNF-a (100 U/mL) for an additional 2 hours, and the levels of p38 
M A P K and P-actin were semi-quantified by RT-PCR. In the presence of 
staurosporine, the level of TNF-a-induced p38 M A P K expression decreased when the 
concentration of staurosporine was increased, and about 50% inhibition were ‘ 
r 
f, 
observed with higher concentrations of staurosporine (Fig. 17a). Similar to the effect 
of Ro31, staurosporine did not affect the expression of p38 M A P K at all 
concentrations of inhibitor tested (Fig 17b). Together with the observation that P M A 
activated p38 M A P K induction, these results suggest that P K C is involved in 
mediating the induction of p38 M A P K by TNF-a in C6 cells. Similar to previous 
finding (Tsang et al., 1997), Ro31 was a much more effective inhibitor than 
staurosporine. 
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M C 0.0162 0.162 1.62 16.2 162 PMA (nM) 
p38 MAPK ! _縛越餐磁•—磁 f a s S ^ ^ i f e ' i F ! .301 bn 
1 5.73 4.86 5.14 6.19 0.98 
Fig. 15 Effect of P M A on the levels p38 M A P K and p-actin m R N A in C6 cells. C6 
cells were treated with 0.0162 to 162 n M of P M A for 2 hours and the total 
R N A was extracted and followed by RT-PCR as described in the methods. 
The untreated cell (C) serve as the control. Other details were as described 
in Fig. 11. Data presented are representatives of three separate experiments 
with similar results. 
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a) R o 3 1 ( n M ) + T N F - a 
I 1 
M C T N F - a 10 50 100 200 
P 麗 A P K 301 bn 
1 7.34 3.21 2.37 1.29 1.08 
一 ^ ^ E ^ B 福 p 
b) M C 10 50 100 200 R o 3 1 
(nM) 
p38 M A P K ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ -301 bp 
1 1.26 1.17 1.29 1.13 
Fig. 16 Effect of Ro31 on the level p38 M A P K m R N A in the presence or absence 
of TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a 
alone for 2 hours, or pre-treated with 10 to 200 n M of Ro31 for 2 hours 
before the addition of TNF-a. (b) C6 Cells were treated with 10 to 200 nM 
Ro31 only for 4 hours. The untreated cells serve as the control (C). The 
sizes, in bp, of the PCR bands were indicated on the right. The total R N A 
was extracted and followed by RT-PCR and other details were as described 
in the Methods and Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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a) staurosporine (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 200 500 
-301 bp 




M C 10 50 100 200 500 (nM) 
p38 IVIAPIC "301 bp 
• i M M M 
1 0.92 0.98 0.94 1.03 1.16 
p.aeti„ -201 bp i 
Fig. 17 Effect of staurosporine on the level p38 M A P K m R N A in the presence or 
absence of TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL 
TNF-a alone for 2 hours, or pre-treated with 10 to 500 n M of staurosporine 
for 2 hours before the addition of TNF-a. (b) C6 Cells were treated with 10 
to 500 n M staurosporine only for 4 hours. The untreated cells serve as the 
control (C). The sizes, in bp, of the PCR bands were indicated on the right. 
The total R N A was extracted and followed by RT-PCR and other details 
were as described in the Methods and Fig. 11. Data presented are 
representatives of three separate experiments with similar results. 
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3.7.3.2 The Involvement of PKA in TNF-a-Induced p38 MAPK Expression in C6 
Cells 
P K A pathway is an important second messenger system in many tissues (Yao & 
York, 1998; Saxena et al., 1999). In this study, the effect of protein kinase A (PKA) 
activator, N^-2'-dibutyryl cyclic adenosine-3 ‘ ,5, monophosphate (dbcAMP) 
(Messens & Siegers, 1992) and two selective P K A inhibitors: 14-22 (Paman, et al., 
1998; Rimon & Rubin, 1998) and H-89 (Chijiwa et al., 1990; Siegers & Anciaux, 
1997) were used to study the role of P K A on the induction of p38 M A P K in C6 cells. 
Following treatment of cells with 10^ 10^ 10^ 10^ or 10^ n M of dbcAMP, the 
contents of p38 a M A P K and P-actin m R N A were semi-quantified by RT-PCR. p38 
M A P K m R N A level was increased as the concentration of dbcAMP increased. The 
induction with 10^ and 10^  n M dbcAMP was similar to that with 100 U/mL of TNF-a 
(Fig. 18). This result suggests that activation of P K A can increase p38 M A P K in C6 
cells and that there is a good correlation with the concentration of activator acted. 
In order to ensure the stimulatory effect seen with dbcAMP and to examine 
whether the action of TNF-a was mediated through PKA, the inhibitory effects of 14-
22 and H-89 on the TNF-a-induced-p38 M A P K was studied. The dosage effects of a 
selective P K A inhibitor, 14-22 in the presence or absence of TNF-a (100 U/mL) on 
the expression of p38 M A P K was studied. In this study, C6 cells were pretreated with 
10, 50, 100, 200 and 500 n M 14-22 alone for 2 hours, and followed by the addition of 
TNF-a (100 U/mL) for another 2 hours, and the m R N A levels of p38 M A P K and P-
actin were semi-quantified by RT-PCR (Fig. 19a). The TNF-a-induced p38 M A P K 
was suppressed and a 75% inhibition was observed with 200 n M of 14-22, while the 
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levels of P-actin was relatively unaffected (Fig. 19a). 14-22 alone at all concentrations 
tested did not cause any clear changes in the expression of p38 M A P K and p-actin 
m R N A (Fig. 19b). 
Another P K A inhibitor, H89 was used to confirm the role of P K A in the TNF-a-
induced p38 M A P K expression. In this study, C6 cells were pretreated with 0, 1，2.5, 
5, 10 and 25^iM H-89 alone for 2 hours, then exposed to TNF-a (100 U/mL) for an 
another 2 hours, and the m R N A levels for p38 M A P K and P-actin were semi-
quantified by RT-PCR (Fig. 20). It was found that the TNF-a-induced p38 M A P K 
level was suppressed by the addition of H-89, and 55% and 83% inhibition were 
observed with 10 and 25 |liM, respectively (Fig. 20a). This P K A inhibitor alone at all 
concentrations tested did not cause any significant changes on the expression of p38 
M A P K and P-actin (Fig 20a and 20b). Together with the observation with dbcAMP 
activated p38 M A P K expression, these results suggest that P K A involve in regulation 
of the induction of p38 M A P K by TNF-a in C6 cells. As there is a relatively large 
difference in the dosages of the two inhibitors used, it would suggest that the P K A in 
C6 cells is more sensitive to 14-22. 
3.7.4 Relationship Between p38 MAPK and B-Adrenergic Mechanisms in C6 
Cells 
Regulation of C6 cell and astrocyte proliferation through TNF-a is not the only 
mechanism since recent studies show that P-adrenergic mechanism also regulates C6 
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M C TNF-a lO' 10' dbc AMP 
^ ^ H n B H H B ^ H H H H H H H 禪 ） 
p38 MAPK -301 bp 
1 5.12 4.81 4.96 3.18 5.72 2.36 
- ctin -201 bp 
Fig. 18 Effect of various concentrations of dbcAMP on the levels of p38 M A P K 
m R N A in C6 cells. C6 Cells were treated with 10^  to 10^ n M of dbcAMP 
for 2 hours, total R N A extracted and followed by RT-PCR as described in 
the methods. The untreated cells (C) served as the control. Other details 
were as described in Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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a) 14-22 ( _ + T N F - a 
I 1 
M C T N F - a 10 50 100 200 500 
P38 MAPK . : -301 bp 
1 7.94 6.53 3.16 4.88 1.97 2.17 
-201 bp 
b) M C 10 50 100 200 500 14.22 
. - , - ; 、 . ， . . 。 々 , ； 、 、 . 代 , , � < ^^ v jiS^^^Y^™ . TV 〜 '：，、：， , � “ � (nIVI) 
ivi/vrjv -301 h n 
1 1.27 1.13 1.08 1.33 1.25 
3-a。tin -201 bp 
Fig. 19 Effect of 14-22 on the level p38 M A P K m R N A in the presence or absence 
of TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a 
alone for 2 hours, or pre-treated with 10 to 500 n M of 14-22 for 2 hours 
before the addition of TNF-a. (b) C6 Cells were treated with 10 to 500 n M 
14-22 only for 4 hours. The untreated cells serve as the control (C). The 
sizes, in bp, of the P C R bands were indicated on the right. The total R N A 
was extracted, followed by RT-PCR and other details were as described in 
the Methods and Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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a) H-89 (^iM) + TNF-a 
I 1 
M C TNF-a 1 2.5 5 10 25 
p38 MAPK -301 bp 
1 9.12 8.16 8.73 5.46 3.79 1.56 
^ B B B 福 p 
b) M C 1 2.5 5 10 25 h-89 
p38 IVIAPIC -301 bn 
H M M i i B 
1 1.23 1.18 1.13 1.28 1.24 
p-actin 
-201 bp 
Fig. 20 Effect of H-89 on the levels p38 M A P K and p-actin m R N A in the presence 
or absence of TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL 
TNF-a alone for 2 hours, or pre-treated with 1 to 25 ^iM of H-89 for 2 
hours before the addition of TNF-a. (b) C6 Cells were treated with 1 to 25 
|iM H-89 only for 4 hours. The untreated cells serve as the control (C). The 
sizes, in bp, of the PCR bands were indicated on the right. The total R N A 
was extracted and followed by RT-PCR and other details were as described 
in the Methods and Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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cell (Liu, 1996) and astrocyte proliferation (Hodges-Savola et al., 1996; Sutin & 
Griffith, 1993). More recently，Lung (1999) in our laboratory had found clear that p-
adrenergic mechanism participates in C6 cell proliferation. Supporting this notion is 
the report that activation of p38 M A P K was required for up-regulation of GFAP 
synthesis following high concentrations of dopamine treatment in C6 cells as the 
dopamine-stimulated GFAP production can be completely inhibited by the 
pretreatment of cells with SB 203580, a highly selective inhibitor of p38 M A P K 
(Tony et al., 1997). Therefore, it seems that p38 M A P K plays a role in 
catecholamines-stimulated GFAP expression and perhaps reactive gliosis. In this 
section, we try to examine whether P-adrenergic mechanism play a role in p38 M A P K 
expression by RT-PCR technique as described in Section 2.4. 
3.7A1__Effects of Tsoproterennl and Propranolol on p38 mRNA Levels in r 6 
Cells 
In this study, C6 cells were exposed to different dosages (0.01 to 10 jiM) of 
isoproterenol for 2 hours, and the expression of p38 M A P K were semi-quantified by 
RT-PCR (Fig. 21). The expression of p38 M A P K was enhanced by all concentrations 
of isoproterenol tested and there was a dose-dependence, particularly at low 
concentrations of isoproterenol. The stimulatory effect of isoproterenol was 
comparable to that of TNF-a even at low concentrations of this P-adrenergic agonist. 
Consistent with the involvement of (3-adrenergic mechanism, propranolol suppressed 
the TNF-a-induced p38 M A P K expression, again the inhibition dose-dependent; the 
inhibitory percentages were 12，39, 76, 84 and 86 in the presence of 1, 2.5, 5, 10 and 
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^^ ^ _ Isoproterenol 
M C T N F - a 0.01 0.1 1 10 100 ,、，、 
" M A P K - 遍 P 
1 5.19 4.73 4.96 8.28 4.86 7.49 
Fig. 21 Effect of various concentrations of isoproterenol on the levels of p38 
M A P K m R N A in C6 cells. C6 Cells were treated with 0.01 to 100 juM of 
isoproterenol for 2 hours and the total R N A was extracted and followed by 
RT-PCR 
as described in the methods. The untreated cells (C) served as the 
control. Other details were as described in Fig. 11. Data presented are 
representatives of three separate experiments with similar results. 
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) propranolol (|liM) + T N F - a 
) I 1 
M C T N F - a 1 2.5 5 10 25 
p38 MAPK -301 bp 
1 8.49 7.87 5.44 2.17 1.43 1.29 
-201 bp 
b) M C 1 2.5 5 10 25 propranolol 
p38 MAPK -301 bp 
1 1.20 1.18 1.07 1.03 1.14 
^ ^ H I H I I H I H I H H I ^ I -201 bp 
Fig. 22 Effect of various concentrations of propranolol on the levels p38 M A P K 
m R N A in the presence or absence of TNF-a. (a) C6 Cells were treated with 
100 U/mL TNF-a alone for 2 hours, or pre-treated with 1 to 25 \iM of 
propranolol for 2 hours before exposed to lOOU/mL TNF-a for another 2 
hours, (b) C6 Cells were treated with 1 to 25 of propranolol only for 4 
hours. The untreated cells serve as the control (C). The sizes, in bp, of the 
PCR bands were indicated on the right. The total R N A was extracted and 
followed by RT-PCR and other details were as described in the Methods 
and Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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25 i^M of propranolol respectively. These suggest that the P-adrenergic mechanism 
exert regulation on the TNF-a-induced p38 M A P K expression in C6 cells. 
3.7.4.2 Effects of Bl-Agonist and -Antagonist on p38 MAPK mRNA Expression 
in C6 Cells 
Since we previously observed that TNF-a induced the expression of both pl-
and P2-AR and that dobutamine induced but atenolol reduced TNF-a-induced TNF-
R2 expression (Shan, 2000), we therefore examined the effects of dobutamine, a 
selective pi-AR agonist, and atenolol, a specific pi-AR antagonist, on p38 M A P K 
expression. In this study, C6 cells were treated with 5, 10, 50, 100 and 500 n M 
dobutamine for 2 hours, and the m R N A levels ofp38 M A P K and p-actin were semi-
quantified by RT-PCR. The p38 M A P K expression was enhanced in cells exposed to 
dobutamine. This induction was dose-dependent and maximum induction was 
observed with 500 n M that was similar to that with TNF-a (Fig. 23). On the other 
hand, the m R N A of P-actin was relatively constant at all concentrations of 
dobutamine tested. This finding suggests that activation of pi-AR can increase the 
p38 M A P K expression in C6 cells. 
In order to make sure the observation with dobutamine really reflected that pi-
adrenergic mechanism was involved in regulating p38 M A P K expression in C6 cells, 
the effect of a pl-antagonist, atenolol, on TNF-a-induced p38 M A P K expression was 
studied. In this study, C6 cells were pretreated with 10，50, 100, 500 and 1000 n M 
atenolol for 2 hours, followed by exposure to TNF-a (100 U/mL) for an additional 2 
hours，and the levels for p38 M A P K and P-actin were semi-quantified by RT-PCR 
1 0 6 
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(Fig. 24). The TNF-a-induced p38 M A P K level was suppressed by the pretreatment 
with 500 n M and 1000 n M atenolol by 70 % and 60 %, respectively (Fig. 24a). 
atenolol alone did not cause any clear changes on the expression ofp38 M A P K and P-
actin m R N A at all concentrations tested (Fig. 24b). 
The above finding, taken together with the observation with dobutamine-induced 
p38 M A P K expression suggest that pi-adrenergic mechanism was involved in 
regulating p38 M A P K expression in C6 cells. 
3.7.4.3 Effects of B2-Agonist and -Antagonist on p38 MAPK mRNA Expression 
in C6 Cells 
As previous study in our laboratory (Shan, 2000) showed that P2-AR expression 
was induced by TNF-a and that p2-agonist stimulated TNF-R2 expression, while p2-
antagonist suppressed the TNF-a-induced TNF-R2 expression, it is of interest to see 
whether P2-agonist and -antagonist affect p38 M A P K m R N A induction. Therefore, 
the effects of a selective P2-AR agonist, procaterol (Koganei et al., 1995) and an 
antagonist, ICI 118,551 (Deighton et al., 1992), on the p38 M A P K expression were 
examined. In this study, C6 cells were treated with different dosages (5, 10, 50, 100 
and 500 nM) procaterol for 2 hours, and the m R N A levels of p38 M A P K and P-actin 
were semi-quantified by RT-PCR. p38 M A P K induction was enhanced at all 
concentrations of procaterol tested and relatively high induction was observed with 50 
and 500 n M (Fig. 25). On the other hand, P-actin m R N A was relatively constant at all 
concentrations of procaterol examined. This finding suggests that activation of P2-AR 
can increase the p38 a M A P K expression in C6 cells. 
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M C TNF-a 5 10 50 100 500 Dobutamine 
p38 MAPK .301 bn 
''〜'“‘“々//爲'丄'"：'；..：,A： ,——.二 
1 5.13 2.64 2.87 3.18 4.16 4.93 
Fig. 23 Effect of various concentrations of dobutamine on the levels of p38 M A P K 
m R N A in C6 cells. C6 Cells were treated with 5 to 500 n M of dobutamine 
or TNP-a (lOOU/mL) for 2 hours, the total R N A was extracted and 
followed by RT-PCR as described in the methods. The untreated cells (C) 
served as the control. Other details were as described in Fig. 11. Data 
presented are representatives of three separate experiments with similar 
results. 
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a) atenolol (nM) + TNF-a 
I 1 
M C T N F - a 10 50 100 500 1000 
M A P K ^ ^ ^ ^ B H I H H I ^ I ^ ^ I 
-301 bp 
1 7.43 6.79 6.14 7.28 2.31 2.76 
M c « „ 捕 bp 
b) M C 10 50 100 500 1000 atenolol (nM) 
隱 P K ^^mm - 船 p i 
1 1.24 1.09 1.17 1.06 1.13 J 
3-actin 年々：场:::�：^ ' ' . . � ’ - - • ‘ 
m m m m m ^ ^ m M ；丨 
Fig. 24 Effect of various concentrations of atenolol on the level p38 M A P K and 
m R N A in the presence or absence of TNF-a in C6 cells, (a) C6 Cells were 
treated with 100 U/mL TNF-a alone for 2 hours, or pre-treated with 10 n M 
to 1 ^ iM of atenolol for 2 hours before exposed to lOOU/mL TNF-a for 
another 2 hours, (b) C6 Cells were treated with 10 n M to 1 ^ M of atenolol 
only for 4 hours. The untreated cells serve as the control (C). The sizes, in 
bp, of the PCR bands were indicated on the right. The total R N A was 
extracted and followed by RT-PCR and other details were as described in 
the Methods and Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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In order to make sure the observation with procaterol really reflected that |32-
adrenergic mechanism was involved in regulating p38 M A P K expression in C6 cells, 
the effect of a p2-antagonist，ICI 118,551, on the TNF-a-induced p38 M A P K was 
examined. In this study, C6 cells were pretreated with different dosages (10, 50, 100， 
500 and 1000 nM) ICI 118,551 for 2 hours, then exposed to TNF-a (100 U/mL) for 
an another 2 hours, and the m R N A levels for p38 M A P K and P-actin were semi-
quantified by RT-PCR (Fig. 26). The addition of ICI 118,551，at all concentrations 
tested，almost completely reduced the TNF-a-induced p38 M A P K expression (Fig. 
26a). ICI 118,551 alone did not cause any clear changes on the expression of p38 
M A P K and P-actin m R N A at all concentrations tested (Fig. 26b). As the 
concentration of ICI 118,551 used in this study was relatively low, it is likely that the 
effector observed is real. 
These results, taken together with the observation that procaterol induced p38 
M A P K selectively, suggest that p2-adrenergic mechanism was involved in regulating 
p38 M A P K expression in C6 cells. This finding together with the observations that 
both pi-adrenergic agonist and antagonist were effective suggest that both pi and (32 
adrenergic mechanism can regulate the TNF-a-induced p38 M A P K expression in C6 
cells. This is not surprising as C6 cells express both receptor subtypes (Lung, 1999). 
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Procaterol 
M C T N F - a 5 10 50 100 500 (nM) 
p38 MAPK ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ -301 bp 
1 8.16 5.79 4.26 7.64 4.81 8.03 
P - a c t i n -201 bp 
Fig. 25 Effect of various concentrations of procaterol on the levels of p38 M A P K 
m R N A in C6 cells. C6 Cells were treated with 5 to 500 n M of procaterol or i 
TNF-a (100 U/mL) for 2 hours and the total R N A was extracted and J 
followed by RT-PCR as described in the methods. The untreated cells (C) 
served as the control. Other details were as described in Fig. 11. Data 
presented are representatives of three separate experiments with similar 
I 
results. 
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a) 
ICI 118,551 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 500 1000 
P38 MAPK -301 bp 
1 6.49 0.87 0.94 0.96 1.13 0.81 
p-actin “ ‘ ， 〈 一 � 辩 - 2 0 1 bp 
b) M C 10 50 100 500 1000 ICI 118 551 
P38MAPK 
！ 
1 1.13 1.07 1.21 1.14 1.06 
P - a c t i n -201 bp ’ 
Fig. 26 Effect of various concentrations of ICI 118,551 on the level p38 M A P K 
m R N A 
in the presence or absence of TNF-a in C6 cells, (a) C6 Cells were 
treated with 100 U/mL TNF-a alone for 2 hours, or pre-treated with 10 to 1 
I^M of propranolol for 2 hours before exposed to TNF-a. (b) C6 Cells were 
treated with 10 to 1 |LIM of propranolol only for 4 hours. The untreated cells 
serve as the control (C). The sizes, in bp, of the PCR bands were indicated 
on the right. The total R N A was extracted and followed by RT-PCR and 
other details were as described in the Methods and Fig. 11. Data presented 
are representatives of three separate experiments with similar results. 
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3.8 Effects of p38 MAPK on Inducible Nitric Oxide Synthase riNOS) Expression 
in C6 Cells 
Recently, studies showed that LPS plus cytokines (Feinstein et al, 1994) or 
TNF-a alone can induce iNOS activity (Lung, 1999) in C6 cells. N O is produced by 
the enzyme N O synthase (NOS) which catalyses the conversion of L-arginine and 
oxygen to L-citrulline and N O (Bama et al., 1996; Togashi et al., 1997). Since one of 
the N O S subtypes, inducible N O S (iNOS), can be induced by TNF-a in C6 cells 
(Feinstein et al., 1994; Lung, 1999) and more recently, a study showed that p38 
M A P K mediated iNOS activity as measured by nitrite oxide (NO) production and 
immunoblot analysis in C6 glioma cells (Xu & Malave, 2000), attempts were made to 
study the involvement of p38 M A P K in the TNF-a-induced iNOS gene expression by 
RT-PCR. 
3.8.1 Effects of TNF-a on the iNOS Expression in C6 Cells 
i 
First, we examined the effect of TNF-a on the iNOS expression in C6 cells. The 
m R N A levels of iNOS and P-actin in C6 cells were monitored after exposure to TNF-
a (100 U/ml) for various time intervals. This concentration of TNF-a had been found 
to elicit maximum proliferation effect (Liu, 1996). The iNOS m R N A level in cells 
treated with 100 U/mL TNF-a was stimulated by 2.7 folds at 2 minutes, the level 
continued to rise up to 4 hours, and maximum response was observed at 4 hours (Fig. 
27). Thus, the induction was time-dependent. On the other hand, the m R N A levels of 
P-actin in all samples were relatively constant. This indicates that TNF-a induced 
iNOS expression in C6 cells. 
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M C 2 5 15 30 60 120 240 (min) 
- b p 
1 2.69 3.45 4.72 6.18 7.16 9.41 12.98 
3-actin 
I ^ ^ ^ ^ ^ ^ H ^ ^ H H B H H M H l -201 bp 
Fig. 27 Effects of TNF-a on the levels of iNOS m R N A in C6 cells. C6 Cells were 
treated with 100 U/mL from 2 minutes to 4 hours, the total R N A extracted 
and followed by RT-PCR as described in the Methods. After 30 cycles of 
amplification, a 5卞L aliquot of the PGR product was electrophoresed on a 
2 % agarose gel, stained with ethidium bromide and photographed. The 
untreated cells (C) served as control. The sizes, in bp, of the PGR products 
were indicated on the right. The D N A markers (M) were also run on the 
same gel. The amounts of the PGR products were semi-quantified by 
densitometry, and the value below each band represents the relative 
intensity after normalization with respect to that of P-actin. Data presented 
are representative of three separate experiments with similar results. 
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3.8.2 Role of TNF-Receptor (TNF-R) Subtypes in the TNF-q-Induced iNOS 
Expression in C6 Cells 
Results described in Section 3.7.2 showed that TNF-R2 was the major TNF-R 
subtype mediating p38 M A P K expression, attempts were made to elucidate whether 
TNF-Rl or TNF-R2 was responsible for mediating the induction of the in TNF-a-
induced iNOS expression. 
In this experiment, cells were treated with TNF-Rl antiserum (0.08 jug/ml) or 
TNF-R2 antiserum (0.08 ^ ig/ml) for different time periods (1, 2, 5, 20, 30, 60 and 120 
minutes). Then TNF-a (100 U/mL) was added to the culture for another 2 hour. After 
R N A extraction, the TNF-a-induced iNOS expression and p-actin were then 
measured by RT-PCR. No significant changes in the expression of iNOS and P-actin 
were observed in cells treated with TNF-Rl antiserum at all time pints studied (Fig. 
28). On the other hand, the addition of TNF-R2 antiserum effectively blocked the 
induction of iNOS as the exposure time increased, at 20 minute 55% inhibition was | 
i 1 
observed and longer exposure times completely blocked the TNF-a-induced iNOS 
expression (Fig. 28). Therefore, it suggests that the TNF-a-induced iNOS expression 
was mediated by binding to TNF-R2. 
3.8.3 The Signaling System Mediating the TNF-q-Induced iNOS Expression in 
C6 Cells 
The above findings showed that TNF-a induced iNOS expression in C6 cells, 
however, the underlying signaling mechanism mediating this effect is still unknown. 
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a) TNF-Rl Ab Treatment 
M C T N F - a 1 2 5 20 30 60 120 (min) 
i N O S -301 bp 
1 5.17 5.23 5.47 4.13 5.39 4.58 5.41 5.24 
…aetm —201 bp 
b) TNF-R2 Ab Treatment 
iNOS :''‘::广）、 V^-v^ ；：-'. ：；：,；/：,.：：； 301 bn 
iM•翻 _ _ 圓 國 圓 丨 . 
I 
1 6.71 6.23 5.36 6.82 3.01 1.39 1.03 1.28 
i 
I 
Fig. 28 Effects of TNF-receptors (TNF-Rs) expression in the TNF-a-induced iNOS 
expression in C6 cells. C6 Cells were treated with TNF-Rl antiserum (0.08 
|ig/mL) or TNP-R2 antiserum (0.08 ^ ig/mL) alone in different time periods 
(1, 2, 5, 20, 30, 60 and 120 minutes). Then, 100 U/mL TNF-a was added to 
the cells for another 2 hour. The total R N A was extracted and followed by 
RT-PCR 
as described in the Methods. The untreated cells (C) served as 
control. The sizes, in bp, of the PCR products were indicated on the right. 
The D N A markers (M) were also run on the same gel. Data presented are 
representative of three separate experiments with similar results. 
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Previous study in our laboratory (Lung, 1999) found that P K C is not involved in 
mediating the inductive effect of TNF-a, therefore, we attempted to see if the p38 
M A P K and P K A pathway were involved in the TNF-a-induced iNOS expression in 
C6 cells. 
3.8.2.1 The Involvement of p38 MAPK in TNF-g-Induced iNOS Expression in 
C6 Cells 
At present, little is known about the intracellular signaling pathways of iNOS 
induction in C6 cells and astrocytes. Recent study showed that p38 M A P K was 
involved in the regulation of iNOS expression (Jean et al, 1997) in mouse astrocytes, 
we attempted to see whether p38 M A P K would play a role in the regulation of iNOS 
I 
expression in C6 cells. Another reason is the finding that p38 M A P K mediated iNOS 
activity as measured the nitrite oxide production and immunoblot analysis in C6 
glioma cells (Xu and Malave, 2000). Therefore, attempts were made to study the 
involvement of p38 M A P K in the iNOS gene expression by RT-PCR 
In this study, p38 M A P K inhibitor SB203580 was used to investigate whether this 
inhibitor would suppress the iNOS expression in TNF-a-treated cells. C6 cells were 
pretreated with 1，2.5, 5, 10 and 25 [xM SB 203580 alone for 2 hours, then exposed to 
TNF-a (100 U/mL) for another 2 hours, and the levels of iNOS and p-actin were 
semi-quantified by RT-PCR (Fig. 29). The TNF-a-induced iNOS expression was 
reduced in the presence of this inhibitor. For example, 63 and 73% inhibition were 
observed in the presence of 10 and 25 u M SB203580, respectively. It is likely that the 
TNF-a-induced iNOS expression in C6 cells is mediated through p38 M A P K . 
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a) SB 203580 (|iM) + TNF-a 
I 1 
M C TNF-a 1 2.5 5 10 25 
iNOS -302 bp 
1 9.36 7.32 4.95 6.12 3.46 2.51 
3-actin 
H ^ f j u J I ^ ^ ^ I ^ ^ ^ ^ ^ ^ ^ g -201 bp 
b) M C 1 2.5 5 10 25 SB 203580 
… 一 -302 bD 
1 1.16 1.21 1.10 0.97 1.02 
Met ln ^ ^ ^ ^ ^ ^ ^ -201 bp I 
Fig. 29 Effect of SB 203580 on the level iNOS m R N A in the presence or absence 
of TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a 
alone for 4 hours, or pre-treated with 1 to 25 ^ M of SB 203580 for 2 hours 
before the addition of TNF-a. (b) C6 Cells were treated with 1 to 25 |iM of 
SB 203580 only for 4 hours. The untreated cells serve as the control (C). 
The sizes, in bp, of the PGR bands were indicated on the right. The total 
R N A was extracted and followed by RT-PCR and other details were as 
described in the Methods and in Fig. 11. Data presented are representatives 
of three separate experiments with similar results. 
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3-8.3.2 The Involvement of PKA in the TNF-q-Induced iNOS Expression in C6 
Cells 
As mentioned before, P K A pathway is an important second messenger system in 
many tissues (Yao & York, 1998; Saxena et al., 1999) and that P K A mediated the 
TNF-a-induced p38 M A P K expression (Section 3.7.3.2); we, therefore, examined the 
role of P K A in iNOS expression. First, cells were exposed to different dosages (10^ 
10,10,10 and 10 nM) of dbcAMP and the contents of iNOS and p-actin were 
semi-quantified by RT-PCR. iNOS m R N A level was elevated as the concentrations of 
dbcAMP increased (Fig. 30). In the presence of lO^nM of dbcAMP, the level of iNOS 
induced was higher than that with TNF-a (100 U/mL), and the most pronounced 
effect was seen with lO
6
 n M dbcAMP. This result suggests that activation of P K A can 
I 
increase iNOS expression in C6 cells. | 
In order to ensure the stimulatory effect seen with dbcAMP was specific and that I 
action of TNF-a was mediated through PKA, the inhibitory effects ofH-89 on TNF-a 
induction of iNOS was studied. In this study, C6 cells were pretreated with 1.0 to 25 
^iM ofH-89 alone for 2 hours, then exposed to TNF-a (100 U/mL) for an additional 2 
hours, and the levels for iNOS and P-actin were semi-quantified by RT-PCR (Fig. 31). 
The TNF-a-induced iNOS level was suppressed by the addition H-89. In the presence 
of 5 i^M of H-89, a selectively low concentration, the inhibition was 55% that was the 
maximum (Fig. 31). This P K A inhibitor alone did not cause any significant changes 
on the expression of basal iNOS and P-actin m R N A at all concentrations of inhibitor 
tested (Fig. 31). Together with the observation with dbcAMP activated iNOS 
induction, these results suggest that P K A mediates the induction of iNOS by TNF-a 
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in C6 cells. As both P K A and p38 M A P K induced iNOS expression and that the 
induction of p38 M A P K was mediated through PKA, it is likely that TNF-a activates 
P K A then p38 M A P K and followed by iNOS induction. 
3.9 The Relationship between p38 MAPK on cAMP Responsive Element-Binding 
Protein fCREB) 
To date, little is known about the transcription factors that are activated in glial 
and C6 cells. Recent studies showed that kainate-induced neuronal injury leads to 
persistent phosphorylation of c A M P response element-binding protein (CREB) in 
glial and endothelial cells in the hippocampus (Ong et al., 2000). CREB has been 
regarded as the downstream target of p38 a M A P K (Tan & Rouse, 1996; Raingeaud 
and Whitmarsh, 1996). It has been postulated that phosphorylation of CREB could 
drive the expression of downstream genes in these cells to promote cell proliferation 
and survival (Walton et al., 1999). W e therefore, examined whether CREB respond to 
TNF-a and other related drug treatment in C6 cells. 
3.9.1 Effects of TNF-a on CREB Expression in C6 Cells 
A time course experiment on the effect of TNF-a on the CREB expression was 
performed. Fig. 32 showed the m R N A levels of the CREB in C6 cells was elevated 
after exposure to TNF-a (100 U/ml) for various time intervals, about 2.5 fold increase 
was observed at 5 minutes, continued to rise to about 4-5 folds, then leveled off. Thus, 
the induction was time-dependent. On the other hand, the m R N A levels of p-actin 
were relatively constant throughout the study. 
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M C TNF-a 10^ 10^ 10^ 10^ 10^ 
dbc AMP 画 y n U H m O B I : ) 
1 5.23 1.29 6.81 7.13 5.14 8.46 
P-actin ^ ^ ^ ^ ^ B P W U P W i m i H W I -201 bp 
Fig. 30 Effect of various concentrations of dbcAMP on the levels of iNOS m R N A 
. I 
m C6 cells. C6 Cells were treated with 10^ to 10^ n M of dbcAMP for 2 i 
• || ！! 
hours, the total R N A extracted and followed by RT-PCR as described in the 
Methods. The untreated cells (C) served as the control. Other details were as 
described in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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a) H-89 瞬） + TNF-a 
I 1 
M C TNF-a 1 2.5 5 10 25 
iNOS -302 bp 
1 8.45 9.12 7.61 3.84 4.32 5.71 
b) M C 1 2.5 5 10 25 H-89 
一 ( _ 
iNOS -302 bp 
• • • • • 1 1 
1 1.02 1.21 1.16 0.96 1.04 i 
D-actin -201 bp 
Fig. 31 Effect of H-89 on the level iNOS m R N A in the presence or absence of 
TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a alone 
for 2 hours, or pre-treated with 1 to 25 )LIM of H-89 for 2 hours before the 
addition of TNF-a. (b) C6 Cells were treated with 1 to 25 p M H-89 only for 
4 hours. The untreated cells serve as the control (C). The sizes, in bp, of the 
PCR bands were indicated on the right. The total R N A was extracted and 
followed by RT-PCR and other details were as described in the Methods 
and Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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M C 2 5 15 30 60 120 240 (min) 
CREB -352 bp 
1 1.59 2.48 4.53 4.14 4.36 4.04 5.73 
R . • P P P P f l i i i i i l 
p-actm -201 bp 
Fig. 32 Effects of TNF-a on the levels of C R E B m R N A in C6 cells. C6 Cells were 
treated with 100 U/mL TNF-a for 2 minutes to 4 hours, the total R N A 
extracted and followed by RT-PCR as described in the Methods. After 30 
i 
cycles of amplification, a 5-|LIL aliquot of the PCR product was I 
electrophoresed on a 2 % agarose gel, stained with ethidium bromide and | 
photographed. The untreated cells (C) served as control. The sizes, in bp, of | 
the P C R products were indicated on the right. The D N A markers (M) were 
also run on the same gel. The amounts of the P C R products were semi-
quantified by densitometry, and the value below each band represents the 
relative intensity after normalization with respect to that of P-actin. Data 
presented are representative of three separate experiments with similar 
results. 
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3.9.2 Role of TNF-Receptor (TNF-R) Subtype in the TNF-g-Induced CREB 
Expression in C6 Cells 
Recent studies in our laboratory showed that TNF-a selectively induced the 
expression of TNF-R2 (Huang et al” 1998) and that as demonstrated by selective 
TNF-R anti-body studies, TNF-R2 was found to be responsible for the proliferative 
effects in C6 cells (To, 1999). Moreover, we found that the TNF-a-induced p38 
M A P K expression was mainly mediated through TNF-R2 (Section 3.7.2), we 
attempted to elucidate whether TNF-Rl or TNF-R2 or both subtypes were responsible 
for the TNF-a-induced C R E B expression. 
In this experiment, cells were treated with TNF-Rl Ab (0.08 jug/mL) or TNF-R2 
Ab (0.08 ^ ig/mL) for different time intervals (1, 2, 5, 20, 30, 60 and 120 minutes). 
f 
Then, TNF-a was added to the culture for another 2 hours. After R N A extraction, the 
TNF-a-induced C R E B expression and P-actin were monitored by RT-PCR. It was 
found that there were no significant changes in the expression of TNF-a-induced 
CREB expression in cells pretreated TNF-Rl antiserum. Also, addition of TNF-Rl 
antiserum had no effect on the basal level of CREB expression (Fig. 33a). On the 
other hand, the addition of TNF-R2 antiserum effectively blocked the induction of 
CREB by TNF-a, at 2 minutes 11% reduction was observed and the inhibition was 
progressively elevated as the exposure time to TNF-R2 antiserum increased. At 60 
and 120 minutes, almost complete inhibition was observed (Fig. 33b). Therefore, 
these findings suggest that the TNF-a-induced CREB expression is mediated by TNF-
Rl. 
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a) TNF-Rl Ab Treatment 
M C T N F - a 1 2 5 20 30 60 120 (min) 
j l l l l l i i i l l H ^ ^ 驚 
CREB n n m i l l l l l l l l l i i l l ^ j ^ ^ l j ^ ^ ^ ^ ^ ^ ^ ^ ^ -352 bp 
1 5.72 6.14 5.38 6.31 5.94 5.25 6.23 5.12 
b) TNF-R2 Ab Treatment 
I 
1 5.27 5.65 4.68 3.23 3.97 2.31 1.04 1.13 
-201 
Fig. 33 Role of TNF-receptor (TNF-R) subtype in the TNF-a-induced CREB 
expression in C6 cells. C6 Cells were treated with TNF-Rl antiserum (0.08 
l^g/mL) or TNF-R2 antiserum (0.08 jig/mL) alone for different time 
intervals (1, 2, 5, 20, 30, 60 and 120 minutes). Then, 100 U/mL TNF-a was 
added to the cell for another 2 hours. The total R N A was extracted and 
followed by RT-PCR as described in the Methods. The untreated cells (C) 
served as control. The sizes, in bp, of the PGR products were indicated on 
the right. The D N A markers (M) were also run on the same gel. Data 
presented are representative of three separate experiments with similar 
results. 
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3.9.3 Signaling Systems Mediating TNF-oc-Induced CREB Expression in C6 Cells 
The above study showed that TNF-a-induced C R E B expression by interacting 
with TNF-R2. which activated p38 M A P K (Fig. 33). Recent study on Schwann cell 
proliferation showed that P K A and P K C pathways were involved in the CREB 
phosphorylation (Matthew et al,, 1999). Therefore, it is of interest to determine 
whether C R E B expression was regulated by P K A and/or P K C pathway. Recently, we 
found that TKF-a induced the expression of P K C in C6 cells (Lung, 1999). 





Previous studies showed that TNF-a selectively induced the expression of p38 
M A P K (Fig. 11), we, therefore, examined whether the induction of CREB is mediated 
through p38 M A P K . In this study, a p38 M A P K inhibitor SB 203580 (Tong et al., 
1997; Wilson & McCaffrey, 1997), was used to investigate whether this inhibitor 
could reduce the TNF-a induced CREB expression. C6 cells were pretreated with 1, 
2.5, 5, 10，and 25 [iM SB 203580 alone for 2 hours, followed by the addition ofTNF-
a (100 U/mL) for an another 2 hours, and the m R N A levels of CREB and P-actin 
were semi-quantified by RT-PCR as described in Fig 11. The inhibition of the TNF-a-
induced CREB expression was dose-dependent, and around 74% inhibition with 10 
u M of SB 203580 (Fig. 34a). This inhibitor had no effect on the basal level of CREB 
at all concentrations of inhibitor treated (Fig. 34b). Therefore, it is likely that the 
TNF-a-induced CREB expression was mediated through p38 M A P K . 
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A) S B 2 0 3 5 8 0 (|LIM) + T N F - a 
I 1 
M C T N F - a 1 2.5 5 10 25 
C M B - 352 bp 
1 6.43 3.19 2.81 2.37 1.14 2.67 
P-aetin ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ -201 bp i 
B) M C 1 2.5 5 10 25 SB 203580 
(juM) 
C R E B ‘ 
-352 bp 
1 1.21 1.17 1.26 1.13 1.29 
P-actin ^ ^ ^ ^ ^ ^ ^ ^ ^ -201 bp 
Fig. 34 Effect of SB 203580 on the levels C R E B m R N A in the presence or absence 
of TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a 
alone for 4 hours, or pre-treated with 1 to 25 juM of SB 203580 for 2 hours 
before the addition of TNF-a. (b) C6 Cells were treated with 1 to 25 jiM of 
SB 203580 only for 4 hours. The untreated cells serve as the control (C). 
The sizes, in bp, of the PCR bands were indicated on the right. The total 
R N A was extracted and followed by RT-PCR and other details were as 
described 
in the Methods and in Fig. 11. Data presented are representatives 
of three separate experiments with similar results. 
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3.9.3.2 Involvement of PKC in TNF-g-Induced CREB Expression in C6 Cells 
In this study, the effects P M A and Ro-31, on the induction of C R E B were 
investigated. These agents were found to be selective activator and inhibitor of P K C 
in C6 cells (Tsang et al., 1997). 
For the activator study, different dosages: 0.0612, 0.162, 1.62, 16.2 and 162 
n M of P M A were added to cultures. The contents of C R E B and p-actin m R N A were 
semi-quantified by RT-PCR. As shown in Fig. 35, the m R N A levels of CREB was 
elevated by 2 to 4 folds as the concentrations of P M A increased from 0.0162 to 16.2 
n M (Fig. 35). The most pronounced effect on C R E B expression was observed with 
162 n M of P M A in which a 4.8-fold increase was observed. On the other hand, the p_ 
actin level remains relatively constant at all P M A concentrations tested. This result 
suggests that activation of P K C can increase CREB expression in C6 cells and there is 
concentration dependence particularly at low concentrations of P M A . 
In order to ensure the stimulatory effect found with P M A was specific and that 
the action of TNF-a was mediated through PKC, the inhibitory effect of Ro31 on the 
TNF-a induction of CREB was studied. The dosage effects of Ro31 in the presence 
and absence of TNF-a on the m R N A levels of CREB was shown in Fig. 36a. In this 
study, C6 cells were pretreated with 10, 50, 100, 200 and 500 n M Ro31 alone for 2 
hours, then exposed to TNF-a (100 U/mL) for an another 2 hours, and the levels of 
CREB and P-actin m R N A were semi-quantified by RT-PCR. Ro31 alone did not 
cause any significant changes in the expression of CREB m R N A at all concentrations 
of Ro31 tested (Fig. 36b). The inhibitory action of Ro31 on the TNF-a induction of 
CREB was dose-dependent, and greater than 50 % inhibition were observed with 100, 
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200 and 500 n M of Ro31，and 23% inhibition was observed with 50 n M of Ro31. It 
should be noted that Ro31 at all concentrations did not decrease the basal C R E B level 
(Fig. 36b). Also, Ro31 alone or in the presence of TNF-a did not change the level of 
p-actin (Fig. 36). Only the effect of Ro-31 was tested as this is a more potent P K C 
inhibitor of TNF-a-induced p38 M A P K expression (Figs. 16 & 17). Together with the 
observation that P M A activated C R E B 24.expression, these results suggest that P K C 
is involved in mediating the induction of C R E B by TNF-a in C6 cells. 
3.9.3.3 Involvement of PKA in TNF-a-Induced CREB Expression in C6 Cells 
Cross-talk between cAMP-dependent P K A and M A P kinase has been reported in 丨 
some tissues (Imprey et al., 1998; Saxena et al., 1998) and that this pathway had been 
shown to mediate CREB phosphorylation in Schwann cells (Matthew et al., 1999), we 
examined the possible involvement of P K A in the TNF-a-induced CREB expression. 
In this study, the effect dbcAMP and two P K A inhibitors: 14-22 and H-89 were 
studied. First, cells were treated with different dosages: 10^ 10^ 10^ 10^  and 10^  n M 
of dbcAMP for 2 hours, then the m R N A contents of CREB and p-actin were semi-
quantified by RT-PCR. This P K A activator progressively elevated the CREB m R N A 
level as the concentration of dbcAMP increased. The most prominent effect was seen 
with 105 n M dbcAMP, and at this concentration of dbcAMP, the stimulatory effect 
was comparable to that with TNF-a (Fig. 37). This result suggests that activation of 
P K A can increase CREB expression in C6 cells. 
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M C 0.0162 0.162 1.62 16.2 162 p ^ A (nM) 
CREB _3Qj bp 
1 2.38 3.13 4.79 2.47 4,81 
P - a c t i n .201 bp 
Fig. 35 Effect of P M A on the levels CREB m R N A in C6 cells. C6 Cells were 
treated with 0.0162 to 162 n M of P M A for 2 hours, the total R N A was 
extracted and followed by RT-PCR as described in the methods. The 
untreated cells (C) serve as the control. Other details were as described in 
Fig. 10. Data presented are representatives of three separate experiments 
with similar results. 
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a) Ro31 (nM) + T N F - a 
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M C T N F - a 10 50 100 200 500 
C R E B I ^ H H H H B H H H H 
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1 1.07 1.03 1.16 1.04 1.09 
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Fig. 36 Effect of Ro31 on the levels CREB m R N A in the presence or absence of 
TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a alone 
for 2 hours, or pre-treated with 10 to 500 n M of Ro31 for 2 hours before the 
addition of TNF-a. (b) C6 Cells were treated with 10 to 500 n M Ro31 only 
for 4 hours. The untreated cells serve as the control (C). The sizes, in bp, of 
the PCR bands were indicated on the right. The total R N A was extracted 
and followed by RT-PCR and other details were as described in the 
Methods and in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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In order to ensure the stimulatory effect seen with dbcAMP was specific and that 
the action of TNF-a was mediated through PKA, the inhibitory effect of 14-22 and H-
89 on the TNF-a induction of C R E B was studied. The dosages used were similar to 
those p38 M A P K expression study (Figs. 19 & 20). The TNF-a-induced C R E B level 
was suppressed as the concentration of 14-22 increased; 55% with 100 n M of this 
inhibitor and 79% with 200 n M (Fig. 38). The levels of P-actin with or without drug 
treatment were relatively unaffected (Fig. 38). It should also be noted that 14-22 alone 
did not cause any clear changes in the expression of CREB and p-actin m R N A at all 
concentrations of 14-22 tested (Fig. 38). 
Another P K A inhibitor-H89 was used to ensure the inhibitory effect of 14-22 on 
the TNF-a-induced C R E B expression. In this study, C6 cells were pretreated with 1, 
2.5, 5, 10 and 25 jiM of H-89 alone for 2 hours, then exposed to TNF-a (100 U/mL) 
for another 2 hours, and the m R N A levels for CREB and p-actin were semi-quantified 
by RT-PCR. H-89 suppressed the TNF-a-induced CREB in a dose-dependent manner 
and the inhibitory effect increased from 28% to 74% as the concentration of H-89 
increased (Fig. 39). This P K A inhibitor alone did not cause any significant changes on 
the expression of CREB and P-actin m R N A at all concentrations tested (Fig. 39). 
Together with the observation with dbcAMP activated CREB expression, these results 
suggest that P K A also regulates the induction of CREB by TNF-a in C6 cells. 
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M C TNF-a 10^ 10^ 10^ 10^ 10^   
dbc AMP 
l ^ j u i i i i i i i i j m j m j j j i ( n M ) 
CREB -352 bp 
1 5.84 3.12 5.17 5.03 5.91 3.81 
Fig. 37 Effect of various concentrations of dbcAMP on the levels of CREB m R N A 
in C6 cells. C6 Cells were treated with 10^  to 10^ n M of dbcAMP for 2 
hours. The total R N A was extracted and followed by RT-PCR as described 
in the methods. The untreated cells (C) served as the control. Other details 
were as described in Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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a) 14-22 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 200 500 隱 iTrmn 
1 10.52 9.23 7.16 4.73 2.17 3.02 一 B B B H i i i f l — 
b) M C 10 50 100 200 500 14-22 
— — ’ （nM) 
1 1.16 1.08 1.19 1.03 1.05 
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Fig. 38 Effect of 14-22 on the levels CREB m R N A in the presence or absence of 
TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a alone 
for 4 hours, or pre-treated with 10 to 500 n M of 14-22 for 2 hours before the 
addition of TNF-a. (b) C6 Cells were treated with 10 to 500 n M 14-22 only 
for 4 hours. The untreated cells serve as the control (C). The sizes, in bp, of 
the PCR bands were indicated on the right. The total R N A was extracted 
and followed by RT-PCR and other details were as described in the 
Methods and in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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a) H-89 ( _ ) + T N F - a 
I 1 
M C T N F - a 1 2.5 5 10 25 
c 删 
1 8.46 6.08 5.43 3.71 3.69 2.14 
(3-actin 
a) M C 1 2.5 5 10 25 H-89 
_ (|iM) 
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Fig. 39 Effect of H-89 on the levels CREB m R N A in the presence or absence of 
TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a alone 
for 2 hours, or pre-treated with 1 to 25 juM of H-89 for 2 hours before the 
addition of TNF-a. (b) C6 Cells were treated with 1 to 25 |LIM H-89 only for 
4 hours. The untreated cells serve as the control (C). The sizes, in bp, of the 
PCR bands were indicated on the right. The total R N A was extracted and 
followed by RT-PCR and other details were as described in the Methods 
and in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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3.9.4 Relationship Between B-Adrenergic Mechanism and CREB Expression in 
C6 Cells 
Regulation of C6 cells proliferation through TNF-a is not the only mechanism 
since our recent studies showed that P-adrenergic mechanism also regulate C6 cells 
proliferation (Liu, 1996; Lung, 1999) and P-adrenergic mechanism participate in 
astrocyte proliferation (Hodges-Savola et al,, 1996; Sutin & Griffith, 1993). Since 
C R E B also participate in cell proliferation (Walton et al., 1999) we try to examine 
whether P-adrenergic mechanism had any effect on C R E B expression by RT-PCR 
technique as described in Section 2.12. 
3-9.4.1_Effects of Isoproterenol and Propranolol on CREB mRNA l evels in C(^  
Cells 
In this study, C6 cells were exposed to different dosages (0.01 to 100 juM) of 
isoproterenol for 2 hours, and the expression of C R E B semi-quantified by RT-PCR 
(Fig. 40). The expression of C R E B was enhanced by all concentrations of 
isoproterenol tested and the induction was dose-dependent. At relatively high 
concentration of isoproterenol (100 |LIM), the inhibition was comparable to that of 
TNP-a (Fig. 40). Consistent with the involvement of an P-adrenergic mechanism, the 
P-antagonist, propranolol, suppressed the TNF-a-induced C R E B expression and 
greater than 60% inhibition was observed with concentrations higher than 5 |iM (Fig. 
41). These suggest that p-adrenergic mechanism exert regulation on TNF-a-induced 
C R E B expression in C6 cells. 
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M C TNF-a 0.01 0.1 1 10 100 Isoprotemioi 
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CREB ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ .352 bD 
-o^L Dp 
1 8.37 2.57 3.51 4.78 6.25 7.16 
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Fig. 40 Effect of various concentrations of isoproterenol on the levels of CREB 
m R N A in C6 cells. C6 Cells were treated with 0.01 to 100 juM of 
isoproterenol for 2 hours, the total R N A extracted and followed by RT-PCR 
as described in the methods. The untreated cells (C) served as the control. 
Other details were as described in Fig. 11. Data presented are 
representatives of three separate experiments with similar results. 
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Fig. 41 Effect of 
various concentrations of propranolol on the levels of CREB 
m R N A in the presence or absence of TNF-a in C6 cells, (a) C6 Cells were 
treated with 100 U/mL TNF-a alone for 4 hours, or pre-treated with 1 to 25 
|LIM of propranolol for 2 hours before exposed to lOOU/mL TNF-a for 
another 2 hours, (b) C6 Cells were treated with 1 to 25 fiM of propranolol 
only for 4 hours. The untreated cells serve as the control (C). The sizes, in 
bp, of the PCR bands were indicated on the right. The total R N A was 
extracted and followed by RT-PCR and other details were as described in 
the Methods and in Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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3.9.4.2 Effects of Bl-Agonist and -Antagonist on CREB mRNA Expression in C6 
Cells 
Since we observed that the TNF-a-induced CREB expression was regulated by 
P-adrenergic mechanism and that both pi- and p2-ARs existed in C6 cells (Shan, 
2000), we therefore examined the effects of dobutamine, a selective pi-AR agonist, 
and atenolol, a specific pi-AR antagonist, on CREB expression. In this study, C6 
cells were treated with 5, 10, 50, 100 and 500 n M dobutamine for 2 hours, and the 
m R N A levels of CREB and p -actin were semi-quantified by RT-PCR. The CREB 
expression was progressively enhanced in cells as the concentration increase from 5 to 
50 n M dobutamine, and maximum induction of CREB were observed with 500 n M of 
dobutamine. At this concentration of dobutamine, the induction was only slightly 
lower than that with TNF-a (Fig. 42). On the other hand, the level of P-actin was 
relatively constant at all concentrations of dobutamine tested. This finding suggests 
that activation of pi-AR can increase the CREB expression in C6 cells. 
In order to make sure the observation with dobutamine really reflected that pi-
adrenergic mechanism was involved in regulating the TNF-a-induced CREB 
expression in C6 cells, the effect of a p 1-antagonist, atenolol, was investigated. In this 
study, C6 cells were pretreated with 10, 50, 100, 500 and 1000 n M atenolol for 2 
hours, then in the presence of TNF-a (100 U/mL) for an additional 2 hours, and the 
m R N A levels for CREB and P-actin were semi-quantified by RT-PCR. The TNF-a-
induced CREB levels were suppressed by the addition of 10 n M and 50 n M atenolol 
by 58 % and 68 %, respectively, and maximum inhibition was observed with 1000 n M 
(Fig. 43). The latter observation is likely pharmacological. One observation was that 
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M C TNF-a 5 10 50 100 500 Dobutamine 
(nM) 
CREB -352 bp 
1 8.25 2.58 3.92 5.42 2.61 7.36 
3-actin -201 bp 
Fig. 42 Effect of 
various concentrations of dobutamine on the levels of CREB 
m R N A in C6 cells. C6 Cells were treated with 5 to 500 n M of dobutamine 
for 2 hours and the total R N A was extracted and followed by RT-PCR as 
described in the methods. The untreated cells (C) served as the control. 
Other details were as described in Fig. 11. Data presented are 
representatives of three separate experiments with similar results. 
1 4 0 
~ R e s u l t s 
a) atenolol (nM) + TNF-a 
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b) M C 10 50 100 500 1000 
atenolol (nM) 
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Fig. 43 Effect of various concentrations of atenolol on the levels of CREB m R N A 
in the presence or absence TNF-a in C6 cells, (a) C6 Cells were treated 
with 100 U/mL TNF-a alone for 4 hours, or pre-treated with 10 n M to 1 
I^M of atenolol for 4 hours before exposed to 100 U/mL TNF-a for another 
2 hours, (b) C6 Cells were treated with 10 n M to 1 \iM of atenolol only for 
4 hours. The untreated cells serve as the control (C). The sizes, in bp, of the 
PCR bands were indicated on the right. The total R N A was extracted and 
followed by RT-PCR and other details were as described in the Methods 
and in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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the effect of atenolol at 100 and 500 n M were less effective compared to those with 
10 and 50 nM. This reason is unclear at present. Atenolol alone did not cause any 
clear changes on the basal expression of CREB and that of P-actin m R N A at all 
concentrations tested (Fig. 43). 
This finding, taken together with the observation that dobutamine induced CREB 
expression in a dose-dependent manner, suggests that pi-adrenergic mechanism was 
involved in modulating/mediating TNF-a-induced CREB expression in C6 cells. 
3.9.4.3 Effects of B2-Agonist and -Antagonist on CREB mRNA Expression in C6 
Cells 
To understand the role of P-adrenergic mechanism better, we also examined the effect 
of (32 agonist and antagonist on the expression of CREB. Procaterol, a selective P2-
A R agonist, (Koganei et al., 1995) and ICI 118,551, an antagonist, (Deighton et al., 
1992) were used in this study. For the agonist study, C6 cells were treated with 
different dosages (5, 10，50, 100 and 500 nM) of procaterol for 2 hours, and the 
m R N A levels of CREB and P-actin were semi-quantified by RT-PCR. The CREB 
induction was enhanced as the concentration of procaterol increased, and maximum 
induction of CREB was observed with 500 n M (Fig. 44). However, the levels of P-
actin were relatively constant at all concentrations of procaterol tested. At relatively a 
high concentration of procaterol (500 nM), the induction was comparable to that with 
TNF-a. This finding suggests that activation of P2-AR can increase the CREB 
expression in C6 cells. 
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To ensure the observation with procaterol reflected that p2-adrenergic 
mechanism was involved in regulating TNF-a-induced C R B E expression in C6 cells, 
the effects of an p2-antagonist, ICI 118,551, was investigated. In this study, C6 cells 
were pretreated with different dosages (10, 50, 100, 500 and 1000 nM) of ICI 118,551 
for 2 hours, then exposed to TNF-a (100 U/mL) for another 2 hours, and the m R N A 
levels of C R B E and P-actin were semi-quantified by RT-PCR. The TNF-a-induced 
C R E B level was suppressed, in a dose-dependent manner, by the addition of ICI 
118,551, and maximum inhibition (60%) was observed with 500 n M (Fig. 45). ICI 
118,551 alone did not cause any clear changes on the expression of C R B E and (3-actin 
m R N A at all concentrations tested (Fig. 45). 
These results, taken together with the observation that procaterol induced CREB 
selectively, suggests that (32-adrenergic mechanism was involved in regulating or 
mediating TNF-a-induced CREB expression in C6 cells. 
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Procaterol 
(nM) 
M C TNF-a 5 10 50 100 500 
CREB -352 bp 
1 8.24 1.44 2.67 4.71 5.28 6.09 
-201 
Fig. 44 Effect of various concentrations of procaterol on the levels of C R B E m R N A 
in C6 cells. C6 Cells were treated with 5 to 500 n M of procaterol for 2 
hours and the total R N A was extracted and followed by RT-PCR as 
described in the methods. The untreated cells (C) served as the control. 
Other details were as described in Fig. 11. Data presented are 
representatives of three separate experiments with similar results. 
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Fig. 45 Effect of various concentrations of ICI 118,551 on the levels of C R B E 
m R N A in the presence or absence of TNF-a in C6 cells, (a) C6 Cells were 
treated with 100 U/mL TNF-a alone for 4 hours, or pre-treated with 10 to 
1000 n M of ICI 118,551, for 2 hours before exposed to lOOU/mL TNF-a 
for another 2 hours, (b) C6 Cells were treated with 10 to 1000 n M of ICI 
118,551 only for 4 hours. The untreated cells serve as the control (C). The 
sizes, in bp, of the PCR bands were indicated on the right. The total R N A 
was extracted and followed by RT-PCR and other details were as described 
in the Methods and in Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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3.10 The relationship Between p38 MAPK and Transcription Factor c-fos 
Expression 
3.10.1 Effect of TNF-a on the Expression oi c-fos in C6 Glioma Cells 
Following the elucidation of some of the second messengers involved in the 
TNF-a signaling pathway, we attempted to examine the response of two transcription 
factors-c-/as and NF-KB. The “ third messenger" c-fos has been shown to be 
activated by TNF-a in a number of cell types (Lin & Vilcek, 1987). Besides, recent 
findings showed that this transcription factor was involved in the induction of cell 
proliferation and differentiation (Condorelli et al., 1989). In our previous study (Lung, 
1999), we found that the c-fos m R N A level increased sharply in cells treated with 
TNF-a for 5 minutes, it seems that the TNF-a-induced proliferation may be mediated 
through the activation of c-fos. Therefore, it is of interest to investigate the signaling 
pathway mediating the expression of this factor in C6 cells. 
3.10.2 Role of TNF-Receptor (TNF-R) Subtypes in the TNF-g-Induced c-fos 
Expression in C6 Cells 
Results presented earlier (Section 3.7.2) showed that the TNF-a-induced p38 
M A P K was mediated by TNF-R2 and that this kinase regulated c-fos expression, 
attempts were made to elucidate whether TNF-Rl or TNF-R2 was responsible to 
mediate the proliferative effects in TNF-a-induced c-fos expression. 
In this experiment, cells were treated with TNF-Rl antiserum (0.08 |Lig/mL) or 
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TNF-R2 antiserum (0.08 ^ ig/mL) for 1,2,5, 20，30, 60 and 120 minutes; then exposed 
to TNF-a for another 2 hours and the R N A extraction. The TNF-a-induced c-fos 
expression and P-actin were monitored by RT-PCR. It was found that not much 
changes in the expression of c-fos and (3-actin in the TNF-Rl antisemm-treated cells 
(Fig. 46). On the other hand, the addition of TNF-R2 antiserum effectively blocked 
the induction of c-fos; inhibition was observed at around 5 minute, and near complete 
blockade was observed after 120 minutes of TNF-R2 antiserum treatment (Fig. 46). 
The finding that TNF-a-induced c-fos expression was decreased with the addition of 
anti-TNF-R2 antiserum, but not by TNF-Rl antiserum, suggests that the TNF-a-
induced c-fos expression was mediated by binding to TNF-R2. 
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a) TNF-Rl Ab Treatment 
M C T N F - a 1 2 5 20 30 60 120 (min) 
c-fos -325 bp 
1 4.61 4.59 3.14 3.07 4.97 3.26 4.45 3.91 
P-actin ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ -201 bp 
b) TNF-R2 Ab Treatment 
1 3.79 3.94 4.21 2.07 2.54 1.53 1.26 1.02 
Fig. 46 Effects of TNF-receptor antisera on the TNF-a-induced c-fos expression in 
C6 cells. C6 Cells were treated with TNF-Rl antiserum (0.08 ^ ig/mL) or 
TNF-R2 antiserum (0.08 \ig/mL) alone for 1, 2, 5, 20，30, 60 and 120 
minutes, then exposed to TNF-a (100 U/mL) for another 2 hours. The total 
R N A was extracted and followed by RT-PCR as described in the Methods. 
The untreated cells (C) served as control. The sizes, in bp, of the PCR 
products were indicated on the right. The D N A markers (M) were also run 
on the same gel. Data presented are representatives of three separate 
experiments with similar results. 
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3.10.3 The Signaling Systems Mediating the TNF-a-Induced c-fos Expression in 
C6 Cells 
Results presented earlier (Section 3.7.3) showed that the TNF-a-induced p38 a 
M A P K expression was mediated through P K C and PKA, we examined the role of 
these two pathways in the TNF-a-induced c-fos expression. 
3.10.3.1 The Involvement of p38 MAPK in TNF-a-Induced c-fos Expression in 
C6 Cells 
Results presented earlier (Section 3.6.3) showed that p38 M A P K was induced by 
TNF-a. In this study, an p38 M A P K inhibitor SB 203580 was used to investigate 
whether this inhibitor would reduce c-fos expression in the presence of TNP-a. C6 
Cells were pretreated with 1, 2.5, 5，10 and 25 SB 203580 alone for 2 hours, 
followed by the addition of TNF-a (100 U/mL) for an another 2 hours, and the levels 
of c-fos and P-actin were semi-quantified by RT-PCR (Fig. 47). TNF-a induced the 
expression of c-fos expression by more than 7 folds, and the TNF-a-induced c-fos 
expression was reduced by the addition of SB 203580 in a dose-dependent manner, 
and greater than 50% inhibition was observed with 10 and 25 u M of this inhibitor. 
Therefore, it shows that p38 M A P K is one of the signal transduction mechanisms 
mediating the TNF-a-induced expression of c-fos. 
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a) SB 203580 (|iM) + TNF-a 
( 1 
M C T N F - a 1 2.5 5 10 25 
一 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ -325 bp 
1 7.27 5.82 5.65 4.19 3.03 2.12 
P-actin -201 bp 
b) M C I 2.5 5 10 25 SB 203580 
mm 跚丨『1_丨丨1 薩 __丨丨丨圏丨丨丨 WiiMiffiBIMIMilBMIfliillilli^^ (jLllVI) 
c-fos I ^ J ^ g j P B ^ ^ ^ ^ P ^ ^ ^ ^ ^ ^ -325 bp 
1 1.14 1.06 1.21 0.97 1.03 ,• — … 
3-actin -201 bp 
Fig. 47 Effect of SB 203580 on the levels of c-fos m R N A in the presence or 
absence of TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL 
TNF-a alone for 2 hours, or pre-treated with 1 to 25 ^ iM of SB 203580 for 2 
hours before exposed to TNF-a. (b) C6 Cells were treated with 1 to 25 |LIM 
of SB 203580 only for 4 hours. The untreated cells serve as the control (C). 
The sizes, in bp, of the PCR bands were indicated on the right. The total 
R N A was extracted and followed by RT-PCR and other details were as 
described in the Methods and in Fig. 11. Data presented are representatives 
of three separate experiments with similar results. 
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3.10.3.2 The Involvement of PKC in the TNF-a-Induced c-fos Expression in C6 
Cells 
In this study, the effects of a P K C activator, P M A , and a P K C inhibitor, Ro-31, 
on the induction of c-fos was investigated. These agents were found to be selective 
activator and inhibitor of P K C in C6 cells (Tsang et al., 1997). 
For the P K C activator study, cells were treated with 0.0612, 0.162, 1.62, 16.2 
and 162 n M of P M A for 2 hours and the levels of c-fos and P-actin were semi-
quantified by RT-PCR. As shown in Fig. 48, the level of c-fos was induced as the 
concentration of P M A increased from 0.162 to 16.2 n M showing concentration 
dependence, and the most prominent effect on c-fos expression was observed with 
162 n M of P M A . With this concentration, the induction was about 7 folds. On the 
other hand, the p-actin level remained relatively constant at all concentrations of 
P M A investigated. This result suggests that activation of P K C increased c-fos 
expression in C6 cells. 
In order to ensure the stimulatory effect seen with P M A was specific and that the 
TNF-a-induced c-fos expression was mediated through PKC, the inhibitory effect of 
Ro31 on the TNF-a-induced on c-fos expression was studied. The dosage effect of 
Ro31 on the TNF-a-induced c-fos expression was shown in Fig. 49. Ro31 alone did 
not affect to any significant extent the basal expression of c-fos at all concentrations 
of Ro31 tested (Fig. 49b). However, the inhibitory action of Ro31 on the TNF-a 
induction of c-fos was dose-dependent, and greater than 50 % inhibition was observed 
with 100, 200 and 500 n M of Ro31. 
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M C 0.0162 0.162 1.62 16.2 162 P M A (nM) 
C-fos fe暴感，：杂:翻Tte"':，： - - -325 bp 
II、,�:,；、丨lytiiifiiiiif^fhirii'iiifirmiff ' --''-；'--=--------: 
1 2.79 3.03 3.58 4.24 6.91 
一 mmmmm 
Fig. 48 Effect of P M A on the levels of c-fos m R N A in C6 cells. C6 cells were 
treated with 0.0162 to 162 n M of P M A for 2 hours, the total R N A extracted 
and followed by RT-PCR as described in the Methods. The untreated cell 
(C) serve as the control. Other details were as described in Fig. 11. Data 
presented are representatives of three separate experiments with similar 
results. 
1 5 2 
~ R e s u l t s 
Ro31 (nM) + TNF-a 
a) ( 1 
M C TNF-a 10 50 100 200 500 
c-fos op 
1 5.92 4.76 4.13 2.19 2.26 2.04 
B-actin f — 
b) M C 10 50 100 200 500 RO31 
( n M ) 
• M i M B I l i 
1 1.17 1.09 1.23 1.19 1.02 
Fig. 49 Effect of Ro31 on the levels of c-fos m R N A in the presence or absence of 
TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a alone 
for 4 hours, or pre-treated with 10 to 500 n M of Ro31 for 2 hours before 
exposed to TNF-a. (b) C6 Cells were treated with 10 to 500 n M Ro31 only 
for 4 hours. The untreated cells serve as the control (C). The sizes, in bp, of 
the PGR bands were indicated on the right. The total R N A was extracted 
and followed by RT-PCR and other details were as described in the 
Methods and in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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Together with the observation that P M A activated c-fos induction, these results 
suggest that P K C is involved in mediating the induction of c-fos by TNF-a in C6 
cells. Moreover, P K C exerts its effect on c-fos expression by activating p38 M A P K as 
P K C can activate p38 M A P K (Section 3.7.3.1) and that p38 M A P K can induce c-fos 
expression (Section 3.10.1). 
3.10.3.3 The Involvement of PKA in TNF-a-Induced c-fos Expression in C6 Cells 
The other important second messenger system investigated was PKA. The reason 
being that P K A can induce the expression of p38 M A P K (Section 3.7.3.2) and that 
this kinase can activate c-fos expression (Section 3.10.1). In this study, the effect of 
dbcAMP, a protein kinase A (PKA) activator, (Messens & Siegers, 1992) and a P K A 
inhibitor, H-89, were studied. First, cells were exposed to different dosages: 10^ 
104, 10^  and 10^ n M of dbcAMP, and the contents of c-fos and P-actin were semi-
quantified by RT-PCR. c-fos m R N A level was increased by the addition of the 10^ 
104 and 10^ n M of dbcAMP, and at n M dbcAMP, the induction was only slightly 
lower than that with TNF-a (Fig. 50). This result suggests that activation of P K A can 
increase c-fos in C6 cells. The lack of effect of 10^  and 10^  n M of dbcAMP was 
unclear. It could be that 10 were too low to elicit an induction. 
In order to ensure the stimulatory effect seen with dbcAMP was specific and that the 
action of TNF-a was mediated through PKA, the inhibitory effects of H-89 on the 
TNF-a-induced c-fos was studied. In this study, C6 cells were pretreated with 1, 2.5, 
5, 10, and 25 [iM of H-89 alone for 2 hours, then exposed to TNF-a (100 U/mL) for 
another 2 hours, and the levels for c-fos and P-actin were semi-quantified by RT-PCR 
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M C TNF-a 10^ 10' 10^ dbc AMP 
(nM) 
c-fos -325 bp 
1 8.92 2.36 6.21 6.85 2.04 5.59 
P-actin ^ ^ B j u p u w n m u m w u m -201 bp 
Fig. 50 Effect of various concentrations of dbcAMP on the levels of c-fos m R N A in 
C6 cells. C6 Cells were treated with 10^  to 10^ n M of dbcAMP for 2 hours, 
the R N A extracted and followed by RT-PCR as described in the methods. 
The untreated cells (C) served as the control. Other details were as 
described in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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a) 
H-89 (|iM) + TNF-a 
I 1 
M C TNF-a 1 2.5 5 10 25 
1 7.02 8.24 5.47 4.05 3.63 2.01 
P-actin ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^201 bp 
, . H-89 
b) M C 1 2.5 5 10 25 
(m) 
c-fos ^ m i m n m i i i i i i i i n i i n i i i i i 
1 1.26 1.19 1.11 1.25 1.13 
p-actin ^ ^ I H H H I H I H H I H ^^ 
• U i U i U i p 
Fig. 51 Effect of H-89 on the levels of c-fos m R N A in the presence or absence of 
TNP-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a alone 
for 4 hours, or pre-treated with 1 to 25 \iM of H-89 for 2 hours before 
exposed to TNF-a (100 U/mL). (b) C6 Cells were treated with 1 to 25 jdM 
H-89 only for 4 hours. The untreated cells serve as the control (C). The 
sizes, in bp, of the PCR bands were indicated on the right. The total R N A 
was extracted and followed by RT-PCR and other details were as described 
in the Methods and in Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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as described in Fig. 51. The TNF-a-induced c-fos level was suppressed by the 
addition of H-89 in a dose-dependent manner (except that with 1 |LIM), and greater 
than 50 % inhibition was observed with 10 and 25 jiM (Fig. 51) This P K A inhibitor, 
at all concentrations tested, did not cause any significant changes on the basal 
expression of c-fos, nor did it had any effects on P-actin level (Fig. 51). Together with 
the observation that dbcAMP activated c-fos induction, these results suggest the TNF-
a-induced c-fos expression was mediated through P K A in C6 cells. 
3.10.4 Relationship Between c-fos Expression and P-Adrenergic Mechanism in 
C6 Cells 
As reported before, the induction of p-adrenergic mechanism seems to be closely 
related to the TNF-a-induced C6 proliferation (Liu, 1996; Lung, 1999) and that P-
adrenergic mechanism was found to involve in the TNF-a-induced p38 M A P K 
expression in C6 cells (Section 3.7.4), therefore, we examined the role of p-agonists 
and -antagonists on c-fos expression. 
3.10.4.1 Effects of Isoproterenol and Propranolol on c-fos mRNA Levels in C6 
Cells 
To investigate whether |3-adrenergic mechanism may be involved in the TNF-a-
induced c-fos expression, the effects of isoproterenol and propranolol on the TNF-a-
induced c-fos expression were studied. They are common in P-adrenergic agonist and 
antagonist, respectively. In this study, C6 cells were exposed to different dosages 
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M C TNF-a 0.01 0.1 1 10 100 Isoproterenol 
( _ 
1 5.73 1.85 1.03 3.94 5.37 4.91 
3-actin H ^ H H H H H H H m H 
-201 bp 
Fig. 52 Effect of various concentrations of isoproterenol on the levels of c-fos 
m R N A in C6 cells. C6 Cells were treated with 0.01 to 100 ^ M of 
isoproterenol for 2 hours and the total R N A was extracted and followed by 
RT-PCR as described in the methods. The untreated cells (C) served as the 
control. Other details were as described in Fig. 11. Data presented are 
representatives of three separate experiments with similar results. 
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a) Propranolol (^ iM) + TNF-a 
I 1 
M C TNF-a 1 2.5 5 10 25 
-325 bp 
c-fos 
1 9.76 4.68 4.03 4.19 2.05 3.73 
^ W B B B B B B B B B I I B B B i -201 bp 
3-actin 
b) M C I 2.5 5 10 25 P ? 二 
-325 bp 
c-fos W B M i i i i H i i i i i i i i i i i i i l l l i i 
1 1.15 1.02 1.07 0.94 0.98 
^ ^ B H H H H I W -201 bp 
Fig. 53 Effect of various concentrations of propranolol on the levels of c-fos m R N A 
in the presence or absence of TNF-a in C6 cells, (a) C6 Cells were treated 
with 100 U/mL TNF-a alone for 4 hours, or pre-treated with 1 to 25 |LIM of 
propranolol for 2 hours before exposed to lOOU/mL TNF-a for another 2 
hours, (b) C6 Cells were treated with 1 to 25 |LIM of propranolol only for 4 
hours. The untreated cells serve as the control (C). The sizes, in bp, of the 
PCR bands were indicated on the right. The total R N A was extracted and 
followed by RT-PCR and other details were as described in the Methods 
and in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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(0.01 to 100 |iM) of isoproterenol for 2 hours, and the expression of c-fos were semi-
quantified by RT-PCR (Fig. 52). The expression of c-fos was enhanced with 1，10, 
100 i^M of isoproterenol tested, and at 1 ^ iM the induction was about 4 folds while at 
10 i^M the induction was comparable to that with TNF-a (100 U/mL), Consistent 
with the involvement of an P-adrenergic mechanism, propranolol suppressed the 
TNF-a-induced c-fos expression by about 50% when the concentration of propranolol 
was equal to and greater than 2.5 juM; and optimum inhibition was observed with 10 
|LIM where the inhibition was about 79% (Fig. 53). These suggest that P-adrenergic 
mechanism exert regulation on the TNF-a-induced c-fos expression in C6 cells. 
3.10.4.2 Effects of pi-Agonist and Antagonist on c-fos m R N A Expression in C6 
Cells 
Since previous study in our laboratory found observed that TNF-a induced the 
expression of both pi- and P2-AR (Shan, 2000) and as described in Section 3.10.4.1 
3-adrenergic mechanism participated in the TNF-a-induced c-fos expression, we 
therefore examined the effects of dobutamine, a selective pi-AR agonist, and 
atenolol, an antagonist, on c-fos expression. In this study, C6 cells were treated with 5， 
10, 50, 100 and 500 n M dobutamine for 2 hours, and the m R N A levels of c-fos and p-
actin were semi-quantified by RT-PCR. The c-fos expression was enhanced with 5, 
50, 100 and 500 n M dobutamine, and the maximum induction of c-fos were observed 
with 500 n M at the latter concentration, the induction was similar to that with TNF-a 
(Fig, 54). On the other hand, the m R N A of (3-actin was relatively constant at all 
concentrations of dobutamine tested. This finding suggests that the activation of pl-
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A R can increase the c-fos expression in C6 cells. The lack of effect with 10 n M 
dobutamine was unclear at present. 
In order to make sure the observation with dobutamine reflected that (31-
adrenergic mechanism was involved in regulating c-fos expression in C6 cells, the 
effect of atenolol was examined. In this study, C6 cells were pretreated with 10, 50, 
100 and 500 n M atenolol for 2 hours, then in the presence of TNF-a (100 U/mL) for 
an additional 2 hours, and the m R N A levels for c-fos and P-actin were semi-
quantified by RT-PCR (Fig. 55). The TNF-a-induced c-fos level was suppressed by 
the addition of atenolol in a dose-dependent maimer and greater than 50 % inhibition 
was observed with 100 and 500 n M (Fig. 55). However, atenolol alone did not cause 
any clear changes on the expression of c-fos and P-actin m R N A at all concentrations 
tested (Fig. 55). 
This finding, taken together with the observation that dobutamine induced c-fos, 
suggests that pi-adrenergic mechanism was involved in regulating the TNF-a-
induced c-fos expression in C6 cells. This observation is not too surprising as previous 
results in our laboratory showed that TNF-a induced the expression of both p-AR 
subtype expression (Lung, 1999; Shan, 2000) and that P-adrenergic mechanism 
participated in the TNF-a-induced c-fos expression (Section 3.10.4.1) 
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M C TNF-a 5 10 50 100 500 Dobutamine 
(nM) 
1 6.38 4.92 0.95 3.83 4.18 6.01 
-201 bp 
Fig. 54 Effect of various concentrations of dobutamine on the levels of c-fos m R N A 
in C6 cells. C6 Cells were treated with 5 to 500 n M of dobutamine for 2 
hours, the total R N A extracted and followed by RT-PCR as described in the 
Methods. The untreated cells (C) served as the control. Other details were as 
described in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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a) atenolol (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 500 
c-fos ^ ^ ^ ^ m m P H J I I I I I I I I I I I I H -325 bp 
1 6.38 5.06 4.14 2.39 1.57 
701 hn 
b) M C 10 50 100 500 atenolol (nM) 
C-fos ^^mmrnrnm：-! -325 bp 
1 1.15 1.21 1.02 1.13 
Fig. 55 Effect of various concentrations of atenolol on the levels of c-fos m R N A in 
the presence or absence of TNF-a in C6 cells, (a) C6 Cells were treated 
with 100 U/mL TNF-a alone for 2 hours, or pre-treated with 10 to 500 n M 
of atenolol for 2 hours before exposed to lOOU/mL TNF-a for another 2 
hours, (b) C6 Cells were treated with 10 to 500 n M of atenolol only for 4 
hours. The untreated cells serve as the control (C). The sizes, in bp, of the 
PCR bands were indicated on the right. The total R N A was extracted and 
followed by RT-PCR and other details were as described in the Methods 
and in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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3.10.4.3 Effects of p2-Agonist and -Antagonist on c-fos m R N A Expression in C6 
Cells 
In addition to examine the role of pi-adrenergic mechanism, we also 
investigated the effect of procaterol, a selective p2-AR agonist, procaterol (Koganei et 
al., 1995) and an ICI 118,551, a selective P2-AR antagonist (Deighton et al., 1992). 
For p2-agonist study, C6 cells were treated with different dosages (5, 10, 50, 100 and 
500 nM) of procaterol for 2 hours, and the m R N A levels of c-fos and P-actin were 
semi-quantified by RT-PCR. The c-fos induction was elevated as the concentration of 
procaterol increased and in the presence of 100 nM, the stimulation was similar to that 
with (100 U/mL) TNF-a (Fig. 56). The m R N A of P-actin was relatively constant at 
all concentrations of procaterol tested. This finding suggests that the activation of p2-
A R can increase c-fos expression in C6 cells. 
In order to make sure the observation with procaterol reflected that p2-adrenergic 
mechanism was involved in regulating the TNF-a-induced c-fos expression in C6 
cells, the effect of an p2-antagonist, ICI 118,551 was studied. In this study, C6 cells 
were pretreated with different dosages (10, 50, 100，500 and 1000 nM) of ICI 118,551 
for 2 hours, and then exposed to TNF-a (100 U/mL) for another 2 hours, and the 
m R N A levels for c-fos and P-actin were semi-quantified by RT-PCR (Fig. 57). The 
TNF-a-induced c-fos level was suppressed and greater than 58% inhibition was 
observed with 50 n M of ICI 118,551 (Fig.57). ICI 118,551 alone at all concentrations 
tested did not cause any clear changes in c-fos and P-actin expression (Fig. 57). 
These results, taken together with the observation that procaterol induced c-fos, 
suggests that p2-adrenergic mechanism was involved in regulating the TNF-a-
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induced c-fos expression in C6 cells. Comparing the effectiveness of pi- and p2-
antagonist, it appears that atenolol was more potent in inhibiting the TNF-a-induced 
c-fos expression (Figs. 55 & 57). Summing up the results observed with P-adrenergic 
agonists and antagonists, it is tempting to conclude that P-adrenergic mechanism 
participate in the TNF-a-induced c-fos expression in C6 cells. This action of P-
adrenergic compound is likely mediated through p38 M A P K as this kinase was 
activated by P-adrenergic mechanism (Section 3.7.4). 
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M C TNF-a 5 10 50 100 500 Procaterol 
(nM) 
f .325 .P 
1 7.45 1.03 3.82 2.04 6.91 5.35 
Fig. 56 Effect of various concentrations of procaterol on the levels of c-fos m R N A 
in C6 cells. C6 Cells were treated with 5 to 500 n M of procaterol for 2 
hours, the total R N A extracted and followed by RT-PCR as described in the 
Methods. The untreated cells (C) served as the control. Other details were as 
described in Fig. 11. Data presented are representatives of three separate 
experiments with similar results. 
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a) ICI 118,551 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 500 
C-fos -301 bp 
1 5.82 4.61 2.03 4.97 5.01 
3. t. -201 bp 
b) M C 10 50 100 500 1000 ICI 118,551 
一 -325 bp 
1 1.25 1.18 1.16 0.93 0.97 
P-actin 蒙 急 二 、 • 、 心 ’ ’ — “ ^ ^ -201 bp 
Fig 57 Effect of various concentrations of ICI 118,551 on the levels of c-fos 
m R N A in the presence or absence of TNF-a in C6 cells, (a) C6 Cells were 
treated with 100 U/mL TNF-a alone for 2 hours, or pre-treated with 10 to 
500 n M of ICI 118,551 for 2 hours before exposed to TNF-a (100 U/mL) 
TNF-a for another 2 hours, (b) C6 Cells were treated with 10 to 500 n M of 
ICI 118,551 for 4 hours. The untreated cells serve as the control (C). The 
sizes, in bp, of the PGR bands were indicated on the right. The total R N A 
was extracted and followed by RT-PCR and other details were as described 
in the Methods and in Fig. 11. Data presented are representatives of three 
separate experiments with similar results. 
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3.11 T h e Relat ionship Between p38 M A P K and Transcript ion Factor NF-KB 
Express ion 
3.11.1 Ef fec t of T N F - a on the Express ion of NF-KB in C6 Gl ioma Cells 
The expression of NF-KB, is the other transcription factor studied to further 
understand the third messenger involved in the TNF-a-induced proliferation in C6 
cells. NF-KB has been shown to be activated by TNF-a in a number of cell types 
(Baeurle & Baltimore, 1988; Israel et al., 1989; Osbom et al., 1989). Besides, recent 
findings suggest that this transcription factor is involved in the induction of cell 
proliferation and differentiation (Siebenlist et al., 1994). Previous study in our 
laboratory (Lung, 1999) showed that a significant increase in NF-KB/p50 was 
observed in cells treated with TNF-a (100 U/mL) for 20 minutes, and maximum 
response was observed after 2 to 4 hours of treatment. Therefore, it is of interest to 
investigate the role of the two TNF - R subtype, PKC and p38 M A P K on NF-KB 
expression in C6 cells. 
3.11.2 Role of TNF-Receptor (TNF-R) Subtypes in the TNF-a - Induced NF-KB 
Expression in C6 Cells 
Results presented before (Section 3.7.2) showed that TNF-R2 was the major 
receptor subtype responsible for the activation of p38 M A P K (Fig. 14). Therefore, 
attempts were made to elucidate whether TNF-Rl or TNF-R2 was responsible for 
mediating expression of NF-KB induced by TNF-a. 
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In this experiment, cells were treated with TNF-Rl antiserum (0.08 jug/mL) or 
TNF-R2 antiserum (0.08 |ig/mL) alone for 1, 2, 5, 20, 30, 60 and 120 minutes, then 
TNF-a (100 U/mL) was added to the culture for another 2 hours. After R N A 
extraction, the TNF-a-induced N F - K B expression and p-actin were monitored by RT-
PCR. It was found that following the addition of TNF-a, there were not much 
changes in the expression of N F - K B and P-actin in TNF-Rl antiserum-treated cells 
(Fig. 58). On the other hand, the exposure to TNF-R2 antiserum effectively blocked 
the induction of N F - K B by TNF-a. After the addition of this antiserum, near complete 
blockade of the N F - K B expression was observed with longer pretreatment times. 
Therefore, it suggests that the TNF-a-induced NF-KB expression was mediated by 
binding to TNF-R2. This finding is in agreement with results presented earlier that 
TNF-R2 was mainly responsible for the expression of p38 M A P K (Fig. 14) and that 
the TNF-a-induced NF-KB was mediated by p38 M A P K (Fig. 58). 
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a) TNF-Rl Ab Treatment 
M C TNF-a 1 2 5 20 30 60 120 (min) 
Z'so ^ ^^ggg^^ -823 bp 
1 4.89 4.53 3.89 3.97 3.42 4.76 4.24 4.31 
MHHHMI 
3-actin "201 bp 
b) TNF-R2 Ab Treatment 
1 5.08 5.03 4.56 3.01 2.32 1.05 1.48 1.17 
Fig. 58 Effects of TNF-receptor antisera on the TNF-a-induced NF-KB expression 
in C6 cells. C6 Cells were treated with TNF-Rl antiserum (0.08 ^ ig/mL) or 
TNF-R2 antiserum (0.08 |ig/mL) alone for 1, 2, 5, 20, 30, 60 and 120 
minutes, then exposed to TNF-a (100 U/mL) for another 2 hour. The total 
R N A was extracted and followed by RT-PCR as described in the Methods. 
The untreated cells (C) served as control. The sizes, in bp, of the PCR 
products were indicated on the right. The D N A markers (M) were also run 
on the same gel. Data presented are representative of three separate 
experiments with similar results. 
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3.11.3 T h e Signal ing System Mediat ing TNF-a - induced NF-KB Express ion in C6 
Cells 
3.11.3.1 T h e Invo lvement o f p 3 8 M A P K in T N F-a - I n d u c e d NF-KB Express ion in 
C6 Cells 
The effect of a p38 M A P K inhibitor, SB 203580 on the induction of NF-KB was 
investigated. In this study, C6 cells were pretreated with 1，2.5, 5, 10 and 25 |LIM SB 
203580 alone for 2 hours, exposed to TNF-a (100 U/mL) for another 2 hours, and the 
levels for NF-KB and P-actin were semi-quantified by RT-PCR (Fig. 59). The TNF-a-
induced NF-KB expression was suppressed by the pretreatment with SB 203580, and 
about 59% inhibition was observed with 10 \iM of this inhibitor (Fig. 59). The result 
suggests that p38 M A P K is one of the mediator involved in the TNF-a-induced NF-
KB expression. 
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a) SB 203580 (|LIM) + T N F - a 
I 1 
M C TNF-a 1 2.5 5 10 25 
N F KB/p5o nmuiiQiiQi^^i^^miQ^i 
1 7.86 4.65 4.18 4.53 3.26 0.89 
(3-actin -201 bp 
b) M C 1 2.5 5 10 25 SB 203580 
NF-KB/p50 -823 bp 
1 1.25 1.19 1.08 1.13 1.16 
P-actin -201 bp 
Fig. 59 Effect of various concentrations of SB 203580 on the levels of NF-KB 
m R N A in the presence or absence of TNF-a in C6 cells, (a) C6 Cells were 
treated with 100 U/mL TNF-a alone for 2 hours, or pre-treated with 1 to 25 
\xM of SB 203580 for 2 hours before the addition of TNF-a. (b) C6 Cells 
were treated with 1 to 25 ！^M of SB 203580 only for 4 hours. The untreated 
cells serve as the control (C). The sizes, in bp, of the PCR bands were 
indicated on the right. The total R N A was extracted and followed by RT-
P C R as described in Fig. 11. Data presented are representatives of three 
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separate experiments with similar results. 
3.11.3.2 T h e I n v o l v e m e n t of P K C in the T N F-a - I n d u c e d NF-KB Express ion in C6 
Cel ls 
In this study, the effects of a P K C activator, P M A and a P K C inhibitor, Ro-31, on 
the induction of NF-KB were investigated. These agents were found to be selective 
activator and inhibitor of P K C in C6 cells (Tsang et al., 1997). 
In the presence of different dosages (0.0612, 0.162, 1.62 and 16.2 nM) of P M A 
The level of NF-KB was enhanced as the concentration of P M A increased from 
0.0162 to 16.2 nM. In the presence of 0.0162 n M of P M A , the induction of NF-KB 
was similar to that with TNF-a (100 U/mL) (Fig. 60). The P-actin level remained 
relatively constant at all P M A concentrations tested. This result suggests that 
activation of P M A can increase NF-KB expression in C6 cells. 
In order to ensure the stimulatory effect seen with P M A was specific and that the 
TNF-a-induced NF-KB expression was mediated through PKC, the inhibitory effect 
of Ro31 on the TNF-a-induced NF-KB expression was studied. The dosage effect of 
Ro31 on the TNF-a-induced NF-KB expression was shown in Fig. 61. Ro31 alone did 
not affect to any significant extent on the basal expression of NF-KB at all 
concentrations of Ro31 tested (Fig. 61). However, the inhibitory action of Ro31 on 
the TNF-a induction of NF-KB was dose-dependent, and the greatest inhibition was 
observed with 100 n M of Ro31. 
Together with the observation with P M A activated NF-KB induction, these 
results suggest that P K C is involved in mediating the induction of NF-KB by TNF-a 
in C6 cells. 
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M C 0.0162 0.162 1.62 16.2 PMA (nM) 
NF-KB/D50 摊辦暴：淨•'�A: ：=人知，�“�“‘‘：“' -823 bp 
1 5.83 6.03 6.96 7.03 
P-actin ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ .201 bp 
Fig. 60 Effect of P M A on the levels of NP-KB m R N A in C6 cells. C6 cells were 
treated with 0.0162 to 162 n M of P M A for 2 hours, the total R N A extracted 
and followed by RT-PCR as described in the methods. The untreated cell 
(C) serve as the control. Other details were as described in Fig. 11. Data 
presented are representatives of three separate experiments with similar 
results. 
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a) Ro31 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 200 500 
NF-KB 
1 5.26 4.93 5.16 2.31 1.79 1.97 
- tin -201 bp 
b) 
M C 10 50 100 200 500 RO31 
^ ^ ^ ^ • • • • • • • I H ^ H B I ( n M ) 
NF-KB -823 bp 
1 1.17 1.09 1.03 1.02 0.98 
p-actin 勢 梦 歡 
-201 bp 
Fig. 61 Effect of Ro31 on the levels of NF-KB m R N A in the presence or absence of 
TNF-a in C6 cells, (a) C6 Cells were treated with 100 U/mL TNF-a alone 
for 4 hours, or pre-treated with 10 to 500 n M of Ro31 for 2 hours before 
exposed to TNF-a. (b) C6 Cells were treated with 10 to 500 n M Ro31 only 
for 4 hours. The untreated cells serve as the control (C). The sizes, in bp, of 
the P C R bands were indicated on the right. The total R N A was extracted 
and followed by RT-PCR and other details were as described in the 
Methods and in Fig. 11. Data presented are representatives of three separate 
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Chapter 4: DISCUSSION 
4.1 Effects of Tumor Necrosis Factor-g (TNF-a) on C6 Cell Proliferations 
In this study, we made use of the astrocyte-derived C6 glioma cell line to 
examine the signaling pathway mediating the proliferative action of TNF-a. C6 cells 
exhibit many properties of astrocytes (Kempski et al., 1992; Vemadakis et al, 1992)， 
including expression of the astrocyte-specific markers glial frillary acidic protein and 
S-100 protein (Pfeiffer et al., 1992). Moreover, they are easy to grow in culture and 
with short population doubling time (Benda et al., 1968; Westermark et al., 1973). 
Previous studies in our laboratory (Liu, 1996; Lung, 1999) showed that TNF-a 
could induce C6 cell proliferation and maximum effect was observed with 100 U/mL. 
This finding is in agreement with reports that TNF-a stimulates proliferation in 
primary cultured astrocytes, both in vivo and in vitro (Selmaj et al., 1990), as well as 
in rat C6 glioma cells (Munoz-Ferandez & Fresno, 1993). More recently, we found 
the TNF-a selectively induced the expression of TNF-R2 in C6 cells (Huang et al., 
1998) and cultured astrocytes (Lung et al., 2001), and that TNF-R2 was via the 
receptor subtype responsible for the TNF-a-induced proliferation in C6 cells (To, 
1999). In addition, we found that TNF-a activated the PKC pathway to induce C6 cell 
proliferation (Lung, 1999). However, the underlying mechanism linking PKC and 
proliferation remains unclear, and the issue whether PKC is the only signaling 
pathway mediating the action of TNF-a is still under investigation. 
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In m y study, fluorescent differential display (FDD) was applied to screen the up-
or down-regulated genes, apart from PKC, after TNF-a treatment (Liang & Pardee, 
1995, 1998; Jones et al 1997; Ito et al, 1999). Figure 3 showed the F D D gel and 
some differentially expressed genes. Following sequencing, three differentially 
expressed c D N A fragments Al, A2 & A3 were observed and corresponding to rat 
5' A M P protein kinase, rat ribosomal protein L7a and rat p38 M A P K , respectively 
(Table 5). Among these three genes, p38 M A P K was chosen for further study as this 
gene had been shown to be a stress-activated serine/threonine protein kinase and that 
proinflammatory cytokines, TNF-a and IL-1, had been shown to trigger p38 M A P K 
protein kinase cascades (Herlaar & Brown, 1999). Moreover, several lines of evidence 
showed that p38 M A P K regulated the (pro)inflammatory molecules expression, since 
intervention of p38 M A P K kinase pathway by inhibitors, e.g. SB 203580 prevented 
the expression of cytokines including IL-1, IL-6 and TNF-a (Lee et al, 1994; 
Raingeaud et al., 1995; Wysk et al., 1999). Another reason is that p38 M A P K has 
been causally implicated in ischemic heart disease (Wang & Huang, 1998), focal 
cerebral ischemia (Irving & Barone, 2000) human immunodeficiency vims infection 
(Kumar et al., 1996; Cohen et al., 1997;), and Alzheimer‘ s disease (Hensley & 
Floyd, 1999); all of these are closely related to actions of cytokines, including TNF-a. 
Finally, activation of p38 M A P K resulted in phosphorylation of a wide range of 
cellular substrates which in turn led to cell cycle regulation through modulation of 
transcriptional activities (Takenaka et al., 1998), development (Adachi-Yamada et al, 
1999; Suzanne et al, 1999) cell differentiation (Morooka & Nishida, 1998; Zetser et 
al., 1999; Iwasaki et al., 1999) and proliferation (Nagata et al., 1998; Maher, 1999; 
Rausch & Marshall, 1999). These indicated that the p38 M A P K signaling pathway is 
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important for cellular growth and differentiation. Thus, understanding the TNF-a-
induced p38 M A P K signaling cascade showed give us insight into the mechanism 
mediating the TNF-a-induced C6 proliferation as well as developing effective 
therapeutic treatments for a variety of diseases，including TNF-a. 
4.2 The Signaling System Involved in TNF-q-Induced p38 M A P K Expression in 
C6 Cells 
To date, four different genes encoding p38 M A P K isoforms: p38a (Han et al., 
1995), p38(3 (Jiang et al., 1996), p38y (Lechner et al., 1996; Li et al., 1996; Cuenda et 
al., 1998; Hu & Tan, 1999), p385 (Jiang et al., 1997; Kumar et al, 1997) had been 
cloned recently, but their expressions in C6 cells have not been revealed. Our results 
showed that p38a, p, y, 5 were expressed in unstimulated cells through the levels of 
the first two isozymes were higher (Fig. 13). This finding is in line with reports that 
p38 a, p isozymes were more abundantly expressed in brain than in peripheral tissues 
(Jiang et al., 1996) and that p38a and, p38|3 are the major forms of p38 M A P K s in the 
brain (Lee & Park, 1999, 2000). 
Upon exposure to TNF-a, the four p38 M A P K isozymes: p38a, (3, 丫 and 6 were 
all up-regulated but their responses to TNF-a were somewhat different in terms of 
sensitivity to TNF-a. The p38 a isozyme was induced as early as 2 minutes, while 
other isoforms of p38 M A P K were induced at later times and to lesser extents. These 
observations correlated well with the distribution and functions of p38 MAPKs. p38 y 
was predominately expressed in skeletal muscle (Lechner et al., 1996; Li et al,, 1996) 
while p38 5 was mainly found in lung, kidney, testis, pancreas, and small intestine 
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(Kumar et al, 1997). More interestingly, p38 y expression was induced during muscle 
differentiation and p38 5 expression was shown to be developmentally regulated 
(Lechner et al., 1996; Hu & Wang, 1999). Thus, the finding that p38 a M A P K was 
the isoform mainly affected suggests that this isoform plays important role in 
regulating C6 cells proliferation. This notion is supported by reports that p38 M A P K 
modulates transcription factors expression (Takenaka et al., 1998), cell differentiation 
(Morooka & Nishida, 1998; Zetser et al, 1999) and cell proliferation (Maher et al., 
1999). 
For TNF-a to elicit its influence on the target cells, the first step is to bind to the 
TNF-receptors (TNF-Rs) on the cells. Recently, two subtypes of TNF-Rs have been 
identified, namely, TNF-Rl and TNF-R2, and they are found in many cell types 
(Tartaglia et al., 1992, 1993; Barbara et al,, 1994). In our laboratory, we have found 
that C6 cells (Huang et al., 1998; Lung, 1999; To, 1999) contain both receptor 
subtypes and TNF-a selectively induced the expression of TNP-R2 as well as its 
protein in a time- and dose- dependant manner (Huang et al, 1998; Lung, 1999). 
Recently, the importance of TNF-R2 in C6 cell proliferation was clearly demonstrated 
by To (1999) in our laboratory by using selective TNF-R antibodies. W e found that 
TNF-R2 antibody, but not TNF-Rl antibody, inhibited the proliferative effect of TNF-
a in C6 cells. Similar finding has been reported in cultured microglia (Dopp et al, 
1997). Therefore, it is of our interest to investigate which receptor subtype is 
responsible for mediating the effects of TNF-a in the expression of p38 M A P K , 
iNOS, and the third messenger, such as c-fos, CREB and NF-KB. From the present 
study, we showed that p38 M A P K induction was almost completely blocked at around 
20 minutes after TNF-R2 antibody treatment, but only a much mild inhibition 
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occurred after the addition of TNF-Rl antibody (Fig. 14). This observation is unlikely 
due to the possibility that the murine recombinant TNF-a, unlike the human 
recombinant TNF-a has been shown to bind to both receptor (Tartaglia et al., 1991), 
used in this study could not bind to both receptor subtypes as nor the lack of effect 
could be explained by the absence of TNF-Rl as we found that TNF-Rl was 
expressed at a higher concentration in control cells (Huang et al., 1998). Thus, our 
study demonstrated that p38 M A P K induction was mediated mainly through TNF-R2, 
and that the role of TNF-Rl was relatively minor and occurred at a later time (Fig. 
14). 
Recent studies showed that cross-talks existed between distinct p38 M A P K and 
protein kinases, such as protein kinase A and C, and that the latter kinases cooperate 
in the integration of the signals delivered through the p38 M A P K (Robinson & Cobb, 
1997; Moroo & Tatsuno, 1998; Zhang & Xin, 1999). Our study showed that the 
dbcAMP, a well-established activator of P K A (Messens & Siegers, 1992), did elevate 
the p38 M A P K expression in C6 cells (Fig. 18) while 14-22 and H-89 treatment 
inhibited the TNF-a-induced p38 M A P K expression (Figs. 19 & 20). Thus, it is likely 
that the P K A was involved in the TNF-a-induced p38 M A P K gene expression in C6 
glioma cells. The participation of the P K A in the differential modulation of p38 
M A P K pathway has been documented. For example, p38 M A P K activation was 
partially inhibited by 14-22 and H-89, both are selective PKA inhibitors, suggesting 
that activation of p38 M A P K involved PKA (Hansen et al” 2000). This was in 
agreement with recent data from Blanco-Aparicio et al. (1999), who reported that 
P K A prevented dephosphorylation and cytoplasmic retention of p38 M A P K by 
inhibiting protein tyrosine phosphatase PTP-SL. Whether TNF-a exerts its action in 
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C6 cells via a similar process remains to be elucidated. 
P K C is a common second messenger in many cell types, an it has been found to 
be the signal transduction mediating TNF-a action in human erythroblatoid leukemic 
K562 cell line (Zhang et al, 1994) and C6 cell proliferation (Lung, 1999). Also, 
several reports suggested an important role for P K C in the regulation of regeneration 
of peripheral nerves and neurite outgrowth, since inhibition of this kinase led to 
reduced growth activity in PC-12 cells (Hall & Femyhough, 1988; Altin & Wetts, 
1992). W e found that P M A induced p38 M A P K m R N A level in C6 cells (Fig. 15), 
while Ro31 and staurosporine, both are selective P K C inhibitors (Tsang et al, 1997), 
suppressed the TNF-a-mediated p38 M A P K expression (Figs. 16 & 17). This 
demonstrated that the activation of p38 M A P K pathway was regulated by PKC. The 
above findings suggest that both P K A and P K C regulate the expression of p38 
M A P K induced by TNF-a, and this effect of TNF-a is likely mediating by TNF-R2 
as the induction of p38 M A P K was blocked by TNF-R2 antiserum treatment (Fig. 
14). The mechanism involved beyond TNF-R2 interaction is not clear at present. In 
view of the fact that changes in protein phosphorylation is a frequent mechanism 
employed by cells to regulate transcription factor activity (Whitmarsh & Davis, 
2000), it is possible that these two kinases regulate or mediate the TNF-a-induced 
p38 M A P K expression in C6 cell via a similar mechanism. Though the mechanism 
related to the action of p38 M A P K in C6 cells was not studied in the present study, it 
is anticipated that this kinase may exert its specific function by interacting with 
scaffold proteins, a mechanism which had been demonstrated in yeasts and mammals 
(Whitmarsh & Davis, 1998) and results in sequential phosphorylation (Treisman et 
al, 1996). Our results were in line that the phosphorylation of p38 M A P K was 
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enhanced after the TNF-a treatment (Fig. 12). 
p38 M A P K pathway behaves as a multimolecular complex of receptors and 
regulatory and adaptor proteins, which are functionally assembled around a modular 
core of the mitogen protein kinase (Schaeffer & Weber, 1999). A major mechanism of 
internal regulation and signal amplification of these cascades is the sequential 
phosphorylation and activation of the kinases with its kinase module, leading to 
activation in the cytoplasm of the effector kinases such as p38 M A P K , and their 
translocation to the nucleus, where phosphorylation of transcription factors takes 
place (Karin et al, 1995; Treisman et al, 1996). The specificity of activation and 
function of M A P K signaling modules is determined, in part, by scaffold proteins that 
create multi-enzyme complexes. In Saccharomyces cerevisiae, two MAPK-scaffold 
proteins have been identified. Recent studies of mammalian cells have also led to the 
identification of putative scaffold proteins. These scaffold proteins appear to facilitate 
M A P K activation (Whitmarsh & Cavanagh, 1998), in response to specific 
physiological stimuli, and to insulate the bound M A P K module against activation by 
irrelevant stimuli. Scaffold proteins are therefore critical components of M A P K 
modules and ensure signaling specificity (Whitmarsh & Davis, 1998). A study 
revealed that phosphorylation loop 12 (L 12) influences the substrate specificity and 
autophosphorylation of p38 M A P K (Jiang & Li, 1997). In addition, the crosstalk 
between distinct M A P K kinase cascades as well as with protein kinases from other 
pathways, such as P K A or PKC respectively, cooperates in the integration of signals 
delivered through the M A P kinases (Robinson & Cobb, 1997). 
Previous studies in our laboratory showed that isoproterenol induced C6 cells 
proliferation, while propranolol inhibited the TNF-a-induced proliferation (Lung, 
1999). More recently, Shan (2000) in our laboratory found that TNF-a induced the 
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expression of pl-AR and P2-AR. In C6 cells, both p-ARs were tightly coupled to the 
Gs-cAMP-dependent pathway (Fishman & Mallorga, 1981; Kassis & Zaremba, 1985; 
Fitzgerald & Li, 1996) and thus this cell line provides a suitable model system for the 
general study of intracellular p-AR-mediated signal transduction events. Moreover, 
C6 glioma cells expressed receptors and a coupling machinery for mitogen-induced 
signaling (Pasumarthi & Jin, 1997), and these offering additional advantages, 
opportunities to explore the potential for drug-induced multiplex signaling lying 
downstream of the pAR binding sites. Furthermore, an effect of p-AR stimulation on 
M A P K kinase activity had been reported in PC-12 cells (Frodin & Peraldi, 1994) and 
that stimulation of P-AR by isoproterenol, a common P-agonist, induced a time- and 
dose-dependent increase in p38 M A P K activation in cardiac myocytes (Zheng & 
Zhang, 2000). This is of considerable interest since a large fraction of P-ARs is 
present on glia rather than neurons in the brain (Stone & Ariano, 1989). 
Indeed, results in the present study showed that isoproterenol induced p38 
M A P K expression (Fig. 21) while the propranolol suppressed the TNF-a-induced p38 
M A P K m R N A expression (Fig. 22). This observation suggests that the TNF-a-
induced p38 M A P K is mediated through P-AR. As stated before, there are two types 
of P-AR in C6 cells, we attempted to examine which receptor subtype plays a more 
important role in inducing p38 M A P K expression in C6 cells. Our study showed that 
both (31-agonist, dobutamine (Fig. 23)，and p2-agonist, procaterol, could induce p38 
M A P K expression (Fig. 25). This indicated that activation of both [31- and (32-AR 
could result in the induction of p38 M A P K gene expression in C6 cells. Supporting 
this notion is our finding that the TNF-a-induced p38 M A P K gene expressions were 
inhibited by selective (31-antagonist, atenolol (Fig. 24) and (32-antagonist, ICI 118,551 
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(Fig. 26). Thus, this suggests that both (31- and P2-AR could regulate the expression 
of p38 M A P K induced by TNF-a in C6 cells. This may be due to the fact that both 
receptor subtypes are expressed in C6 cells (Lung, 1999; Shan, 2000). 
Comparing the results obtained with selective (31- and p2-agonists (Figs. 23 & 
25) and antagonists (Figs. 24 & 26), P2-AR appeared to play a more important role in 
p38 M A P K gene expression. The physiological significance of this observation is not 
immediately clear and certainly deserves more detail study. 
4.3 The Signaling System Involved in TNF-g-Induced iNOS Expression in C6 
Cells 
Recent reports have shown that nitric oxide (NO), a short lived gaseous 
molecules, is a potent biological mediator in the vascular, immune, and nervous 
systems (Moncada & Higgs, 1991; Nathan et al., 1992) and traumatic diseases 
(Koprowski et al., 1993). N O is synthesized from L-arginine by the enzyme nitric 
oxide synthase (NOS). It has been reported that there are 3 isoforms of NOS: 
endothelial N O S (eNOS), neuronal N O S (nNOS) and inducible N O S (iNOS) (Wang 
&Marsden, 1995). 
In our laboratory, we have found that the iNOS gene in C6 cells was induced 
after TNF-a treatment (Lung, 1999). This finding correlates well that the observations 
TNF-a or LPS alone induced the production of N O in C6 cells and primary astrocytes 
(Feinstein et al., 1994; Pahan et al., 1998). More recently, several laboratories have 
demonstrated that certain stimuli, such as local ischemic damage (Endoh et al., 1993), 
post-ischemic reperfusion (Holtz et al, 2001), intense neuronal activity, and kainic 
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acid lesions, could stimulate astroglial N O S expression. This is of particular interest 
as TNF-a was elevated in ischemia damaged brain (Endoh et al., 1993), focal cerebral 
ischemia (Buttini & Appel, 1996) and that the p38 M A P K pathway was activated up 
to 24 hours following transient ischemia in the neurons and glia of rat (Irving & 
Barone, 2000) and in microglia (Walton et al., 1998). Therefore, we examined the role 
of p38 M A P K and P K A pathway in the TNF-a-induced iNOS activity, iNOS was 
chosen in this study as this form was induced in C6 cells (Lung, 1999). 
The signals and mechanisms that regulate iNOS expression in C6 glial cells are 
not well understood. Studies with various immune cell systems have suggested that 
the regulation is complex and contains multiple factors, such as nuclear factor kappa 
B (NF-KB) (Xie et al., 1994; Nishiya et al, 1995), P K C (Chen et al., 1998) and 
M A P K (Bhat et al, 1998, 1999). Our finding showed that the iNOS transcript was 
dramatically decreased after p38 M A P K inhibitor treatment (Fig. 29). Thus, it is very 
likely the TNF-a-induced iNOS expression in C6 cells was mediated through the 
activation of p38 M A P K as this M A P K kinase was greatly induced by TNF-a (Fig. 
13). However, Guan et al. (1997) reported that the activation of p38 M A P K by IL-1(3, 
had been shown to inhibit N O biosynthesis in mesangial cells. The discrepancy may 
be due to the functions of different cytokines used and the action of cytokines in 
different cell types. 
Our observation showed that TNF-a-induced iNOS expression was mediated 
through the activation of p38 a M A P K . However, it is still unclear which TNF-R 
subtype is responsible for the mediation. Using TNF-Rl and TNF-R2 antibodies 
pretreatment, we found that the expression of iNOS was mediated through TNF-R2, 
but not TNF-Rl (Fig. 28). This finding is in line with the observation that TNF-R2 
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was major subtype responsible for mediating the induction of p38 M A P K (Fig. 14). 
Previous study (Lung, 1999) have shown that the TNF-a-induced iNOS 
expression was not mediated through the P K C pathway. Therefore, we only attempted 
to see whether P K A was a possible pathway responsible for this induction. Our study 
showed that dbcAMP, a well-established activator of PKA, elevated the iNOS m R N A 
level in C6 cells (Fig. 30). Moreover, the TNF-a-induced iNOS expression was 
suppressed by the treatment of H-89, a selective inhibitor of P K A (Fig. 31). This 
suggests that P K A regulate the TNF-a-induced p38 M A P K , which in turn control 
iNOS expression in C6 cells. 
4.4 The Signaling System Involved in TNF-a-Induced CREB Expression in C6 
Cells 
To date, little is known about signal transduction pathways and transcription 
factors that are activated in reactive glial cells. Reactive glial cells were found in 
nervous tissues exposed to mechanical and chemical insults, where in these cases 
cytokines were elevated (Benveniste & Benos, 1995). A potential candidate is the 
inducible transcription factor, CREB, which is an important component in the 
regulation of gene expression in response to extracellular stimuli (Herdegen & Leah, 
1998). Recently, a study showed that kainate-induced neuronal injury, a process likely 
required TNF-a (Bruce et al., 1996), led to phosphorylation of CREB in glial and 
endothelial cells in the hippocampus (Ong and Lim, 2000). Also, CREB 
overexpression could protect cells from toxin-induced apoptosis in vitro and this 
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factor was phosphorylated following hypoxic-ischemic brain injury in vivo (Walton et 
al., 1996), focal ischemia (Tanaka & Nagata, 1999; Tanaka & Nogata, 1999). In this 
connection, it is interesting to note that TNF-a had been shown to protect neurons 
against metabolic-excitotoxic insults (Cheng et al., 1994). Thus, the C R E B protein 
and the C R E site could be potential targets for both existing and future 
neuroprotective agents (Walton et al” 1999). Our study showed that the CREB 
expression was elevated as early as 5 minutes and remained elevated up to 4 hours 
after the TNF-a treatment (Fig. 32). This suggests that C R E B is one of the 
transcription factors activated by TNF-a in C6 cells. 
As there are two TNF-a receptors, namely TNF-Rl and TNF-R2, in C6 cells, we 
investigated the receptor subtype responsible for the TNF-a-induced CREB 
expression using TNF-Rl or TNF-R2 antibody pre-treatment. The finding that CREB 
expression was not affected after the TNF-Rl antibody treatment, but the CREB 
expression was greatly attenuated after the TNF-R2 antibody treatment (Fig. 33). This 
showed that TNF-a bound to TNF-R2 to elicit the expression of CREB. This 
observation supported the study by To (1999) in our laboratory who showed that the 
TNF-R2 antibody, but not TNF-Rl antibody, inhibited the proliferative effect of TNF-
a in C6 cells and that this subtype was responsible for p38 M A P K expression (Fig. 
14). 
It has shown that CREB is one of the downstream targets of p38 M A P K and that 
phosphorylation of CREB at Serl33 induced by fibroblast growth factor (FGF) and 
sodium arsenite was prevented by the specific p38 M A P K inhibitor, SB 203580, in 
PC-12 cell (reviewed by Ono and Han, 2000). Our results showed that SB 203580 
greatly attenuated the TNF-a-induced CREB gene expression (Fig. 34). This supports 
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the activation of C R B E expression in C6 cells was mediated by p38 M A P K . 
Apart from p38 M A P K pathway, activation of other intracellular signal 
transduction pathways, like PKA, has been reported to be able to phosphorylate 
Serl33 of CREB, leading to a transcriptional activation of target genes through CREs 
(Gonzalez and Montminy 1989). Our results also showed that dbcAMP elevate the 
C R E B expression in C6 cells (Fig. 37), while the two P K A inhibitor, H-89 and 14-22, 
could potently inhibited the expression of C R E B induced by TNF-a (Figs. 38 & 39). 
Taken together, P K A also participated in the regulation of the expression of CREB 
induced by TNF-a. This action of P K A is likely mediated through p38 M A P K as the 
expression of this kinase was modulated by PKA. 
Previous study showed that P K C also played a role in the phosphorylation of the 
nuclear factor C R E B (Yuan et al., 2000; Solomou et al., 2001). Another study showed 
that tetradecanoylphorbol acetate (TPA) treatment which strongly decreased the levels 
of conventional P K C isozyme caused an almost complete inhibition of C R B E 
phosphorylation and that the down-regulation of conventional P K C isoforms also 
showed a reduced activation of M A P K in response to TPA in cortical oligodendrocyte 
progenitor (OP) cells. This raise the possibility that in OP cells conventional PKC 
functioned as an upstream regulator of M A P K pathway, which in turn led to CREB 
phosphorylation (Pende and Fisher, 1997). In agreement with these findings, our 
study showed that P M A treatment up-regulated CREB expression about 5 fold (Fig. 
35), while the Ro31 pre-treatment suppressed the TNF-a-induced CREB expression 
(Fig. 36). These findings were in line with our previous observations that TNF-a-
induced the expression of some PKC isozymes in C6 cells (Lung, 1999) and that 
activation of PKC induced p38 M A P K expression (Figs. 15-17). However, it is not 
known whether PKC is also a mediator of CREB phosphorylation in C6 cells. 
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Therefore, C R E B seemed to act as an element of convergence and cross-talk 
between distinct signaling pathways, rather than as a target of one single pathway. 
Taken together, this raised the possibility that P K A and/or P K C was the upstream 
regulator of the p38 M A P K pathway, which in turn led to the induction of C R E B as 
well as the phosphorylation of C R E B in C6 cells. As stated before, over-expression of 
C R E B could promote the nerve cell survival in PC 12 cell (Walton et al., 1999) and 
these authors also reported that C R E B regulated cell cycling by modulating cyclin A 
gene expression (Desdouets et al, 1995), therefore, this also raised the possibility that 
activation of C R E B might have a protective role in C6 cells. If similar processes also 
occurred in the injured CNS, our finding might offer an explanation why TNF-a had a 
protective effect in excitotoxic-induced toxicity in hippocampal neurons in culture 
(Cheng et al” 1994) and in ischemic rain injury in mice (Bruce et al., 1996). 
As stated before, (3-AR is one of the mediators for the signal transduction events 
in C6 cells and astrocytes. Recent study showed that isoproterenol increased the 
phosphorylation state of some several nuclear modulators like CREB and NF-KB 
(Storm and Khawaja, 1999). In agreement with this finding, our data showed that 
isoproterenol induced the expression of CREB in a dose-dependent manner (Fig. 40) 
while propranolol inhibited the TNF-a-induced CREB expression by about 50% (Fig. 
40). Furthermore, our study also indicated that the TNF-a-induced CREB expression 
in C6 cells was mediated through (3-AR. This conclusion is in line with our finding 
that TNF-a could induce the expression of p38 M A P K (Fig. 11), a messenger that 
could regulate CREB expression. Our study showed that both p-ARs were involved in 
CREB expression as both selective agonists were effective (Figs. 42 & 44). 
Supporting this notion is our finding that the TNF-a-induced CREB gene expression 
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was inhibited by selective (31-antagonist, atenolol and p2-antagonist, ICI 118,551 
(Figs. 43 & 45). Thus, this suggests that both pi- and P2-AR could regulate the 
expression of C R E B expression in C6 cells and this process was stimulated through 
p38 M A P K . 
Comparing the results obtained with selective (31- and |32-agonists and 
antagonists, it appeared that pl-AR was more effective in regulating C R E B gene 
expression. However, it should be noted that the RT-PCR used in the present study 
was only semi-quantitative, and real time RT-PCR should be used to confirm the 
possibility. 
4.5 The Signaling System Involved in TNF-a-Induced c-fos Expression in C6 
Cells 
Nuclear proto-oncogene has been recognized as components of transmembrane 
signal transport and could be activated by various physiological stimuli (Schonthal et 
al., 1990, 1991). Among them, c-fos belongs to an lEGS which known to have rapid 
but brief responses. In the CNS, induction of c-fos and C-FOS product protein were 
elevated in focal ischemia in rats (Uemura & Kowall, 1991; Gass & Spranger, 1992; 
Zhang & Marsha, 1999). Interestingly, this transcription factor had been reported to 
be activated by TNF-a (Lin & Vilcek, 1987), and several reports suggested that this 
transcription factor expression was associated with cell proliferation (Greenberg and 
Ziff, 1984; Bravo et al., 1987; Fisch et al., 1987; Condorelli et al., 1989) and 
differentiation (Gubits et al., 1988; Bardoscia et al., 1992; Didier et al., 1992) in other 
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cell types. In our laboratory, we found that the c-fos expression in C6 cells was 
enhanced after TNF-a treatment (Lung, 1999)，which is in line with notion that c-fos 
could play an important role in C6 cell proliferation. Together with the study of Kim 
et al, (2000), we hypothesizes that the expression of c-fos induced by TNF-a was 
closely related to the phosphorylation of p38 M A P K pathway in C6 cells. The 
regulation of p38 M A P K , and perhaps c-fos expression in glial cells is not just of 
academic interest. Indeed, Simi et al. (2000) reported that p38 M A P K played a 
distinctive role in cerebral ischemia and that chlomethiazole, an inhibitor of p38 
M A P K , was an effective neuroprotective agent in cerebral ischemia. Also, this agent 
is presently in clinical trials for the treatment of severe stroke. 
Apart the p38 M A P K pathways, c-fos is also induced by multiple intracellular 
second messenger systems such as P K C and PKA. Previously, c-fos expression had 
been shown to be stimulated by PKC, but not P K A in primary cultures of cerebellar 
granule cells (Szekely et al., 1989). In contrast, activation of P K A can produce a mild 
enhancement of c-fos expression in primary cultures of cerebral cortical neurons 
(Vaccarino et al,, 1993). Also, it was found that endothelins induced c-fos expression 
in primary cultures of mouse embryo astrocytes, as well as in C6 cells and that 
inhibition of P K C by staurosporine blocked the endothelin induced c-fos expression 
(Ladenheim et al., 1993). Another study showed that the trophic effect of pituitary 
adenylate cyclase-activating polypeptide (PACAP) stimulated the c-fos gene 
expression and cell survival in rat cerebellar granule neurons through the activation of 
the P K A pathway (Vaudry et al., 1998). Studies with a number of different cell types 
showed that increased transcription of c-fos can be observed following activation of 
either P K A or PKC (reviewed by Sheng and Greenberg, 1990). From our study that 
P M A treatment caused about 6-fold enhancement in c-fos expression, while Ro31 
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suppressed the TNF-a-induced c-fos expression (Fig. 48 & 49). This result suggests 
that TNF-a-induced c-fos gene expression was mediated through P K C pathway. 
Similar to the P K C study, we also found that the c-fos expression was enhanced after 
the dbcAMP treatment by about 6 fold while the TNF-a-induced c-fos expression was 
partially inhibited following the exposure to H-89 (Fig. 50 & 51). From the data of 
Schnmann et al. (1998) and Kim et al (2000), it is likely that the expression of c-fos 
is closely related to the phosphorylation of p38 M A P K pathway in rat C6 cells. Taken 
together, our data indicated that the induction of c-fos expression by TNF-R2 required 
the activation of P K A and P K C pathway which in turn stimulated the phosphorylation 
of p38 a M A P K and then induced c-fos gene transcription to exert the neuroprotective 
effect. 
Results from present study showed that the TNF-a-induced c-fos expression was 
dramatically reduced at around 5 minutes after TNF-R2 antibody treatment, while a 
milder suppression was seen after the addition of TNF-Rl antibody (Fig. 46). These 
data suggests that the TNF-a-induced c-fos expression was mainly elicited through 
TNF-R2. As cultured astrocytes also express both TNF-R subtypes and that TNP-a 
selectively induced the expression of TNF-R2 (Lung et al., 2001), our finding 
suggests that modulation of TNF-R2 expression and/or activity could be another 
therapeutic target, in addition to those of p38 M A P K (Simi et al., 2000), for treatment 
of stroke and cerebral ischemia. 
In addition to the action of the kinases discussed above, p-adrenergic mechanism 
had been shown to play protective role in brain ischemia (Sutin & Griffith, 1993; 
Hodges Savola et al” 1996). It is thus worthwhile to compare the TNF-a and (3-
adrenergic-induced responses of c-fos expression in C6 cells. Recent studies showed 
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that stimulation of central P-ARs in adult rats evoked a maximum increase in c-fos 
expression by 52 folds after 45 minutes of isoproterenol treatment. This coupled to 
our previous finding that TNF-a induced the expression of P-ARs in C6 cell, (Shan, 
2000), make the study of P-adrenergic mechanism on the c-fos expression particularly 
interesting. W e found that c-fos expression was enhanced after the treatment with 10 
p M isoproterenol (Fig. 52) while propranolol could inhibited the TNF-a-induced c-
fos expression by about 50% (Fig. 53). Further study with (31-agonist, dobutamine, 
and (32-agonist, procaterol, showed that both agents could induce the c-fos expression 
in dose-dependent manner (Figs. 54 & 56). Supporting the notion that P-adrenergic 
mechanism mediated the TNF-a-induced c-fos expression were the inhibitory effects 
of selective pi-antagonist, atenolol and p2-antagonist, ICI 118,551 (Figs. 55 and 57). 
Thus, this suggests that both (31- and |32-AR could regulate the expression of c-fos 
induced by TNF-a in C6 cells. Again, these observations suggest that regulation of p-
A R activity may offer an alternative treatment of brain injury. 
4 .6 The Signaling System Involved in TNF-G - Induced NF-KB Expression in C6 
Cells 
NF-KB levels was increased as a consequence of brain injury. An increase in NF-
KB was observed in the ischemic cortex (Salminen et al., 1995) and a long lasting 
increase in NF-KB was observed even in the cerebral cortex ipsilateral to the site of 
injury (Yang & Mu, 1995). Also, NF-KB was activated by IL-1 in C6 cells (Moynagh 
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& Williams, 1993). It is possible that brain injury leads to an increase in production of 
TNF-a and/or IL-1, which then activate NF-KB and leads to induction of the 
expression of a range of pro-inflammatory genes (0，Neill et al” 1997). These 
correlate well with the study in our laboratory that NF-KB was elevated after TNF-a 
treatment in C6 cells (Lung, 1999). 
Studies have shown that p38 M A P K has been implicated in the activation of 
transcription factor like NF-KB. For example, activation of p38 M A P K was reported 
to have anti-apoptotic effects in some cell lines and play a role in cell proliferation in 
other systems (Rausch et al., 1999; Craxton & Shu，1998; Roulston & Reinhard, 
1998). Lim & Zaheer (2000) showed that the p38 M A P K inhibitor SB 203580, 
suppressed the G M F (glial maturation factor)-activated NF-KB in the glia maturation 
GMF-transfected C6 rat glioma cells. These suggest that p38 M A P K could regulate 
NF-KB expression. Our study showed that SB 203580, suppressed the TNF-a-induced 
NF-KB expression (Fig. 59), and this suggests that TNF-a-induced NF-KB expression 
is mediated by p38 M A P K . This is in agreement with the notion that p38 M A P K 
acted as one of the essential components in the early response to TNF-a, and in 
combination with NF-KB could modulate survival signals that protected cells from 
apoptosis (Roulston & Reinhard, 1998). Apart from p38 M A P K , PKC has also been 
suggested to be involved in NF-KB induction. Our result shows that P M A could 
elevate NF-KB expression while Ro31 suppressed the NF-KB (Fig. 60 & 61). 
Our study with TNF-R antibodies showed that the NF-KB expression was 
reduced after TNF-R2 antibody treatment, but not affected after the TNF-Rl antibody 
treatment (Fig. 62). This is in agreement that early transient activation of NF-KB and 
p38 M A P K is mediated through TNF receptor associated factor 2 (TRAF2) which 
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binds directly to TNF-R2 (Roulston & Reinahrd, 1998). The signaling cascade 
describe above may coordinate protective signals, preventing apoptosis and allowing 
a wide range TNF-a-mediated cellular effects (Roulston & Reinhard, 1998). 
4.7 Conclusion 
Brain injury is one of the major causes of morbidity and mortality (Marshall et 
aL, 1991; Gennarelli, 1993; Jennett, 1993). The post-traumatic inflammatory response 
is believed to be one of the causes contributing to tissue damage as well as to the 
induction of neuroprotective mechanisms (Benveniste et al., 1995; Balasingam and 
Yong, 1996; Hessen et aL, 1996; Kossmann et al., 1996, 1997). TNF-a is elevated in 
the serum and cerebrospinal fluid of humans after TBI (Goodman et al., 1990; Ross et 
al., 1994) and acute increases in TNF-a m R N A and protein have also been observed 
in injured rat brain (Fan et aL, 1996; Scherbel et al., 1999). Therefore, TNF-a plays a 
main role in post-traumatic brain injury. However, the signaling cascade leading to 
elevation of TNF-a after brain injury is still unclear. 
By applying fluorescent differential display (FDD) technique, the differential 
expressed genes are believed to be TNF-a responsive genes and can be screen out 
effectively. In m y study, F D D technique has helped me to screen out at least three 
responsive genes following the TNF-a treatment. It is likely that this process mimicks 
the production of TNF-a after post-traumatic response. In the initial screening, three 
differentially expressed c D N A fragments: Al, A2 & A3 were derived from three 
known genes encoding rat 5 ’ A M P protein kinase, rat ribosomal protein L7a and rat 
p38 M A P K respectively. Among these three genes, p38 M A P K was chosen for my 
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further study. This is because TNF-a and IL-1 have been shown to trigger p38 M A P K 
protein kinase cascades (Herlaar and Brown, 1999). Furthermore, p38 M A P K 
modulates transcriptional activity leading to cell cycle regulation (Takenaka et al., 
1998), cell differentiation (Zetser et al” 1999; Morooka and Nishida, 1998) and 
proliferation (Maher, 1999). Finally, p38 M A P K has been causally implicated in 
ischemic heart disease (Wang and Huang, 1998), human immunodeficiency vims 
infection (Kumar et al., 1996; Cohen et al., 1997)，and Alzheimer' s disease 
(Hensley and Floyd, 1999). Thus, understanding the p38 M A P K signaling cascade 
gives us insight to the treatment of a variety of diseases, including brain injury. 
To date, four different genes encoding p38 M A P K isoforms, p38a (Han et al., 
1993), p38p (Jiang et al., 1996), p38y (Lechner et al., 1996; Li et al., 1996; Cuenda et 
al., 1998), p385 (Jiang et al., 1992; Kumar et al., 1997), have been cloned recently. 
Our results showed that p38 a, (3, y, 5 were expressed in unstimulated cells (Fig. 13). 
The tissue distribution of isoenzymes indicated that p38 a M A P K was more 
abundantly expressed in brain than in peripheral tissues (Jiang et al,, 1996). p38a, 
p38p are the major forms of p38 M A P K s in the brain (Lee & Park, 1999, 2000), and 
p38a, p38(3 genes are ubiquitously expressed (Jiang et al., 1996). However, p38 y and 
5 are differentially expressed in different tissues. p38 y is predominately expressed in 
skeletal muscle (Lechner et al., 1996; Li & Jiang, 1996) and p38 6 is enriched in lung, 
kidney, testis, pancreas, and small intestine (Kumar et al., 1997). p38 y expression 
was reported to be induced during muscle differentiation and p38 5 expression was 
shown to be developmentally regulated (Lechner et al., 1996; Hu & Wang, 1999). 
Upon exposure to TNF-a, p38a, P, y and 6 were up-regulated but their responses 
to TNF-a were somewhat different in terms of sensitivity to TNF-a. p38 a was 
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induced as early as 2 minutes, while the other isoforms were induced at later times 
and/or to a lesser extent. This can be explained by the fact that p38 a was abundantly 
expressed in brain (Lee & Park, 1999, 2000). Our study reports for the first time that 
p38 a M A P K is the isoform selectively induced by TNF-a in C6 rat glioma cells. 
Moreover, if this result can be extrapolated to the cells in brain, this would suggest 
p38 a M A P K is induced in astrocytes. 
For TNF-a to elicit its influence on the target cells, the first step is to bind to the 
TNF-receptors (TNF-Rs) on the cells. Recently, two subtypes of TNF-Rs have been 
identified, namely, TNF-Rl and TNF-R2 in many cell types (Tartaglia et al., 1992; 
Barbara et al., 1994). In our laboratory, we have found that C6 cells (Huang et al, 
1998; Lung, 1999; To, 1999) and cultured astrocytes (Lung et al., 2001), also contain 
both receptor subtypes that TNF-a selectively induced the TNF-a m R N A as well as 
its protein expression in a time- and dose- dependant manner (Shan, 2000; Lung, 
1999; Lung et aL, 2001), we showed that the induction of p38 M A P K , iNOS, CREB, , 
c-fos and N F - K B were blocked following TNF-R2 antibody treatment, but the 
addition of TNF-Rl antibody had no effect. Thus, this demonstrated that the induction 
of p38 M A P K , iNOS, CREB, c-fos and NF-KB were mediated through TNF-R2, 
while the role of TNF-Rl was relatively minor. This finding is in agreement with the 
study of To (1999) in our laboratory by using selective TNF-R antibodies in which 
TNF-R2 antibody, but not TNF-Rl antibody, inhibited the proliferative effect of TNF-
a in C6 cells. Similar finding has been reported in cultured microglia (Dopp et al., 
1997). These studies would demonstrate the importance of TNF-R2 in TNF-a-
induced cell proliferation. 
The present results showed that the TNF-a elicited its proliferative effect by 
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binding to TNF-R2 activated P K C and P K A which in turn evoked the p38 M A P K 
induction in C6 cells. This showed that p38 M A P K pathway is at least one of the 
signaling cascades which could behave as a multimolecular complex of receptors, 
regulatory and adaptor proteins as which are functionally assembled around a modular 
core of the mitogen protein kinase (Schaeffer & Weber, 1999). A major mechanism of 
internal regulation and signal amplification of these cascades is the sequential 
phosphorylation and activation of the kinases with its kinase module, leading to 
activation in the cytoplasm of the effector kinases such as p38 M A P K , and their 
translocation to the nucleus, where phosphorylation of transcription factors takes 
place (Karin et al, 1995; Treisman et al, 1996). The specificity of activation and 
function of M A P K signaling modules is determined, in part, by scaffold proteins that 
create multi-enzyme complexes. In Saccharomyces cerevisiae, two MAPK-scaffold 
proteins have been identified. Recent studies of mammalian cells have also led to the 
identification of putative scaffold proteins. These scaffold proteins appear to facilitate 
M A P K activation (Whitmarsh & Cavanagh, 1998), in response to specific 
physiological stimuli, and to insulate the bound M A P K module against activation by 
irrelevant stimuli. Another study further revealed that phosphorylation loop 12 (L 12) 
influences the substrate specificity and autophosphorylation of p38 M A P K (Jiang & 
Li, 1997). Scaffold proteins are therefore critical components of M A P K modules and 
ensure signaling specificity (Whitmarsh & Davis, 1998). In addition, the crosstalk 
between distinct M A P K kinase cascades as well as with protein kinases from other 
pathways, such as P K A or PKC respectively, cooperates in the integration of signals 
delivered through the M A P kinases (Robinson & Cobb, 1997; Blanco-Aparicio et al., 
1999). This would raise the possibility whether cross-talk between distinct p38 
M A P K cascades with P K A and PKC, in the signaling pathway induced by TNF-a in 
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C6 cells. Indeed our study showed that both P K A and P K C can induce p38 M A P K 
although we do not know whether communication exists between P K A and P K C in 
C6 cells, the fact that both kinases can evoke the p38 M A P K expression suggest that 
TNF-a may use this pathway to amplify its signal. The use of p38 M A P K inhibitor, 
SB 203580, helped us to elucidate the downstream targets or the signaling pathway 
under the control ofp38 M A P K . The results have shown that iNOS, CREB, c-fos and 
N F - K B are possible downstream genes. This indicates that p38 M A P K would mediate 
a wide range of regulation on iNOS, CREB, c-fos and N F - K B SO that the signal 
induced by TNF-a is greatly amplified. 
Recent studies have revealed that P-adrenergic receptor (P-AR) plays an 
important role in the development of reactive gliosis and scar formation (Sutin and 
Griffith, 1993; Mantyh et al., 1995). So, TNF-a could mediate certain pathological 
events after brain injury via (3-adrenergic mechanism. The present studies have shown 
that P-AR could also activate p38 M A P K , then CREB and c-fos expression. These 
data demonstrated that p38 M A P K , CREB and c-fos are possible mechanisms 
involved in gliosis. 
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4.8 Possible Applicat ions 
Selective neuronal vulnerability is a feature of a number of neurodegenarative 
diseases, but the processes that target specific neurons for death while allowing others 
to remain healthy are still unclear. Research in this cell-survival area has focused on 
identifying the key mediators in this survival cascade and has concentrated on 
endogenous neuroprotective messengers, such as neurotrophic factors and various 
cytokines (Mattson et al, 1997). As p38 M A P K work as signaling relays to transmit 
information within the cell, so the cell survival effect was likely to be regulated by 
p38 M A P K activation (Nebreda & Porras, 2000). Recently, studies demonstrated that 
activation of p38 M A P K protects primary neonatal rat cardiomyocytes from 
anisomycin-induced apoptosis (Zechner et al., 1998). Another study reported that 
activation of the transcription factor M E F 2 by p38 M A P K has been shown to be 
required for the survival of developing neurons as the expression of dominant-
negative p38 M A P K MEF2-dependent transcription and induced apoptosis (Mao et 
al” 1999). 
It was believed that the anti-apoptotic effect of p38 M A P K correlate with the 
regulation of the activity (usually associated with phosphorylation) of different 
transcription factors, for example, C/EBP and MEF2 in adipose and muscle cell 
precursors, respectively. Recently, several studies implicated that transcription factor, 
c AMP-response-element-binding protein (CREB), not only in the signaling pathway 
activated by these molecules, but also as a possible regulator of a general survival 
program in neurons (Walton, 2000). The transcriptional activation of CRBE is 
crucially dependent on phosphorylation of Ser 133 through activation of several 
second messengers and kinase, for example, protein kinase C, P K A and M A P K 
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(Robinson et al, 1999). 
Supporting this notion, a study showed that kainate-induced neuronal injury 
leads to persistent phosphorylation of C R E B in glial and endothelial cells in the 
hippocampus (Ong and Han, 2000). Also, the observation that C R E B overexpression 
(and phosphorylation) protects cells against toxin-induced apoptosis in vitro and that 
C R E B protein was phosphorylated following hypoxic-ischemic brain injury in vivo 
(Walton et al., 1996; Hu et al., 1999; Tanaka et al., 1999). PC12 cells that over-
express the gene for C R E B have a decrease susceptibility to okadaic-acid-induced 
apoptosis, and a significant proportion of this effect is dependent on prolonged 
phosphorylation of C R E B at Ser 133 (Walton et al., 1999). Pituitary adenylate-
cyclase-activating polypeptide (PACAP) is another survival factor that might mediate 
its effects through the phosphorylation of CRBE. PACAP or, more specifically, 
PACAP type-I-receptor activation promotes neuronal survival in a number of model 
systems through a pathway that involves cAMP, P K A and M A P K (Campard et al., 
1997; Villalba & Joumot, 1997). Taken together, these suggest that endogenous 
CREB activation is a potent survival signal in times of cellular stress (Walton et al., 
1999). The above findings indicate that the CREB protein and the CRE site are 
potential targets for neuroprotective agents. Exact how the phosphorylation of CREB 
leads to neuronal survival is, as yet, unclear, but is likely to involve combinatorial 
interactions with other transcription factors and to be mediated through regulation of 
the expression of downstream target genes, such as c-fos and Bell, as well as many 
unknown genes (Walton et al, 2000). pCREB could drive the expression of 
downstream genes to promote cell proliferation and survival. pCREB was shown to 
activate downstream genes such as c-fos (Bito et a/.,1996; Deisseroth et al., 1996; Liu 
and Graybriel, 1996). 
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Some evidence supports the role of c-fos in regulating neuronal death pathways. 
Prolonged expression of c-fos correlates with delayed death, whereas transient 
induction of c-fos correlates with neuronal survival in hippocampal regions following 
ischemic assault (Walton et al., 1998; Yoneda et aL, 1998). In the instance of kainate-
induced seizure, reduction or prevention of the extent of seizure and neuronal death 
can result from administration of anti-sense c-fos oligonucleotides (Panegyres & 
Hughes, 1997). In some studies, prolonged c-fos expression has been associated with 
neuronal survival, as occurs with administration of bifemelene，a neuroprotective 
agent, following transient forebrain ischemia (Kuramoto et al, 1998). The Bcl2 gene 
might be another example, as the phosphorylation of C R B E proteins has been shown 
to have a major role in the induction of its expression during the activation of mature 
B cells and during the rescue of immature B cells from Ca^^-dependent apoptosis 
(Wilson et al, 1996). The Bcl2 gene encodes a membrane-associated protein that can 
block apoptosis and promote cell survival in many systems, including the nervous 
system (Merry & Korsmeyer, 1997). 
Apart from CREB, recent study has shown that TNF-a-induced NF-KB is also 
necessary for cell survival (Liu et al., 1996; Wang & Mayo, 1996). This process also 
involves p38 M A P K (Craxton et al., 1998; Roulston & Reinhard, 1998; Rausch et 
al., 1999). Recent study (Lim & Zaheer, 2000) showed that the p38 M A P K inhibitor, 
SB 203580, suppressed the GMF-activated NF-KB in the glia maturation factor 
(GMF)-transfected C6 rat glioma cells. This suggests that p38 M A P K induces NF-KB 
enhanced by GMF. This is in agreement that the p38 M A P K pathway was activated 
up to 24 hours following transient ischemia in the rat (Irving & Barone，2000), and 
p38 M A P K acted as essential components in the early response to TNF-a, and in 
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combination with NF-KB, mediated survival signaling pathway that protect cells from 
apoptosis (Roulston & Reinhard, 1998). Another study also demonstrated that 
activation of p38 M A P K and NF-KB played a critical role in TNF-a-mediated 
survival and proliferation of human leukemia lymphoma cells, and p38 M A P K acts at 
least in part by facilitating the transcription activation function of NF-KB (Liu & Fan, 
2000). Interestingly, these author found that early transient activation of NF-KB and 
p38 M A P K was mediated through TNF-receptor associated protein (TRAF2) which 
bound directly to TNF-R2, the receptor subtype selectively induced by TNF-a. 
Recent study indicated that the NGF-induced NF-KB signaling via p75 plays an 
important role in preventing apoptosis (Foehr & Lin, 2000, Hamanoue et al, 1999) in 
PC-12 cells. Thus, our findings in C6 cells indicate the p38 M A P K signaling cascade 
may coordinate protective signals, prevent apoptosis and activate a wide range TNF-
a-mediated cellular effects to enhance cell survival (Roulston & Reinhard, 1998). 
Although there is no report documented for the survival effects of iNOS, recent study 
showed that N O generation by neuronal N O synthase was calcium-dependent and that 
N O could activate p38 M A P K (Lander et al., 1995). This finding together with a 
report showing that N O potentiates the calcium-induced c-fos expression and calcium-
induced E R K (a well known member of M A P K ) activation (Lee & Kang, 2000) in 
PC 12 cells. N O acted as a separate signaling molecule in lEG expression. 
Furthermore, these findings suggest that these cross-talk represents signal 
amplification process occur at multiple levels. The possible mechanism of 
amplification is the convergence of p38 M A P K at the level of transcription factor. For 
example, the signals from p38 M A P K can converge into CREB as p38 M A P K is 
known to activate CREB directly or indirectly (Gudi & Huvar, 1996). Also, 
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phosphorylation of the transcription factor C R E B appeared to be important in 
mediating the expression of several lEGs (Ginty et al, 1993; Konaradi et al., 1994; 
Yamamoto et aL, 1998). Subsequent to transcription factor C R E B phosphorylation, 
the expression of c-fos can be enhanced as reported both in the hippocampus and the 
cortex (Moore & Waxham, 1996). 
Reactive astrogliosis is the prominent consequences of brain injury. In addition to 
cytokines, p-AR plays an important role in the development of reactive gliosis (Sutin 
& Griffith, 1993; Mantyh et al., 1995). As stated before, astrocytes grown in primary 
cultures express P-adrenergic receptors (McCarthy et al., 1992; Stone et aL, 1989; 
Hansson et al., 1989; Sutin & Shao, 1992). Injured optic increased |32-AR expression 
in astrocyte, (Mantyh et al., 1995), and that infusion of an (3-AR antagonist attenuated 
the hypertrophic change and proliferation of astrocytes (Hodges Savola et aL, 1996) 
and that P-AR antagonist also suppressed the hypertrophy and increase in GFAP after 
sciatic nerve injury (Sutin & Griffith, 1993). Thus, P-adrenergic mechanism also 
plays an important role in reactive gliosis. Our study with C6 cells, a good model for 
studying astrocyte physiology, showed that P-adrenergic mechanism also induced the 
expression of p38 M A P K and other genes which are also induced by TNF-a and 
known to participate in cell proliferation and cell survival, thus these genes, in 
addition to (3-adrenergic mechanism, are potential targets for controlling reactive 
gliosis and perhaps scar formation. 
The above together with the present finding suggest that brain injury leads to an 
increase in production of TNF-a and other cytokines (Goodman et aL, 1990; Ross et 
al., 1994; Fan et al., 1996; Scherbel et al, 1999) which induced certain kinases (PKA, 
PKC and p38 M A P K ) expression and then activate the induction of iNOS, c-fos, 
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C R E B and N F - K B in brain injury. A number of mediators and transcription factors 
were involved in brain injury and the cell survival process and this suggests that the 
signal of cell survival was greatly amplified at multiple levels. Therefore, the 
modulation of the activity of these genes may provide beneficial therapeutic 
intervention in the treatment of brain injury. 
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